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Abbreviations
aa amino acid(s)
AD Alzheimer's disease
APP   Amyloid precursor protein
CHO Chinese hamster ovary
CERT Ceramide transporter
CERTL Ceramide transporter long (isoform)
CNS Central nervous system
ER Endoplasmic reticulum
FAPP2 Four-phosphate-adaptor protein 2
FFAT two phenylalanine amino acids 'FF' in an acidic tract motif
GlcCer Glucosylceramide
GPBP Goodpasture antigen-binding protein
GP Goodpasture 
GPS  Goodpasture syndrome
GSLs Glycosphingolipids 
OLGs Oligodendrocytes 
OSBP Oxysterol-binding protein
NFkB nuclear factor kappa B
NGF Nerve growth factor
PC Phosphatidylcholine
PD Parkinson's disease
PH Pleckstrin homology
Pol K DNA polymerase k
PRD Proline rich domain
SAP      Serum Amyloid P component
SM Sphingomyelin
SMase Sphingomyelinase
SMS      Sphingomyelin synthase
SPR  Surface plasma resonance
SR Serine repeat motif
START Steroidogenic acute regulatory protein (StAR)-related lipid transfer
TNFα Tumor necrosis factor alpha
VAPs Vesicle associated-ER proteins
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Ceramide is an important bioactive lipid that is involved in many of the most
critical cellular processes, ranging from regulation of cell growth to cell cycle
arrest and apoptosis. Ceramide levels are finely regulated within the cell and
alteration of the sphingolipid-ceramide profile has significant relevance in
the development of many age-related, neurological and/or
neuroinflammatory diseases. Ceramide transporter (CERT) and Goodpasture
antigen binding protein (GPBP) are the only proteins known to shuttle
ceramide within the cell. By implication, it is very likely that these proteins
are involved in the molecular mechanisms underlying ceramide-mediated
signaling cascades. These two isoforms, almost identical in their sequence
and highly conserved in evolution, differ in various properties such as tissue
and cellular localization, temporal pattern of expression and mode of action.
Indeed, this diversity is reflected by their research history, with GPBP and
CERT discovered and characterized in the apparently unrelated fields of
autoimmunity and lipid chemistry.
Goodpasture antigen-binding protein (GPBP) is a non conventional serin-
threonin kinase isolated for the first time in the context of a rare
autoimmune disease known as Goodpasture Syndrome (GPS).  This disorder
affects mostly kidney, lung and choroid plexus in the brain. GPBP was found
to bind and phosphorylate the self-antigen against which the antibody-
mediated inflammatory response is directed. Specifically, the target of the
autoantibody attack is the C-terminal noncollagenous-1 (NC1) domain of the
α3-chain of the type IV collagen (a3-(IV) NC1), also known as Goodpasture
antigen (GPA). This autoimmune reaction results in deposits of
autoantibodies along the alveolar and glomerular basement membranes,
causing lung hemorrhage and rapidly progressive glomerulonephritis, the
two cardinal clinical manifestations of GPS. Although the function of this
protein in the autoimmune response of GPS has remained elusive, GPBP
phosphorylation of GPA could regulate molecular processing and
organization of specific structural protein domains, which may lead to the
autoimmune response. In line with this role, high expression levels of GPBP
are found in many autoimmune diseases in which antigens may arise from
abnormal protein domain organization. However, the fact that GPBP takes
its name from GPS is unfortunate and even misleading because this protein
probably plays an important general role in cell physiology and immunology,
not just the disease state.
More recently, a shorter variant of GPBP was shown to be responsible for
the transport of the lipid ceramide within the cell (between the ER and the
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Golgi apparatus) and was thus termed ceramide transporter (CERT). 
GPBP and CERT were therefore characterized in very different contexts and
it is difficult to correlate the intracellular function of the lipid carrier CERT
with the capacity of GPBP to bind and phosphorylate proteins at the
extracellular level. Notably, both isoforms have ceramide binding capability.
Many reports have emphasized the role of ceramide in neurodegenerative
disorders and ceramide transporters are likely to represent pivotal proteins
for brain homeostasis and disease processes. However, until recently there
had been little research into the expression, regulation and function of these
ceramide associated proteins. In this thesis we first aimed to investigate
GPBP and CERT cellular localization and expression in normal rat brain and
establish whether levels of these proteins were altered in models of both
acute brain injury and chronic neurodegenerative diseases. Subsequently, in
an effort to investigate the function of GPBP, we aimed to delineate cellular
and molecular mechanisms underlying its interaction with proteins
associated with neuronal degeneration and immune system response.
Chapter 1 reviews the current state of knowledge on GPBP and CERT,
including the molecular and biochemical characterization of GPBP in the
field of autoimmunity, as well as the fundamental research on CERT in
ceramide transport. Also the functions of these proteins in different
biological and pathological processes are discussed. 
In chapter 2, we present a detailed overview of ceramide biology, including
structure, physical properties and metabolism, followed by recent data on
the role of ceramide as a lipid second messenger in key events of cell
physiology. Finally, we highlight the relevance of ceramide in the progression
of different neurodegenerative diseases. 
In chapter 3, we have investigated the localization of GPBP and CERT in adult
rat brain under basal conditions. Using four different antibodies directed
against distinct epitopes shared by the two isoforms, we described the
cellular localization and expression pattern of GPBP and CERT throughout
the rat brain. 
In chapter 4, in order to analyze a possible role of these proteins in
neuroinflammation and neurodegeneration, we have examined whether
levels of GPBP and CERT were altered in 6-hydroxydopamine (6-OHDA)-
lesioned rat, a well-known acute model of Parkinson's disease (PD). No
differences in GPBP/CERT expression was detected between the 6-OHDA
injected and the control brains. However, injection of 6-OHDA induces acute
effects which differ significantly from the chronic progressive course of PD
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that is characterized by protein aggregates and dysregulation of sphingolipid
metabolism. Therefore, in order to further investigate a possible role for
GPBP and CERT in chronic and progressive neuronal degeneration and
inflammation, we next examined human and transgenic mouse Alzheimer's
disease (AD) brain tissues that better represent the characteristic clinical
and pathological features of neurodegenerative diseases, such as
progressive loss of neurons and deposition of aggregated proteins.
In chapter 5 we have investigated whether GPBP binds directly to human
serum amyloid P component (SAP), a protein concentrated in all types of
amyloid deposits. We undertook an immunohistochemistry study of AD
human brains to reveal whether the cellular localization of GPBP and CERT
are altered in the disease state and whether these proteins localize in the
amyloid plaques of AD brains. This chapter raises the important question of
whether GPBP-SAP interaction could have a role in disease progression and
whether GPBP could be involved in the cellular response to misfolded or
aggregated proteins. This is examined further in chapter 6 where we have
investigated the role of GPBP in the processing of the Alzheimer amyloid
precursor protein (APP) using an in vitro model with elevated levels of
secreted amyloid-β (Aβ) peptide. Firstly, we were able to specifically
describe the cellular localization of the GPBP isoform in normal rat brain.
Secondly, we tested the hypothesis whether GPBP might interact with APP
and Aβ1-42 peptide. Finally, we have investigated how this interaction has a
direct influence upon the in vitro aggregation pattern of Aβ1-42 and how
GPBP takes part in the cellular response against Aβ-induced toxicity in
cultured neurons.
General introduction
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Chapter 1
The ceramide transporter (CERT) and the
Goodpasture antigen-binding protein (GPBP).
One protein - one function?
Chiara Mencarelli, Mario Losen, Caroline Hammels, Jochen De Vry, Matthijs K.C.
Hesselink, Harry W.M. Steinbusch, Marc H. De Baets, and Pilar Martínez-Martínez
Published in: Journal of Neurochemistry 2010; 113, 1369-1386.
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Chapter 1
Abstract
The Goodpasture antigen-binding protein (GPBP) and its splice variant the
ceramide transporter (CERT) are multifunctional proteins that have been
found to play important roles in brain development and biology. However,
the function of GPBP and CERT is controversial because of their involvement
in two apparently unrelated research fields: GPBP was initially isolated as a
protein associated with collagen IV in patients with the autoimmune disease
Goodpasture syndrome. Subsequently, a splice variant lacking a serine-rich
domain of 26 amino acids (GPBPΔ26) was found to mediate the cytosolic
transport of ceramide and was therefore (re)named CERT. The two splice
forms likely carry out different functions in specific sub-cellular localizations.
Selective GPBP knockdown induces extensive apoptosis and tissue loss in
the brain of zebrafish. GPBP/GPBPΔ26 knock-out mice die as a result of
structural and functional defects in ER and mitochondria. Because both
mitochondria and ceramide play an important role in many biological events
that regulate neuronal differentiation, cellular senescence, proliferation and
cell death, we propose that GPBP and CERT are pivotal in neurodegenerative
processes.
In this review, we discuss the current state of knowledge on GPBP and CERT,
including the molecular and biochemical characterization of GPBP in the
field of autoimmunity as well as the fundamental research on CERT in
ceramide transport, biosynthesis, localization, metabolism and cell
homeostasis.
CERT and GPBP: one protein-one function?
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Introduction: CERTain facts about GPBPs
GPBPs are widely distributed in the central nervous system (CNS), where
they are involved in brain development and homeostasis. Different GPBP
isoforms are expressed in the cell. GPBP/CERTL with 26 additional amino
acids (aa) (Ex11+) (Raya et al., 1999) and GPBPΔ26/CERT without 26 aa
(Ex11-) (Hanada et al., 2003) have been studied in detail.
These proteins were characterized in the context of two different biological
processes: GPBP/CERTL was initially isolated in 1999 by Raya and colleagues
and named as Goodpasture antigen-binding protein (Raya et al., 1999).
Goodpasture's syndrome is a strictly human disorder caused by antibodies
directed against the non-collagenous (NC1) domain of the α3-chain of
collagen type IV (α3 (IV) NC1 domain). Collagen is a major component of the
extracellular matrix. The auto-antibodies cause rapid functional disruption
of the basement membrane of lungs, kidneys and the choroid plexus
(Salama et al., 2001). GPBP is a soluble extracellular protein which binds and
phosphorylates the antigen in this syndrome. Its expression is increased in
other spontaneous autoimmune disorders including Goodpasture's
syndrome, lupus erythematosus, pemphigoid and lichen planus (Raya et al.,
2000), suggesting that GPBP might be an important protein in autoimmune
disorders, where autoantigens arise from abnormal protein domain
organization.
Subsequently, in 2003, Hanada and colleagues showed that a spliced variant
of GPBP which lacks a serine-rich domain composed of 26 aa residues was
responsible for the cytosolic trafficking of ceramide from the endoplasmic
reticulum (ER), to the Golgi apparatus. Hence, this isoform was termed as
CERT (Hanada et al., 2003). Since the longer isoform also has ceramide
transport properties in vitro, GPBP was renamed as CERTL (Hanada et al.,
2003).
Thus far it is not clear how the extracellular function of GPBP/CERTL, which
is related to immune complex-mediated pathogenesis, can be conciliated
with the critical role of the protein as a cytosolic ceramide transporter. Much
of the literature involving GPBPs does not distinguish between the different
protein variants and generally refers solely to GPBPΔ26/CERT. This lack of
differentiation between the isoforms hampers the interpretation and
understanding of results and poses the risk of neglecting genuine functional
differences between them. Here we will refer to both splice isoforms as
GPBPs, to the longer splicing variant as GPBP/CERTL and to the shorter
splicing variant as GPBPΔ26/CERT. Despite the difference of 26 amino acids,
18
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GPBP/CERTL and GPBPΔ26/CERT have undistinguishable molecular weights
when analyzed by gelectrophoresis. However, they are not the only isoforms
found in the cell. Smaller and bigger molecular weight isoforms have been
described, which result from an alternative initiation translation site and
poststranslational modifications. Each of these isoforms are addressed
specifically below.
In this review we comprehensively summarize the current knowledge about
GPBPs including their structure, properties and functions. Finally, we will
focus on recent findings which delineate an intriguing picture of biological
and pathological processes, defining GPBPs as pivotal proteins for brain
homeostasis and disease processes
Molecular and biochemical characterization of GPBPs
Two splicing variants: 26 amino acids of difference
GPBP/CERTL and GPBPΔ26/CERT are alternatively spliced variants of 624 and
598 aa respectively that are identical in sequence, except for the 26 aa
serine rich domain (SR2) that is not present in the shorter isoform (Raya et
al., 2000). GPBPs are phylogenetically highly conserved during evolution
between lower vertebrates and mammals at the amino acid level (Fig. 1).
This holds true also for the 26 aa of exon 11 as such, suggesting that the two
isoforms perform crucial and distinct physiological functions.
GPBP has three distinct functional domains; the pleckstrin homology (PH)
domain, the MIDDLE REGION and the START domain (Fig. 2). The amino
terminal ~120 aa region contains the PH domain that targets the protein to
the Golgi apparatus (Hanada et al., 2003). The PH domain recognizes a
specific isomer of phosphatidylinositol phosphates (PIP), namely PI4P which
confers Golgi targeting in mammalian cells (Levine and Munro, 2002).
The mutation G67E in the PH domain present in Chinese hamster ovary
(CHO) mutant cell line LY-A, destroys the PI4P binding activity of this domain,
resulting in an impaired ER-Golgi ceramide transport (Hanada et al., 2003).
The MIDDLE REGION of 250 aa contains a coiled-coil motif that might play a
role in self oligomerization (Raya et al., 2000). Moreover, the presence in this
domain of a FFAT motif (comprising two phenylalanine amino acids 'FF' in an
acidic tract) is essential for GPBPs ER targeting (Kawano et al., 2006). FFAT
interaction with vesicle associated-ER proteins (VAPs) is a common
mechanism where proteins, most of which are involved in lipid metabolism,
target ER membranes (Loewen et al., 2003). The GPBPs' FFAT motif interacts
with the ER resident type II membrane protein VAP, VAP-A and VAP-B.
Mutations in the FFAT motif of GPBPΔ26/CERT destroy the VAP-
CERT and GPBP: one protein-one function?
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Figure 1 Aminoacid sequence aligment of GPBPs in various species. In Drosophila only the
GPBPΔ26/CERT exists.
Figure 2 GPBP/CERTL and GPBPΔ26/CERT domains: N-terminal Pleckstrin homology (PH) domain.
Middle region (MD) with two serine-rich domains (SR1, SR2) and FFAT motif (double phenylalanine in
an acidic tract); the 11th exon, encoding SR2, is deleted in GPBPΔ26/CERT. C-terminal steroidogenic
acute regulatory protein related lipid transfer domain (START). Molecular transfer model of ceramide
from ER to the trans-Golgi region by CERT mediated pathway and by vesicular-dependent minor
pathway.
GPBPΔ26/CERT interaction and, consequently, the GPBPΔ26/CERT -
mediated ER to Golgi transport of ceramide in cells (Kawano et al., 2006).
The carboxyl terminal of 230 aa is a START (steroidogenic acute regulatory
20
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protein-related lipid transfer) domain. This is a structural region that forms
a deep lipid-binding pocket that can extract ceramide from membranes and
transfer the bound ceramide to other membranes (Alpy and Tomasetto,
2005; Tsujishita and Hurley, 2000). GPBPs can transfer natural ceramide
isoforms (C16-dihydroceramide, C16-phytoceramide) and various ceramide
molecular species having C14-C20 amide-acyl chains (Kumagai et al., 2005).
However, GPBPs can not extract any other lipid type such as sphingosine,
sphingomyelin (SM), phosphatidilcholine (PC) or cholesterol (Hanada et al.,
2003).
GPBPs receives multiple phosphorylations at a serine repeat motif (SR1) that
is also present in the GPBPΔ26/CERT isoform and is located after the PH
domain (Kumagai et al., 2007). The hyperphosphorylation at the SR1 domain
down regulates the ER to Golgi transport by repressing the PI4P binding
ability of the PH domain and the ceramide transfer activity of the START
domain (Kumagai et al., 2007).
Loss of SM and cholesterol from the plasma membrane induces the
dephosphorylation of the SR1 motif to activate GPBPΔ26/CERT to target
both the ER and the Golgi membranes (Kumagai et al., 2007). However,
further studies are needed to elucidate how SM/cholesterol rafts affect the
phosphorylation of GPBPΔ26/CERT. The serine rich domain consisting of 26
aa (SR2) located before the START domain is only present in the GPBP/CERTL
isoform and constitutes the crucial site that differentiates the two iso-
proteins (Raya et al., 2000).
One gene, two splicing variants, many isoproteins
The human gene encoding GPBPs, COL4A3BP, is located in chromosomal
5q13.3 region and consists of 17 exons. The controversy over GPBP isoforms
undoubtedly reflects the complex arrangement of this gene: its mRNA
undergoes alternative processing either of exon splicing or rare protein
translation initiation, giving rise to multiple proteins (Fig. 3).
GPBP/CERTL and GPBPΔ26/CERT which are derived from alternative splicing
as mentioned above, exist in turn as different isoforms resulting from the
use of two translation initiation codons: the classical AUG codon and the
rare in frame ACG codon located upstream (-83) of the known AUG start
(Revert et al., 2008). We will refer to the additional GPBP/CERTL isoprotein
resulting from ACG translation initiation as GPBP/CERTLΣ128, since 128
additional amino acids are present at the amino terminus of the protein. It
is not yet known if also the GPBPΔ26/CERT mRNA is subject to the
alternative translation initiation.
A small number of mammalian mRNAs initiate translation from a non-AUG
CERT and GPBP: one protein-one function?
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Figure 3 GPBP/CERTL is expressed as multiple isoforms because of an alternative translation initiation.
GPBP mRNA, in addition to the traditional initiation codon, has a non-canonical translation initiation
site (ACG) located upstream of the known AUG. These conventional and alternative start sites result,
respectively, in the synthesis of two polypeptides of 77 and 91 kDa, harboring different amino
terminal domains that confer distinct functions to the isoforms and control their localizations. The
GPBP/CERTL 91 kDa product (GPBPS128) partly enters the secretory pathway where undergoes
covalent modifications to yield a 120 kDa polypeptide. Similarly, GPBPΔ26/CERT possibly exists as
different isoforms resulting from canonical (77 kDa) and non-canonical (91 kDa and 120 kDa) mRNA
translation initiation. Western blot analysis for GPBP proteins (modified from Mencarelli et al. 2009)
in rat cortical extract shows the presence of high molecular weight isoforms together with other lower
molecular bands products previously described, probably generated from the proteolysis of the
higher molecular weight isoforms.
codon, in addition to initiating at a downstream in-frame AUG codon. Such
mRNAs encode regulatory proteins such as proto-oncogenes, transcription
factors, kinases, or growth factors. Their translation initiation results in the
synthesis of proteins harbouring different amino terminal domains
potentially conferring on these isoforms distinct functions (Touriol et al.,
2003).
22
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GPBP/CERTL alternative initiation codons generate two primary
polypeptides of 77 and 91 kDa, respectively (Fig. 3), leading to the synthesis
of two protein isoforms with differential transcriptional activities and
different sub-cellular localizations as has been described previously for
proteins of the c-myc, FGF and VEFG families (Meiron et al., 2001; Prats et
al., 1989; Touriol et al., 2003). The 77 kDa polypeptide, resulting from
canonical translation, is secreted extracellularly. It is soluble and interacts
with type IV collagen in the extracellular matrix. The 26-residue Ser-rich
region is critical for GPBP/CERTL secretion (Revert et al., 2008) and the FFAT
domain is essential for GPBP/CERTL to enter the secretory pathway (Revert
et al., 2008).
The GPBP/CERTLΣ128 isoform resulting in the 91 kDa isoprotein remains
associated to membranes and it has been suggested that it regulates the
secretion of 77 kDa GPBP/CERTL (Revert et al., 2008).
GPBP/CERTLΣ128 enters the secretory pathway where it undergoes covalent
modifications to yield a 120 kDa polypeptide. However the type(s) of
posttranslational modification(s) that this isoform harbors is not yet known.
In eukaryotes the existence of bifunctional genes where a single transcript
serves as the template for synthesis of both a cytoplasmic isoform and a
mitochondrial isoform has also been postulated (Wang et al., 2003). Each of
these genes encodes mRNAs with distinct 5-ends which are generated from
two alternative in-frame initiation codons. Interestingly, the mitochondrial
forms can be translated from non-AUG codons on the long mRNA, whereas
the cytosolic forms are translated from the second in-frame AUG on the
short mRNA. As a consequence, the mitochondrial enzymes have the same
polypeptide sequences as their cytosolic counterparts, except for a short
amino-terminal mitochondrial targeting sequence (Chen et al., 2009; Tang
et al., 2004). Although so far no direct evidence has been obtained to verify
this hypothesis, recent discoveries indicated a possible role of GPBPs in
mitochondrial function (Wang et al., 2009). So far only a cytoplasmic 77 kDa
iosform of GPBPΔ26/CERT has been described; however it is possible that
also alternative translation initiation isoforms with the amino acids encoded
by exon 11 exist.
A busy gene promoter
COL4A3BP has been found to localize head-to-head with POLK, the gene
encoding DNA polymerase k (Pol K) (Granero et al., 2005). Thus, the
promoters of COL4A3BP and Pol K are overlapping and bidirectional. Pol K is
a DNA polymerase that enhances the frequency of spontaneous mutations
and it plays a role in repairing DNA damage by facilitating base pairing at
CERT and GPBP: one protein-one function?
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aberrant replication forks (Ohashi et al., 2000; Zhang et al., 2000). These
mutations are important when they are introduced into the immunoglobulin
genes of B cells, because they lead to a variety of mutant antibodies with can
be selected for high affinity binding to antigens (Faili et al., 2004). This
specific arrangement suggests the possibility that Pol K and GPBPs are
partners in specific cell programs. An augmented expression of both
COL4A3BP and POLK has been found in patients suffering from skin
autoimmune processes (Granero et al., 2005; Raya et al., 2000).
The bidirectional POLK/COL4A3BP promoter can be activated at three
different regulatory elements; an Sp1 site, a TATA-like sequence and a
nuclear factor kappa B (NFkB)-like site. When Sp1 and NFkB form a complex
containing predominantly Sp1 compared to NFkB, the transcription is more
efficient in the POLK direction. It was shown that tumor necrosis factor (TNF)
induced the transcription of this promoter in the COL4A3BP direction
(Granero et al., 2005). TNF is a crucial pro-inflammatory cytokine mediating
many aspects of immunity (McCoy and Tansey, 2008). Thus the interaction
of TNF with the promoter of COL4A3BP might explain the increased
expression of GPBPs found in several autoimmune disorders. COL4A3BP
promoter activation by other cytokines has not been reported to our
knowledge.
Functional differences between GPBP/CERTL and CERT/GPBPΔ26
Despite the similarity of GPBP/CERTL and CERT/GPBPΔ26 with respect to
their domain organization, several observations suggest important
functional differences between these two splice variants.
Both GPBP/CERTL and CERT/GPBPΔ26 exist as oligomers under native
conditions: they self-associate in vivo to form high molecular weight
aggregates mainly stabilized by non-covalent bonds. The presence of the 26-
residue-serine rich motif in GPBP/CERTL increases this interaction and the
specific kinase activity. Moreover, it allows GPBP/CERTL to be secreted
extracellularly where it exists as a soluble form (Revert et al., 2008).
GPBP/CERTL is able to bind collagen type IV with high affinity, in contrast to
GPBPΔ26/CERT which has low-affinity binding to collagen (Raya et al., 2000).
It was demonstrated that GPBP/CERTL is a non-conventional serine/threonin
kinase active towards extracellular matrix proteins that might contribute to
their proper organization and supramolecular assembly.
GPBPΔ26/CERT is the most common transcript in cells and widely expressed
in normal human tissues, whereas GPBP/CERTL shows preferential
expression in brain, skeletal muscle and heart. Moreover, GPBP/CERTL is
expressed in tissues targeted by autoimmune responses including human
24
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alveolar and glomerular basement membrane, the biliary ducts and the
Langerhans islets (Raya et al., 2000). Overexpression of GPBP/CERTL in mice
causes dissociation of the glomerular basement membrane and subsequent
accumulation of IgA in the absence of an evident autoimmune response
(Revert et al., 2007).
Both isoforms can mediate ceramide transfer from the ER to the Golgi
complex (Hanada et al., 2003), a process critical for the synthesis and
maintenance of normal levels of sphingolipids in mammalian cells. However
the question remains if GPBP/CERTL is able to transport ceramide to other
subcellular localizations including the extracellular milieu and if the function
as a ceramide transporter is related to collagen interaction.
Various animal models have clearly pointed the different role of the two
splicing variants. In zebrafish GPBP/CERTL is mostly expressed at early stages
of embryogenesis compared to GPBPΔ26/CERT, and its knockdown
selectively induces apoptosis in muscle and brain during early development
(Granero-Molto et al., 2008). In Drosophila only the GPBPΔ26/CERT isoform
is present (Fig. 3). Loss of functional GPBPΔ26/CERT in these flies resulted in
changes in membrane properties and decreased physiological functions
caused by increased oxidative stress. In contrast they did not develop
neuronal degeneration in the brain and the aged phenotype that the
animals show is not due to specific damage in the nervous system (Rao et
al., 2007). Homologs of key enzymes belonging to the sphingolipid metabolic
pathway have been discovered in Drosophila melanogaster, making this an
optimal model to study the effects of dysregulation of sphingolipid
metabolism on nervous system development, function and integrity.
Therefore, the presumed lack of GPBP/CERTL isoform here would indeed
merit further investigation.
In rat brain GPBPs are widely distributed and have a higher expression levels
in neurons compared to other cell types (Mencarelli et al., 2009). The
presence of high levels of ceramide and its related metabolic enzymes in
neurons throughout the brain might require a strong expression of its
transporter. Which specific isoform is responsible for this generalized brain
expression still remains to be investigated.
GPBPs, FAPP2 and OSBP1: a structure in common
The intense interest elicited by the lipid-transfer proteins over the last few
years has been driven by the crucial role of lipids in cell, tissue and organ
physiology as demonstrated by many human diseases that involve the
disruption of lipid metabolism. Like GPBPs, other proteins with putative lipid
CERT and GPBP: one protein-one function?
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transfer activity are potentially able to mediate lipid metabolic pathways
and membrane trafficking events in the cell. Specifically, two of them share
similar protein domain organizations with GPBPs: oxysterol-binding protein
(OSBP) (Ridgway et al., 1992) and phosphatidylinositol four-phosphate-
adaptor protein 2 (FAPP2) (Godi et al., 2004) which are both characterized
by a highly homologous N-terminal plecktrin homology (PH) domain that
binds PI4P at the Golgi complex. Beside the PH domain, they also have a
distinct lipid binding/transfer domain at their C-terminus (Fig. 4).
Figure 4 Domain organization of lipid binding/transfer proteins GPBPs, OSBP1 and FAPP2. PH
(pleckstrine homology domain), SR1/SR2 (serine rich domain), PRD (proline rich domain), FFAT (two
phenylalanine in an acidic tract), GLTP (glycolipid transfer protein domain), START (StART related lipid
transfer domain), OSBP (oxysterol binding domain)
OSBP1 is a member of a family of sterol-binding proteins with roles in lipid
metabolism, regulation of secretory vesicle generation and signal
transduction (Lagace et al., 1997; Lagace et al., 1999). It is an 807 aa protein
that comprises, besides an N-terminal PH domain, a FFAT motif that binds
the integral ER membrane proteins VAP-A and VAP-B, and an oxysterol-
binding domain (OxBD). The other members of the family are referred to as
OSBP-related proteins (ORPs), with a highly conserved OSBP-type sterol-
binding domain at the C-terminus (Lehto and Olkkonen, 2003), each subject
to tissue-specific transcriptional regulation (Lehto et al., 2001).
OSBP1 acts at the interface between the ER and the Golgi complex and could
be a mammalian sterol-transfer protein (Ridgway et al., 1992). Consistent
with the high cholesterol content of the brain, OSBP1 and many other ORPs
are highly expressed in the CNS (Laitinen et al., 1999).
FAPP2 is a 507aa protein, with an N-terminal PH domain, a proline rich
domain (PRD) and a glycolipid-transfer-protein (GLTP) homology domain at
its C-terminus. The presence of this GLTP domain raises the interesting
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possibility that FAPP2 itself is a glucosylceramide (GlcCer) transporter
towards appropriate sites for the synthesis of complex glycosphingolipids
(GSLs) (D'Angelo et al., 2007). GSLs constitute a major component of
neuronal cells and are thought to be essential for brain function, as GSL
deficiency has been shown to lead to a down-regulation of gene expression
sets involved in brain development and homeostasis. This trafficking
function of FAPP2 indicates a crucial role for this protein in determining the
lipid composition of the neuronal plasma membrane.
Considering that these proteins have similar binding partners at the Golgi
apparatus (the PI4P through their PH domain) and at the ER (VAPs through
FFAT domain of GPBPΔ26/CERT and OSBP1), a probable cross-interaction
between them is possible.
According to this, it has been shown that OSBP1 can regulate sphingomyelin
synthesis by interacting with GPBPΔ26/CERT, promoting its binding with
VAPs and consequently enhancing GPBPΔ26/CERT-dependent ceramide
transport to the Golgi complex (Perry and Ridgway, 2006). A mutant of
OSBP1 was found to limit transport of a fluorescent ceramide analogue to
sites in the ER, suggesting that the function of OSBP1 involves the transport
of ceramide from ER to the Golgi sites where sphingomyelin synthase is
active (Wyles et al., 2002). The shift of OSBP1 to a Golgi location upon 25OH
(hydroxycholesterol) treatment of cells coincides with Golgi translocation
and activation of GPBPΔ26/CERT (Perry and Ridgway, 2006). Thus,
localization of GPBPΔ26/CERT at the Golgi apparatus seems to be OSBP-
dependent and correlated with increased SM synthesis and ceramide
transport (Perry and Ridgway, 2006). Taken together these observations
suggest that OSBP1 acts as a sterol sensor whose function is to integrate,
possibly via regulation of GPBPΔ26/CERT function, the cellular sterol status
with sphingomyelin metabolism (Olkkonen et al., 2006).
A pleiotropic ceramide
Ceramide is a precursor for the biosynthesis of all complex sphingolipids, as
it is a product of their degradation. It is composed of an N-acylated (14 to 26
carbons) sphingosine (18 carbons). It has been suggested that ceramide and
other sphingolipids found in the phospholipid bilayer membranes are not
only building blocks that confer structural rigidity by virtue of their ability to
form strong hydrogen bonds (Zhang et al., 2009). Besides their structural
role, sphingolipids participate in a variety of activities in diverse cellular and
developmental events and they seem to act as lipid second messengers
involved in many biological events spanning from cell growth (Jayadev and
Hannun, 1996; Schwarz and Futerman, 1997; Spiegel and Merrill, 1996),
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apoptosis (Bose et al., 1995; Gulbins et al., 1995; Haimovitz-Friedman et al.,
1997; Hannun and Obeid, 1995), lifespan (Cutler and Mattson, 2001;
Hannun, 1996; Wang et al., 1999), and vesicular trafficking to neuronal
differentiation and functioning (Bieberich et al., 2001; Toman et al., 2000).
Moreover, data in the fields of immunology, endocrinology and
neurobiology also suggest a fundamental involvement of ceramide in the
onset of several diseases (Mathias et al., 1998; Merrill et al., 1997; Pandey
et al., 2007; Venable et al., 1995). These aspects will be discussed more
extensively later on.
Ceramide production can occur in different ways: de novo synthesis by a
synthase, sphingomyelin-(SM) hydrolysis by various sphingomyelinases
(SMases) or recycling of sphingolipids by different hydrolases (Perry and
Hannun, 1998). Enzymes involved in each of these ceramide generation
pathways are located in distinct subcellular compartments. Since ceramide
is very hydrophobic compared to other lipid species, its concentrations in
the cytosol are extremely low and its molecule is usually trapped in the
membrane where it is formed (Venkataraman and Futerman, 2000). This
hydrophobicity tends to isolate pools of ceramide in different subcellular
compartments. It has been proposed that the compartmentalization of
ceramide might have regulatory functions in the cell (Bionda et al., 2004;
Kolesnick et al., 2000; Liu and Anderson, 1995). The discovery of ceramidase
enzymes in most of the organelles (ER, Golgi, mitochondria, lisosome and
plasma membrane) (El Bawab et al., 2000; Li et al., 1999; Mao et al., 2003;
Tani et al., 2005; Xu et al., 2006) support this view. To better understand the
involvement of GPBPs in cellular biology it is important to review all the
different ways of ceramide production inside the cell.
De novo synthesis of ceramide
De novo synthesis of ceramide requires coordinate action of different
enzymes along a subsequent series of reactions which occur both at the
cytosolic surface of the ER (Perry and Hannun, 1998) (Fig. 5 (1)) and in the
mitochondrial outer and inner membranes (Fig. 5 (1)) (Bionda et al., 2004;
Shimeno et al., 1998). The de novo ceramide biosynthesis, which starts with
the condensation of a serine and a fatty acyl-coA, involves the key enzyme
ceramide synthase (Ichikawa et al., 1996) which catalyzes the acylation of
either sphinganine to form dihydroceramide or sphingosine to form
ceramide. In mammals ceramide synthase, in contrast to the rest of the
enzymes of sphingolipid metabolism, exists as a family of multiple isoforms,
six in humans and mice and each isoform exhibits varying substrate
selectivity and cell specificity (Venkataraman and Futerman, 2000). This
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pathway needs several hours to generate detectable amounts of ceramide
(Bose et al., 1995). Once formed, ceramide is delivered to the luminal
surface of the Golgi membrane for sphingomyelin and glycosphingolipid
synthesis (Fukasawa et al., 1999; Kumagai et al., 2005). There are at least
two pathways by which ceramide is transported from the ER to the Golgi
compartment: an ATP and cytosol dependent major pathway (non vesicular,
GPBPΔ26/CERT mediated) (Hanada et al., 2003) and an ATP or cytosol
independent minor pathway (vesicular transport) (Brugger et al., 2000).
Once in the Golgi apparatus, ceramide can serve as a precursor for
glycosphingolipids or it can be converted to sphingomyelin (SM) by SM
synthase 1 (SMS), that is localized in the trans Golgi region (Fig. 5 (2)) and
catalyzes the transfer of phospatidylcholine to ceramide to produce SM
(Yamaoka et al., 2004).
The downregulation of CERT by RNA interference resulted in a significant but
incomplete reduction of basal SM synthesis but it has no effect on
glycosphingolipid synthesis (Hanada et al., 2003; Huitema et al., 2004).
Ceramide destined for the formation of SM reaches the Golgi by an ATP-
dependent, vesicle-independent transport pathway mediated by
GPBPΔ26/CERT and a minor ATP-independent transport vesicular pathway
(Fukasawa et al., 1999; Funakoshi et al., 2000; Hanada et al., 2003; van Meer
and Holthuis, 2000). On the other hand ceramide destined for conversion to
glucosylceramide (GlcCer) (Fig. 5 (3)) appears to reach the Golgi only by
vesicular transport (Huwiler et al., 2000). This suggests separate ceramide
transport pathways for GlcCer and SM synthesis. GlcCer synthase has been
detected in both the ER and Golgi compartments (Schweizer et al., 1994);
therefore the synthesis of GlcCer may not depend exclusively on the ER-to-
Golgi transport of ceramide. In this regard it is noteworthy that
GPBPΔ26/CERT transfer activity varies according to the acyl chain lengths of
the ceramides. It preferentially transfers C16-18 ceramides rather than
longer ceramides (Kumagai et al., 2005). This correlates with the presence of
a C16-18 acyl chain SM in many tissues and cell lines. Through vesicular
transport, SM and glycosphingolipids reach the plasma membrane where
resides the enzyme SMS2 (Fig. 5 (4)), required for SM homeostasis
regulation of the intracellular levels of ceramide in plasma membranes
(Huitema et al., 2004).
From there, these lipids travel towards the outer, non-cytosolic surface of
the plasma membrane and all membranes of the endocytic system, where
they are eventually degraded.
CERT and GPBP: one protein-one function?
29
Figure 5 Ceramide can be generated by the activity of two general metabolic pathways. (i) The
anabolic pathway that occurs at the cytosolic surface of the ER from condensation of serine with acyl
CoA and acylation of the sphingoid base [de novo synthesis (1)]; once formed, ceramide is delivered
to the luminal side of the Golgi apparatus and converted to sphingomyelin by SMS1 (2) that catalyzes
the transfer of phosphocholine involving the hydrolysis of phosphotidylcholine (PPC) to diacylglycerol
(DAG); ceramide is also converted to glycosylceramide by (GlcCer) glucosylceramide synthase (GCS)
(3). GlcCer is further converted to more complex glycosphingolipids. There are separate ceramide
transporters for the SM and GlcCer synthesis, GPBPs for the former and vesicular flow for the latter.
(ii) The catabolic pathway, that takes place at the membrane of different organelles in which ceramide
is formed by the degradation of sphingomyelin by different sphingomyelinases (SMases) (4, 5).
Ceramide is also formed by the degradation of glycosphingolipids that occur in lysosome
compartments: hydrolisis of ceramide by ceramidases releases sphingosine, which can be further
converted to sphingosine1-phosphate by sphingosine kinase (Sphk) (5). Metabolism of cerebrosides
by cerebrosidase (CRS) also generates ceramide (6). Ceramide is also present in mitochondria where
it is synthesized via de novo pathway and/or activity of the acid sphingomyelinase (1, 4).
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Ceramide catabolic pathway
In contrast to the multi-step de novo pathway, the catabolic pathway for
ceramide generation involves the action of a single class of enzymes namely
sphingomyelinases (SMases). These enzymes are homologues of
phospholipase C, which hydrolyses the phosphodiester bond of SM yielding
ceramide and phosphocholine (Levade et al., 1986). Moreover, if the de
novo synthesis is found in the ER and in the mitochondria, the
sphingomyelin hydrolysis occurs in a variety of membranous systems
(Levade and Jaffrezou, 1999).
Currently five different enzymes have been identified and categorized in
acid, neutral and alkaline SMases that differ in catalytic properties,
subcellular localization, biological effects and probably in their mode of
regulation (Huwiler et al., 2000).
Acidic SMase (A-SMase) (Fig. 5 (5)) was the first sphingomyelin-hydrolysing
enzyme to be purified and it was originally described as an
endosomal/lysosomal hydrolase (pH 4.5-5) required for the turnover of
cellular membranes (Gatt et al., 1966). Sphingolipids, that reach lysosomes
via caveolar and or clathrin-dependent endocytosis, are mainly catabolised
within these organelles.
Impaired sphingolipid degradation, besides affecting a large variety of
cellular processes, has drastic effects on the nervous system, leading to
neurodegeneration, shortened lifespan and early death. In line with this,
several lipid storage disorders are associated with significant progressive
brain degeneration, as discussed below.
Ceramide and GPBPs in mitochondria
Mitochondria contain ceramide with a three-fold higher concentration in
the outer membranes than the inner membranes (Ardail et al., 2001). These
organelles also contain the enzymes responsible for the synthesis (Shimeno
et al., 1998) and hydrolysis of ceramide (El Bawab et al., 2000). The synthesis
of ceramide occurs in the mitochondrial outer and inner membranes (Fig. 5
(1 and 4)) (Bionda et al., 2004). Thus mitochondria have mechanisms for
regulating the level of ceramide. Importantly, mitochondrial ceramide levels
have been shown to be elevated prior to the induction phase of apoptosis
(Birbes et al., 2005; Rodriguez-Lafrasse et al., 2001; Siskind, 2005; Thomas et
al., 1999). In fact, many death signals, including TNF-α, influence
mitochondria function through the activation of pro-apoptotic members of
the Bcl-2 family (Gross et al., 1998).
TNF treatment of cells resulted in increased mitochondrial ceramide levels
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that were associated with Bax translocation to mitochondria (Birbes et al.,
2005). Interestingly TNF is also able to increase the mRNA levels of GPBPs
(Granero et al., 2005).
It is important to mention that most of the experiments with cells and
isolated mitochondria have been carried out using short chain permeable
ceramides in which an acetyl or hexanoyl group replaces the natural long-
chain fatty acid (C2- and C6-ceramide). Ceramides have been reported to
have numerous effects on mitochondria, including the inhibition and/or
activation of the activities of various components of the mitochondrial
electron transport chain (Gudz et al., 1997; Siskind and Colombini, 2000),
the enhanced generation of reactive oxygen species (Zamzami et al., 1995)
and release of intermembrane space proteins (Ghafourifar et al., 1999),
probably by forming large protein permeable channels in planar
phospholipid and mitochondrial outer membranes (Siskind, 2005).
For GPBPs also a function in mitochondria integrity has been described:
mice lacking both GPBP/CERTL and GPBPΔ26/CERT die early in
embryogenesis as a result of structural and functional defects not only in the
ER but also in the mitochondria: both organelles show proliferation,
vesiculation and engorgement appearing aberrant with gross structural
changes and functional defects (Wang et al., 2009). The impact of deficient
ceramide transporters on mitochondrium integrity and functioning is a
surprising finding. These results point to GPBPs as important effectors for
mitochondrial homeostasis. They could exert their action in principally two
different, albeit interconnected, mechanisms: either transferring directly
ceramide outside the mitochondrium or shuttling this hydrophobic lipid
within its complex structure. In both views the loss of GPBPs could lead to
the detected changes in the physiological state of this organelle. The double-
membrane system divides the mitochondrium in two aqueous
compartments, the intermembrane space and the matrix. Due to the highly
insoluble nature of ceramide, there is a large energy barrier inhibiting the
movement of the molecule in these compartments that could give an
explanation for the presence of the ceramide transporters (Goni and Alonso,
2006; Small, 1970; Sot et al., 2005). Ceramide and its related enzymes could
presumably affect membrane dynamics and contribute to crista
reorganization (Montes et al., 2002; Scorrano et al., 2002; Veiga et al., 1999).
Mitochondrial membrane reassembly is required to control many metabolic
processes. Maintenance of normal crista structure is essential for
mitochondrial function (Mannella, 2006). Generation of the characteristic
cristae appearance has been linked to the conduction of protons that
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participate indirectly in ATP synthesis in mitochondrial respiration (Arnoult
et al., 2005; Paumard et al., 2002). In all these dynamic events GPBPs could
quickly redistribute ceramide.
The lack of CERT/GPBPΔ26 in Drosophila, which as aforementioned does not
have the CERT/GPBPL isoform, affects plasma membrane fluidity and
initiates oxidative stress. Flies are viable and fertile even though they die
prematurely as a result of accelerated aging (Rao et al., 2007). The impact of
GPBPs knock-out on mouse embryos causes a series of pathological changes
in ER and mitochondria. This different development in mice supports the
idea that it is the lack of the GPBP/CERTL isoform which is responsible for
this phenotype rather than CERT/GPBPΔ26 which is mostly involved in the
transfer of lipids in different intracellular compartments to ensure correct
lipid synthesis and distribution (Hanada et al., 2007).
CHO cells (Ly-A) which carry a missense mutation in the PH domain of
CERT/GPBPΔ26 do not show mitochondrial defects but only impairment of
SM synthesis (Funakoshi et al., 2000) since the latter is strictly dependent on
CERT transport of ceramide (Hanada et al., 2003). So it is intriguing to
speculate that as these cells do not have mitochondrial impairments, maybe
the GPBPs isoforms related to mitochondria do not need the PH domain to
be functional in these specific organelles. This would also explain why GPBPs
are expressed as different isoforms (Revert et al., 2008).
These studies suggest intimate and direct connections between ceramide,
GPBPs and mitochondria. Interestingly, tissues that show a higher
expression of GPBP/CERTL are brain, muscle and testis, organs that are by
definition highly dependent on aerobic metabolism. The CNS has an
immense metabolic demand because neurons are highly differentiated cells
that need large amounts of ATP for maintenance of ionic gradients across
the cell membranes and for neurotransmission (Kann and Kovacs, 2007).
Since most neuronal ATP is generated by oxidative metabolism, neurons
critically depend on mitochondrial function and oxygen supply (Kann and
Kovacs, 2007). In concordance with this neurons contain high levels of
GPBPs (Mencarelli et al., 2009).
Ceramide and GPBPs in the central nervous system
Among the tissues of the body, the nervous system is one of the richest in
lipid content. Sphingolipids and other complex glycosphingolipids are highly
represented in the brain where they were first discovered more than a
century ago by J. L. W. Thudichum (1884) (van Echten-Deckert and Herget,
2006). They do not only have a structural function but they act as important
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molecular tools in regulating multiple biochemical cell activities (Hannun
and Obeid, 2002; Radin, 2003; Tepper et al., 1999).
Ceramide has been implicated as a prominent mediator in a remarkable
array of cellular processes through a variety of complex pathways induced
by numerous agonists and environmental stimuli. Neurons, as might be
expected, share with other cell types the same wide range of responses
mediated by this pleiotropic lipid.
The nervous system comprises many events of morphological and
biochemical changes during the entire adult life. Generation, shaping and
reshaping of the complex spatial organization, neuronal and glia
differentiation, processes of synaptogenesis and neuritogenesis are typical
phenomena characterizing the nervous system (Nieto-Sampedro and Nieto-
Diaz, 2005). In all these regulated events, of primary importance is the
membrane lipid composition which determines cell surface properties
(Simons and Ehehalt, 2002). Ceramide modulates membrane structure and
dynamics, associates with cholesterol and other sphingolipids and forms
microdomains called lipid rafts. In neurons, lipid rafts accumulate
preferentially on somal and axonal membranes and in the post-synaptic sites
(Suzuki, 2002). Lipid rafts play an important role in neuronal adhesion and in
the modulation of neuronal ion channels, neurotransmitter receptors and in
neurotransmitter release (Chamberlain et al., 2001).
Besides its structural role, ceramide involvement in cellular signaling has
been extensively studied in the CNS and it has become clear that ceramide
content and its spatial/temporal distribution change to some extent during
aging, neuronal survival and apoptosis. Interestingly, information is
beginning to emerge pointing to ceramide levels as triggers of neural
development, differentiation, rate of growth and other cellular physiological
events.
In neurons an increase in ceramide level, originating from neosynthesis
and/or SM degradation, inhibits their proliferation and concomitantly
induces differentiation (Riboni et al., 1995). In glioma cells, elevated
ceramide levels cause growth arrest and process formation (Dobrowsky et
al., 1994). The raised intracellular ceramide levels occur very early and
persist during the differentiation of the cell. Normal ceramide levels are
reestablished after cell differentiation indicating a key role for ceramide in
this process (Riboni et al., 1995).
While ceramide stimulates cell differentiation in unspecialized cells, in post-
mitotic neurons ceramide acts preferentially by accelerating the transition
of neuronal development stages.
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Maturation of cultured granule neurons is associated with an increase of
ceramide levels in sphingolipid rich domains (Prinetti et al., 2001) and
ceramide seems to be essential for cell axon and dendritic growth of
neurons. Ceramide signaling in hippocampal neurons in culture elicits the
early transition of a rounded cell lacking neurites towards one exhibiting
small extended lamellopodia and minor processes (Brann et al., 1999).
Ceramide is also required for the subsequent axonal elongation of neurons
in order to acquire the normal mature phenotype (Brann et al., 1999;
Ledesma et al., 1999; Mitoma et al., 1999). This effect of ceramide is dose-
dependent; lower concentrations of the lipid stimulate cellular growth
whereas higher concentrations induce cell death (Furuya et al., 1998; Irie
and Hirabayashi, 1998). However, ceramide synthesized de novo is not
involved in axonal outgrowth since the development of hippocampal
neurons is not altered by treatment with fumonisin B1, an inhibitor of the
ceramide de novo synthesis. In contrast, the ceramide responsible for
neuronal development is generated via a neutral-SMase (N-SMase) in
response to nerve growth factor (NGF) (Brann et al., 1999), a member of the
neurotrophin family that controls the development of the nervous system in
the embryo and the maintenance of nervous tissue and neural transmission
in the adult (Levi-Montalcini, 1987). The binding of the NGF to the p75
receptor induces N-SMase activation (Brann et al., 1999). N-SMase is the
major form of SMase found in the brain and its expression increases in rat
brain with neuronal maturation (Spence and Burgess, 1978). A-SMase
(reviewed in section "Ceramide catabolic pathway") is highly expressed in
brain cells but its expression level does not change significantly during
development (Spence and Burgess, 1978). A-SMase activation appears to
mediate signaling pathways that induce programmed cell death. Many
studies have presented evidence of ceramide production via A-SMase in
response to apoptotic signals, most notably generated by members of the
NGF/tumor necrosis factor receptor family (Kronke, 1999; Verheij et al.,
1996). A-SMase-deficient mice mimic the lethal, neurovisceral form of the
human sphingomyelin storage disease, known as Niemann-Pick disease
(Otterbach and Stoffel, 1995) (review in the next section).
Excitotoxic cell death, induced after an intense exposure of the neuronal cell
to glutamate or related excitatory amino acids (Choi, 1992), is partially
abolished in A-SMase-deficient neurons. On the other hand, A-SMase-
deficient and wild type neurons are both susceptible to NGF induced
apoptosis (Furuya et al., 1998; Irie and Hirabayashi, 1998). It has been
suggested that N-SMase responds also to high ceramide levels inducing
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neuronal death rather than accelerating axonal outgrowth (Brann et al.,
2002).
The fate of the cell seems to depend exclusively on intracellular ceramide
levels (Brann et al., 1999). Interestingly, in immature neurons apoptosis is
induced even at lower doses of ceramide than in mature neurons (Furuya et
al., 1998; Mitoma et al., 1998). Probably, at certain levels and depending on
developmental stages, ceramide reaches a threshold required for an
apoptotic response.
Experimental manipulations that increase intracellular ceramide level (e.g.
exposure to exogenous ceramide analogs or treatment with bacterial
SMases) potently induce apoptosis in differentiating mammalian cells
(Hannun and Obeid, 1995).
There is good evidence that ceramide synthesized de novo also plays an
important role in neuronal death with the same apoptotic features as
ceramide generated from SM. Indeed, the inhibition of the de novo
biosynthesis by fumonisin B1 stops apoptosis induced by DNA-damaging
agents and TNF. A considerable amount of programmed cell death takes
place in the nervous system during development. In neurodegenerative
diseases neuronal death also occurs extensively. Neurons may use different
apoptotic mechanisms during development or pathological conditions and
ceramide metabolism seems to be a crucial target in both physiological
death and disease. In summary, ceramides have both a structural and a
signaling function in the brain. At present the potential role of ceramide
metabolism points to questions yet to be addressed and more in depth
studies of the ceramide transporters in the CNS will stimulate new avenues
of research in this exciting area.
Ceramide in neurodegenerative diseases
A balance between specific sphingolipids is essential for neuronal function
(Buccoliero and Futerman, 2003). When the sphingolipid metabolism is
dysregulated as in Gaucher, Krabbe or Niemann-Pick disease,
neurodegeneration occurs (Jeyakumar et al., 2002).
Gaucher disease (GD) is caused by mutations in the gene encoding for
glucosylceramidase, an enzyme that catalyzes the hydrolytic cleavage of
glucose from glucocerebrosides to form ceramides during lysosomal
degradation of sphingolipids (Brady et al., 1965). Without
glucosylceramidase, glucocerebroside and related lipids can build up to toxic
levels within cells. Abnormal accumulation and storage of these lipids could
affect calcium homeostasis and contribute to synuclein aggregation,
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neurodegenerative changes and neuronal loss (Manning-Bog et al., 2009;
Pelled et al., 2005).
Krabbe disease is cause by a deficiency of the lysosomal enzyme
galactosylceramidase, which is needed for the conversion of
galactosylceramide to ceramide. The disease is characterized by myelin
disorganization (Pastores, 2009) resulting from accumulation of
incompletely metabolized galactosylceramide.
Niemann-Pick disease refers to a group of lipid storage disorders as well. In
the A and B subtype SMase is deficient with the consequent accumulation
of sphingomyelin (Brady et al., 1966). Type C is characterized by excessive
intracellular accumulation of unesterified cholesterol (Blanchette-Mackie et
al., 1988). The subtypes of this disease have an extremely varied clinical
presentation, but all are characterized by a range of progressive neurological
manifestations (Futerman and van Meer, 2004).
In Farber disease, an increase in ceramide levels, resulting from ceramidase
deficiency, leads to mental retardation and motor dysfunction (Bar et al.,
2001). It is characterized by an accumulation of lipids and patients
frequently die before the age of 2 years.
Beside genetic mutations that affect the functionality of the enzymes
involved in the sphyngolipid metabolism, many stress signals can induce
ceramide overproduction, like cytokines (TNFα, interleukin 1β, Fas ligand),
nitric oxide (NO), and environmental stresses (UV/ionizing radiation, heat
shock and oxidative stress) (Hannun, 1996; Hannun and Obeid, 1995;
Jayadev et al., 1995; Venable et al., 1995; Verheij et al., 1996). Interestingly,
all the pathways involved in ceramide generation participate in response to
these agents (Fig. 5) (Hannun and Luberto, 2000; Kolesnick and Kronke,
1998). The precise nature of ceramide-intracellular targets is controversial
and varies depending on the cell types.(Hannun, 1996; Kolesnick and
Hannun, 1999; Okazaki et al., 1998; Pettus et al., 2002)
Many reports have emphasized the role of ceramide in neurodegenerative
disorders to the extent that serum ceramides have been indicated as early
predictors of cognitive impairment (Mielke et al., 2008). Alterations in
ceramide levels were also detected in the cerebrospinal fluid of AD patients
due to inhibition of the ceramide-metabolizing enzyme GlcCer synthase
(Satoi et al., 2005). It has been found that AD brains contain approximately
three fold more ceramide when compared to age matched controls (Cutler
et al., 2004). Brain regions with extensive β-amyloid plaques (cortex and
hippocampus) were characterized by higher ceramide levels and decreased
SM content (Cutler et al., 2004) and the activity of the enzyme ceramidase
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was found to be elevated, perhaps in response to high ceramide
concentration (Huang et al., 2004). A shift in sphingolipid metabolism
towards upregulation of gene expression of the enzymes controlling de novo
synthesis of ceramide and downregulation of the enzymes involved in
glycosphingolipid synthesis was also evident in early stages of AD.
In vitro exposure of hippocampal neurons to Aβ peptide induces membrane
oxidative stress resulting in perturbed ceramide metabolism. Several studies
have shown that Aβ induces apoptosis via the SM/ceramide pathway in
various brain cells including human and rat primary neurons (Jana and
Pahan, 2004; Malaplate-Armand et al., 2006), rat oligodendrocytes (Cheng
et al., 2003; Lee et al., 2004; Malaplate-Armand et al., 2006; Zeng et al.,
2005), rat astrocytes and glial cells (Ayasolla et al., 2004) and murine
neuroblastoma cells (Obeid et al., 1993; Satoi et al., 2005). The composition
of lipid rafts including SM, cholesterol and ceramide controls amyloid
processing and aggregation. It was shown that β- and 
γ-cleavage of APP occurs inside rafts and both β- and γ-secretase are lipid
raft associated (Rajendran and Simons, 2005; Simons and Vaz, 2004; Vetrivel
et al., 2004). The accumulation of Aβ peptide derived from this process
starts in early endosomes and has been shown to be subsequently released
into the extracellular space in association with exosomes (Rajendran et al.,
2006). Ceramide is highly enriched in exosomes and -possibly thanks to its
cone-shaped structure- it regulates biogenesis and dynamics of membrane
budding (Trajkovic et al., 2008). Whether ceramide per se also plays a role in
mediating Aβ aggregation/disaggregation remains unknown.
OSBP1, which regulates ceramide transport and SM synthesis, has been
found to be involved in the regulation of amyloid precursor protein (APP)
processing (Zerbinatti et al., 2008). Overexpression of OSBP1 downregulates
the amyloidogenic processing of APP: the presence of OSBP1 at the Golgi
complex triggers ceramide transporter activity leading to increased SM
synthesis and consequently reducing ceramide levels. Knockdown of OSBP1
has the opposite effect, thus an increase of ceramide and reduced SM
synthesis, leading to increased Aβ production and aggregation (Zerbinatti et
al., 2008). However, the role of OSBP1 in amyloid processing and regulation
of ceramide levels is still under discussion.Together with the
abovementioned processing of APP, also post translational refolding of
normal prion protein is affected by the content of sphingomyelin,
cholesterol and ceramide in lipid rafts at the level of the plasmatic
membrane (Baron et al., 2002; Kivipelto et al., 2001; Simons et al., 2001;
Taraboulos et al., 1995). If this is the case, abnormal composition of the lipid
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rafts could cause a defective protein folding and trigger consequently the
protein aggregation process, a hallmark of many neurodegenerative
diseases. Ceramides have also been implicated in the pathological death of
neurons that occurs in Parkinson's disease (PD) (Brugg et al., 1996).
Dopaminergic neurons in primary cultures derived from the
mesencephalon, a primary region of neuronal degeneration in PD, undergo
apoptosis through a ceramide-dependent mechanism (Brugg et al., 1996).
TNFα receptors have been found on dopaminergic neurons that degenerate
in PD and TNFα-immunoreactive glia have been detected in close proximity
to degenerating neurons (Boka et al., 1994). Importantly, TNF induces
COL4A3BP expression by regulating the interaction of NFkB with the
COL4A3BP promotor (Granero et al., 2005). NFkB has also been found to be
augmented in the nucleus of dopaminergic neurons in parkinsonian
patients. Thus, it is expected that the augmented levels of TNF and of NFkB
will activate COL4A3PB leading to an increase in GPBPs levels. Higher levels
of the ceramide transporter in this context might help to reduce the
abnormal ceramide concentration and therefore attenuate downstream
effects of ceramide. Moreover, some of the genes involved in the genetics of
Lewy body disease are strictly linked to ceramide metabolism (for review,
see (Bras et al., 2008)). In this regard it has been reported that a knockdown
of the ceramide synthase LASS2 in Caenorhabditis elegans, results in
increased alpha-synuclein inclusions (van Ham et al., 2008). Therefore,
ceramide and its transporters could play a role in protein inclusions
formation. 
Moreover, Sidransky and colleagues found that heterozygous mutations that
occur in the enzyme glucosylcerebrosidase predispose to PD (Aharon-Peretz
et al., 2004; Bras et al., 2009) and Lewy body disorders (Mata et al., 2008)
(Sidransky et al., 2009). Glucosylcerebrosidase is an enzyme that catalyzes
the breakdown of the lipid glucosylcerebroside, which is highly enriched in
the brain, to ceramide and glucose. This correlation between an increase of
ceramide content and the onset of the disease reveals a strong association
between ceramide metabolism and PD. 
Cellular ceramide levels are also important in the regulation of cellular
senescence (Venable et al., 1995). Endogenous levels of ceramide increase
considerably if compared with other lipids as cells enter the senescence
phase (Mouton and Venable, 2000) and exogenous doses of ceramide are
able to induce a senescent phenotype in young cultured cells (Lightle et al.,
2000; Mouton and Venable, 2000). Age-related increases in brain ceramide
and neutral SMase levels have also been reported (Palestini et al., 1993). The
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expression of the ceramide transporter in the CNS is widespread, with high
levels of GPBPs immunoreactivity in neurons of the cortex, hippocampus,
the basal ganglia, the olfactory bulb and some nuclei of the thalamus, the
hypothalamus and the septal area (Mencarelli et al., 2009). Interestingly,
glial cells do not show immunoreactivity for GPBPs suggesting that in this
cell type GPBPs are present at lower levels. In zebrafish, specific knockdown
of GPBP/CERTL is detrimental to normal embryonic development. In this
model the brain is affected, showing a clear reduction of the myelinated
tracts, thin axons, hydrocephaly of the 4 ventricles and apoptosis leading to
brain tissue loss (Granero-Molto et al., 2008).
Taken together, these findings document the significance of ceramides in
the pathophysiology of diverse neurological diseases. GPBPs are regulators
of ceramide which could contribute actively to induce profound changes in
cellular metabolism. The pathways that link this putative second messenger
to neuronal dysfunction remain elusive. Sorting through these complex
interrelationships will be essential to better understand neurodegeneration
in the CNS.
Conclusion
The present review brings together our current knowledge concerning the
isoproteins GPBP/CERTL and CERT/GPBPΔ26, that have generated
controversy regarding their roles in several cellular processes. Although our
understanding on their nature is still incomplete, the existing data allows us
to distinguish the two isoforms by diverse functions in the nervous system.
A deeper knowledge of the complexity of ceramides and GPBPs in cell
signaling will increase our understanding of cell dynamics in various CNS
disorders, opening new opportunities for drug development and therapies
for neurodegenerative diseases.
Take home messages
GPBP/CERTL and GPBPΔ26/CERT are two splice variants of 624 and 598 aa
respectively. GPBP/CERTL, in turn exists in two alternative translation
initiation isoforms, i.e. GPBP/CERTL and GPBPΔ28.
The isoproteins have identical amino acid sequences, except for the
presence of a 26 amino acid serine-rich domain in the GPBP/CERTL isoforms
and 128 additional amino acids in the GPBPΔ128 isoform.
All isoforms function as ceramide transfer proteins.
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GPBP/CERTL is expressed in tissues targeted by autoimmune responses.
Increased expression of GPBP/CERTL has been associated with immune
complex-mediated pathogenesis.
Increased GPBP/CERTL expression induces type IV collagen disorganization
and deposits of immunoglobulin A in glomerular basement membrane.
GPBPΔ26/CERT is a more common splice variant widely expressed
throughout the body.
GPBP/CERTL and GPBPΔ26/CERT, in turn, exist as different isoforms resulting
from canonical (77 kDa) and noncanonical (91 kDa) mRNA translation
initiation.
The 77 kDa GPBP/CERTL behaves as a soluble secretable protein and the 91-
kD GPBP/CERTL as a membrane-bound protein. The 77 GPBPΔ26/CERT is a
cytosolic isoforms.
TNF increases the mRNA levels of GPBPs.
GPBP/CERTL and GPBPΔ26/CERT are differentially expressed during
embryogenesis in zebrafish with GPBP/CERTL expressed at the earlier stage
than GPBPΔ26/CERT.
Specific GPBP/CERTL knockdown results in loss of myelinated tracks in the
CNS and to extensive apoptosis and tissue loss in the brain.
GPBPΔ26/CERT knockdown in Drosophila does not lead to neuronal
degeneration in the brain but in changes in membrane properties that
increase oxidative stress.
Mice lacking both GPBP/CERTL and GPBPΔ26/CERT die prematurely cause
structural and functional defects in the ER and mitochondria.
Neurons express more GPBPs, than astroglial cells.
Expression levels of GPBPs were observed widely throughout the brain.
GPBPs share similar protein domain organization with two other lipid
binding/transfer proteins, OSBP1 and FAPP2.
GPBPs are regulators of ceramide and could be involved in molecular
mechanisms underlying ceramide-mediated signaling cascades.
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Abstract
Ceramide, the precursor of all complex sphingolipids, is a potent signalling
molecule which mediates key events of cellular phatophysiology. In the
nervous system, the sphingolipid metabolism has an important impact.
Neurons are polarized cells and their normal functions, such as neuronal
connectivity and synaptic transmission, rely on selective trafficking of
molecules across plasma membrane. Sphingolipids are abundant on neural
cellular membranes and represent potent regulators of brain homeostasis.
Ceramide intracellular levels are fine-tuned and alteration of the
sphingolipid-ceramide profile contributes to the development of age-
related, neurological and neuroinflammatory diseases.
The purpose of this review is to guide the reader towards a better
understanding of the sphingolipid-ceramide pathway system. First,
ceramide biology is presented including structure, physical properties and
metabolism. Second, we describe the function of ceramide as a lipid second
messenger in cell physiology. Finally, we highlight the relevance of
sphingolipids and ceramide in the progression of different
neurodegenerative diseases.
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Introduction
Ceramides are a family of lipid molecules which consist of sphingoid long-
chain base linked to a fatty acid via an amide bond. Ceramides differ from
each other by length, hydroxylation and saturation of both the sphingoid
base and fatty acid moieties. 
Sphingoid bases are of three general chemical types: sphingosine,
dihydrosphingosine (commonly known as "sphinganine", as it will be
addressed in this review) and phytosphingosine. Based on the nature of the
sphingoid base backbone, we can distinguish 3 main subgroups in the
ceramide family: the compound named ceramide contains sphingosine,
which has a trans-double bond at the C4-5 position in the sphingoid base
backbone; dihydroceramide, the inactive precursor of ceramide, contains
sphinganine which presents a saturated sphingoid backbone devoid of the
4,5-transdouble bond; phytoceramide, the yeast counterpart of the
mammalian ceramide, contains phytosphingosine which has a hydroxyl
group at the C4 position (1) (Figure 1).
The fatty acid components of ceramides vary widely in composition, but
they are typically long. Their acyl chain lengths range from 14 to 26 carbon
atoms (or greater), although the most common fatty acids are palmitic
(C16:0) and stearic (C18:0) non-hydroxy fatty acids. The fatty acids are
commonly saturated or mono-unsaturated.  -Hydroxylated fatty acids (a
hydroxyl group at the C-2 position) and α-hydroxy fatty acid (a hydroxyl
group on the terminal C atom) are often present as well (2).
Activation of Ceramide
Small changes in the molecular structure of ceramide moiety can regulate its
biological function. Dihydroceramide is an early intermediate in the de novo
ceramide biosynthesis. Considered the innocuous precursor of ceramide,
dihydroceramide differs from ceramide only by reduction of the C4-5 trans
double bond in the sphingoid backbone making it inactive (3) or very weakly
active (4) when compared with ceramide moiety. The introduction of a
trans-double bond between C4 and C5 results in a biologically active
molecule. This double bond is introduced by the enzyme (dihydro)-ceramide
desaturase which is localized in the cytosolic leaflet of endoplasmic
reticulum (ER) membrane (5, 6). In this way cells can fine-tune the amount
of biologically active ceramide. The presence of the double bond in the
sphingosine chain determines the tilt of ceramides in the membrane and
enables the lipid to interact with enzymes such as hydrolases and
phosphatases (11). 
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Figure 1 Chemical structure of sphingoid bases (sphinganine, sphingosine, phytosphingosine) and
ceramide species (dihydroceramide, ceramide and phytoceramide ).
The typical phosphosphingolipid in mammalian cells is sphingomyelin, synthetized by the transfer of
the phosphorylcholine moiety to the C-1 hydroxyl group of ceramides. Alternatively, modification of
a ceramide by addition of one or more sugars directly connected at the primary alcohol group yields
complex glycosphingolipids. This class of lipid comprises: cerebrosides, sulfatides, globosides and
gangliosides. Cerebrosides have a single monosaccharide (glucose or galactose) as polar head group.
Sulfatides are the sulfuric acid esters of galactocerebrosides.  Globosides contain multiple sugar
moieties. Gangliosides have a complex oligosaccharide with one or more sialic acids as polar head.
Moreover, unsaturation in the sphingoid backbone augments intramolecular
hydration/hydrogen bonding in the polar region. This may allow the close
packing of the ceramide molecules which exhibit a tighter intramolecular
interaction than comparable lipids (7-9). This higher packing density of
ceramides within the lipid bilayer affects the physical properties of
membranes (10). 
Short chain ceramide
Synthetic short-chain ceramides (N-acyl chains of 2 to 8 carbon atoms) are
commonly used to mimic the mechanisms of action of naturally occurring
Ceramide function in the brain
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long-chain ceramides which are highly hydrophobic compounds.  Short-
chain ceramides are water soluble and membrane-permeable and can be
easily used as experimental tools within living cells (12-16). Small amounts
of C2-ceramide are normal components in brain (10 pmol/g) and liver (25
pmol/g) (17) although the metabolic origin and physiological activity of this
short ceramide are uncertain.
NMR characterization of C-2 and C-18 ceramides showed that the
conformation of the polar region of the two molecules is the same (8). Since
the interaction between ceramides and their ligand molecules probably
occurs through the polar head, the maintenance of the headgroup
conformation irrespective of N-acyl chain length is enough for C-2 ceramides
to reproduce most of the long-chain ceramides signaling effects. However,
the length of the fatty acyl chain modifies significantly the biophysical
properties of the ceramide moieties (18) and in some reports long- and
short-chain ceramides have been found to have different biological effects
(19, 20).
The major difference between short and long ceramides is in the
geometrical shapes they adopt at the membrane level that consequentially
gives rise to different behaviors. The hydrophobic portion of C-2 is smaller
than the polar headgroup. Therefore, C-2 has a shape that favors a positive
curvature in lipid monolayer (21). Long chain ceramides are cone shaped
molecules with opposite geometrical properties which induce a negative
curvature of the two halves of the bilayer towards the aqueous milieu,
leading to membrane trafficking via vesiculation and fusion (22, 23).
Moreover, long-chain ceramides increase the order of the acyl chains in the
bilayers, thus decreasing fluidity and stabilizing the membrane (24-26).
Conversely, short-chain ceramides perturb the structural order of the lipid
bilayer. Long chain ceramides are immiscible with phospholipids, while short
chain ceramides mix much better and are therefore able to spontaneously
overcome membrane barriers (27). Once inside the cell since they possess
the appropriate stereochemistry, short ceramides might bind target proteins
normally inaccessible for the longer species. On the contrary, naturally
occurring long-ceramides are eminently hydrophobic even compared to
other lipid species and as a consequence their concentrations in the cytosol
are extremely low. This hydrophobicity of ceramides justifies the need for a
ceramide transfer protein (CERT) in cells (28). CERT localises inside the cell
and modulation of its activity may result in significant changes in ceramide
levels (put ref for your paper). Therefore, since short chain ceramides
behaves as soluble amphiphiles (29), they are suspected to have cellular
effects that cannot be extrapolated to natural ceramide species (mainly
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insoluble amphiphiles) and their use might lead to confusion on the role of
ceramide in cellular signaling.
Ceramides as precursors of sphingolipids
Free ceramides are molecules known to exert a wide range of biological
functions in many of the most critical cellular events, including growth,
differentiation, apoptosis and oncogenesis. Ceramides are  the core
structure of a class of complex lipid called sphingolipids, ubiquitous
components of eukaryotic cell membranes (30). Sphingolipids were initially
described in brain tissue in the second half of the 19th century (31). The
name sphingolipids denotes their enigmatic (namely sphinx-like) nature
that, despite intense research, still arouses unanswered questions.
Sphingolipids have long been regarded as inactive and stable structural
components of the membrane; however they are now well recognized to be
biologically active in processes of cellular biology.
Sphingolipids are very heterogeneous and are classified depending on their
structural combinations in long-chain (sphingoid) bases, amide-linked fatty
acids (32) and hundreds of headgroup variants (33). 
Sphingolipids are generated by attachment of different polar headgroups at
the primary alcohol group (C1-OH) of a ceramide molecule. Depending on
the type of polar group, two major classes are classified:
phosphosphingolipids and glycosphingolipids (Figure 1). The typical
phosphosphingolipid in mammalian cells is sphingomyelin (SM), synthetized
by the transfer of the phosphorylcholine moiety (from phosphatidylcholine)
to the C-1OH of ceramides.
Alternatively, modification of a ceramide by addition of one or more sugars
yields complex glycosphingolipids. As a result of the great heterogeneity in
the glycan moiety, among glycosphingolipids, much variation exists. The
basic structure for a glycosphingolipid is a monosaccharide, usually glucose
or galactose, attached directly to the ceramide portion of the molecule,
resulting in glucosylceramide (glucocerebroside) and galactosylceramide
(galactocerebroside), respectively. When a single monosaccharide is
present, the glycosphingolipid is referred to as a cerebroside (also known as
monoglycosylceramides). The sulfuric acid esters of galactosylceramide are
the sulfatides. Galactosylceramide and sulfatide are highly enriched in
oligodendrocytes and myelin-forming cells compared to other membranes
(34). By contrast glucosylceramide are not normally found in neuronal cell
membranes. The core glycan moiety may be further extended by additional
monosaccharides which allow the classification of GSLs into subtypes
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according to their specific tetrasaccharide core structures: ganglio-, globo-,
lacto- and (neo)lacto-series GSLs. 
Globosides represent cerebrosides that contain additional carbohydrates
predominantly galactose, glucose or GalNAc. Gangliosides are very similar to
globosides except that they also contain a sialic acid residue such as N-
acetylneuraminic acid ('NANA' or 'SA' or 'Neu5Ac' or 'NeuAc'). Gangliosides
comprise approximately 5% of brain lipids and are mainly present in
astroglia, followed by neurons and oligodendrocytes. Polar carbohydrate
chains of glycosphingolipids extend toward the extracellular milieu, forming
specific patterns on the surface of cells, contributing to cell recognition
during differentiation, development and immune reaction (35). These
different types of sphingolipids can be converted back to ceramide by the
removal of the polar headgroup by specific enzymes.
Ceramide generation
Ceramides can be produced in cells either via the de novo synthesis or via
hydrolysis of complex sphingolipids (36). The activation of different catabolic
enzymes yields ceramide within a few minutes whereas the de novo
synthesis produces ceramide in several hours (37). Different extra- and intra-
cellular stimuli dictate the pathway used for ceramide generation resulting
in distinct subcellular localization of ceramide and different biochemical and
cellular responses.
De novo synthesis of ceramide takes place in the ER
In animal cells, ceramide is de novo-synthesized on the cytoplasmic face of
the smooth endoplasmic reticulum (ER) (5, 38) and in mitochondria (39, 40).
The de novo synthesis of ceramides in eukaryotes begins with the
condensation of serine and palmitoyl-CoA to form 3-ketosphinganine,
through the action of serine palmitoyl transferase (SPT) (Figure 2). This
enzyme is composed of two subunits: Lcb1 and Lcb2. Mutations in the
human Lcb1 gene underlie hereditary autonomous neuropathy, a
neurodegenerative disorder of the peripheral nervous system (41).
Subsequently 3-keto-sphinganine is reduced to the sphingoid base
sphinganine, which is subsequently N-acylated by (dihydro)-ceramide
synthase (CerS) to form dihydroceramide. The enzyme (dihydro)-ceramide
desaturase introduces the double bond to the position C4 to form
mammalian type ceramides (6, 42). 
CerS represents a key enzyme in the pathway for de novo sphingolipid
biosynthesis. Interestingly, these highly conserved transmembrane proteins
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are also known as human homologues of yeast longevity assurance gene
(LASS1).
Figure 2 Overview of the metabolic pathways involved in the synthesis of endogenous ceramide.
Ceramide can be formed by de novo synthesis, by degradation of complex SLs or by re-acylation of
sphingoid long-chain bases (salvage pathway). The de novo pathway involves several enzymatic steps. 
Through catabolic pathways ceramide is generated by either hydrolysis of the membrane lipid
sphingomyelin by the SMase enzymes or by lysosomal breackdown of complex glicosphingolipids.
Ceramide itself is degraded by ceramidase to regenerate sphingoid bases. The sphingosine formed is
then phosphorylated and finally degraded to phosphoethanolamine and C16-fatty aldehyde by the
action of the sphingosine-1-phospate (S1P) lyase.
A salvage pathway uses the enzyme ceramide synthase to produce ceramide from sphingosine. Once
generated, ceramide can serve as a substrate for the synthesis of sphingomyelin and
glycosphingolipids or be converted into various metabolites such as sphingosine or ceramide-1-
phosphate.
Six different CerSs (CerS1-6) have been identified in vertebrates and plants
(43), whereas most of the other enzymes involved in sphingolipids
metabolism exist in only one or two isoforms (43). Each CerS regulates the
de novo synthesis of endogenous ceramides with a high degree of fatty acid
specificity. In line with the presence of multiple CerSs, ceramides occur with
a broad fatty acids length distribution inside the cell. Although some CerSs
are ubiquitously expressed, other isoforms present a very specific
distribution among tissues, according to the need of each tissue for specific
ceramide species (44, 45). CerS1 specifically generates C18 ceramide and is
highly expressed in the brain and skeletal muscles but is almost
undetectable in other tissues. CerS2 mainly generates C20-26 ceramides and
has been found to have the highest expression of all CerSs in
oligodendrocytes and Schwann cells especially during myelination. The
selectivity of different CerS isoforms to synthesize different ceramide
species is important since ceramides with specific acyl chain lengths might
mediate different responses within cells (43). Fumonisins are toxic
mycotoxins with a very similar structure to sphingosine or sphinganine
which is a substrate for CerS. Since these fungal metabolites are able to
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inhibit CerS reaction, they are extensively used to study the role of ceramide
generated through the de novo pathway in the ER (46). On the contrary, the
mitochondrial CerS is not affected by fumonisins, suggesting that its activity
is distinct from the ER resident enzyme (39, 40). 
Neo-synthesized ceramides subsequently traffic from the luminal face of the
ER to the Golgi compartment where different polar heads are incorporated
into the ceramide molecule to form complex sphingolipids (47).
Ceramide transport from ER to the Golgi
The high hydrophobicity and low polarity of ceramide moiety limit free
ceramide to circulate inside the cell or more generally in solution. This may
explain the occurrence of several isoenzymes of ceramide biosynthesis at
different subcellular sites and supports the view that the site of ceramide
formation might determine its function.
On the other hand, the cell needs to transport ceramide from the ER to the
Golgi compartment for the synthesis of glycosphingolipids and SM.
Ceramides destined for conversion to glycosphingolipids appear to reach the
Golgi only via the classical vesicular route  (28). The step-wise addition of
sugar groups  to ceramides is catalyzed by membrane bound
glycosyltransferases and it is restricted to the ER-Golgi complex (57). This
process is followed by the exocytotic vesicular membrane flow of the
growing molecules from the cytosolic side of the Golgi cisternae to the
plasma membrane. 
On the other hand, ceramides destined for the formation of SM reach the
Golgi carried by the protein ceramide transporter (CERT) in a non-vesicular
manner (28, 48-50).  
CERT mediates the transfer of ceramides containing C14-C20 fatty acids but
not longer-chain ceramides (58). This correlates with the presence of a C14-
20 acyl chain SM in many tissues and cell lines whereas glycosphingolipids
are formed by longer ceramides. CERT, works as mediator of sphingolipids
homeostasis. Loss of functional CERT in Drosophila affects plasma
membrane fluidity and increases oxidative stress (59) and CERT is critical for
mitochondrial and ER integrity (60). Interestingly, CERT has an alternatively
spliced isoform characterized by the presence of an additional 26 amino
acids domain, responsible for its localization at the plasma membrane and
consequent secretion to the extracellular milieu, named CERTL or
Goodpasture antigen binding protein (GPBP) (61). These two isoforms are
differentially expressed during development. CERTL is more abundant at
early stages of embryonic maturation and its knockdown leads to severe
developmental deficit in muscle and brain because of increased apoptosis
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(62). As development progresses, the initially very low levels of CERT,
gradually increase. Both isoforms can be detected in adult brain (63). 
Other reports showed elevated CERTL expression levels to be associated
with several autoimmune disorder e.g. Lupus erythromatosus, multiple
sclerosis, myasthenia gravis, Addison disease (64). An efficient execution of
apoptotic signaling is important to inhibit inflammation and autoimmune
responses against intracellular antigens (65) and modulation of CERT/CERTL
levels has a direct influence in ceramide levels and could be responsible for
balancing cell death during embryogenesis and under pathophysiological
condition. 
Once delivered to the Golgi apparatus, ceramide spontaneously translocates
from the cytosolic to the luminal leaflet for SM synthesis. Formation of SM
from ceramide is catalyzed by sphingomyelin synthase (SMS) (51) that
transfers the phosphocholine headgroup from phosphatidylcholine onto
ceramide yielding SM as a final product and diacylglycerol (DAG) as a side
product (52). As ceramide is a key metabolic intermediate for sphingolipids
with an amide backbone, DAG is for glycerol-derived phospholipids
SMS exists in two isoforms, SMS1, faces the lumen of the cis/medial Golgi
(futerman 1990,jeckel 1990, Kobayashi 1989) and it is responsible for the de
novo synthesis of SM (53); SMS2 which resides in the plasma membrane
(52),(54) could instead play a more specific role in signal transduction
events.  In neural cells the de novo SM is mostly synthesized at the plasma
membrane and the production at the cis medial Golgi is less prominent (55,
56). This indicates that the subcellular localization of SM formation is cell
type specific and that SMS activities may be involved in different biological
processes. 
Catabolic pathways for ceramide production
Beside the de novo pathway, significant contribution to intracellular
ceramide levels occur also through hydrolysis of complex sphingolipids by
activation of different hydrolases (66) (Figure 2).
Ceramides derived from SM catabolism require the activation of
sphingomyelinases (SMase) (67), specific forms of phospholipase C, which
hydrolyze the phosphodiester bond of SM yielding water soluble
phosphorylcholine and ceramide (68). Several SMases have been
characterized and classified by their pH optimum, subcellular distribution
and regulation. The best studied of these SMases is the acid
sphingomyelinase (aSMase) which exhibits an optimal enzymatic activity at
pH 4.5-5 (69). This lipase is localized in lysosomes and is required for the
turnover of cellular membranes (70). ASMase is deficient in patients with
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the neurovisceral form (type A) of Niemann-Pick disease, with consequent
abnormal accumulation of SM in many tissues of the body (71). Besides this
lysosomal/endosomal aSMase, a secreted zinc-activated form of aSMase
was first identified in serum (72) and found to be secreted by many cell types
(73, 74). These two aSMases are differentially glycosylated and processed at
the NH2-terminal (72) but they are products of the same gene (73). Neutral
SMases (nSMase) are membrane bound enzymes with an optimal activity at
a neutral pH. Several isoforms have been characterized. NSMase 1 is
localized in the membranes of the endoplasmic reticulum, (75, 76) and it is
ubiquitously expressed and highly enriched in kidney (77). NSMase 2 has a
different domain structure than nSMase 1 and is specifically highly
expressed in brain (78, 79) (80). A third nSMase (nSMase 3) is ubiquitously
present in all cell types and distributed mainly in the ER and Golgi
membrane (81). NSMases are further classified as Mg2+/Mn2+ dependent or
independent. An alkaline SMase exists only in intestinal cells and it is
activated by bile salts (82). The function of these multiple isoforms is still
elusive; however their membrane localization has lead to speculation that
they may contribute to the modification of local microdomains in the
membrane organization during vesicle formation, transport, and fusion (83, 84).
Salvage pathway 
Ceramides can be generated by an alternative acyl-CoA-dependent route
(Figure 2). This pathway relies upon the reverse activity of the enzyme
ceramidase (CDase), which is called the "salvage pathway" since catabolic
fragments are recycled for biosynthetic purposes (85, 86). As the name
suggests, CDase catalyses the hydrolysis of ceramide to generate free
sphingosine and fatty acid. Together with ceramide production, CDase
regulates also sphingosine levels. In fact, it is important to note that whereas
sphinganine is generated by de novo sphingolipid biosynthesis (Figure 2),
free sphingosine seems to be derived only via turnover of complex
sphingolipids, more specifically by hydrolysis of ceramide (5). The
catabolism of ceramide takes place in lysosomes from where sphingosine
can be released (87) in contrast to ceramide which does not appear to leave
the lysosome (88). Free sphingosine is probably trapped at the endoplasmic
reticulum-associated membranes where it undergoes re-acylation
(condensation with a fatty-acylCoA) to again generate ceramide. This
"reverse" activity is carried out by the same CDase (88, 89).
As with SMase, different CDases have been identified associated with
different cellular compartments according to the pH at which they achieve
optimal activity (acid, neutral and alkaline). Acid CDases (aCDase) are
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lysosomal (90-92), whereas neutral/alkaline CDases (nCDase and alCDase)
have been purified from mitochondria (39, 93) and nuclear membranes (94).
CDases have been isolated from soluble fractions of rat brain (95), mouse
liver and human kidney. A purely alkaline CDase has been localized to the
Golgi apparatus and ER (96, 97). Again, this variability in CDases subcelular
localizations and distribution in tissues suggests that these enzymes may
have diverse functions in the biology of the cell.
Neutral/alkaline CDases have been shown to catalyze the reverse reaction to
generate ceramide from sphingosine and fatty acids (89, 96, 98, 99) whereas
the acid isoform resides in lysosome. Mitochondria are also capable of
generating ceramide via the action of reverse ceramidase (39, 93, 100).
Sphingosine 1-phosphate and ceramide 1-phosphate
Phosphorylation/dephosphorylation reactions represent a mechanism
through which cells respond to specific changes: the phosphorylated state of
a molecule often exhibits effects that are diametrically different from those
of the unphosphorylated state. Besides being used to resynthesize
ceramide, sphingosine can be converted into sphingosine-1-phosphate (SP1)
via sphingosine kinase, an enzyme that exists in the cytosol and ER (101,
102) (Figure 2). The terminal catabolism of sphingosine involves the action
of SP1 lyase which degrades the SP1 to form ethanolamine phosphate and a
fatty aldehyde (105). Sphingosine is associated with growth arrest (103)
whereas its phosphorylated form, SP1, is able to promote cell proliferation
and prevent programmed cell death (102, for a review 104).
Ceramide and S1P are two sphingolipids that exert effects of opposite
nature in their regulation of apoptosis, differentiation, proliferation and cell
migration (106, 107). The concentration of ceramide and S1P is counter-
balanced by enzymes that convert one lipid to the other and their levels are
believed to balance between cell viability and cell death.
However, this is not the only way the cell can balance to ensure tissue
homeostasis. Ceramides can also be phosphorylated by the enzyme
ceramide kinase to form ceramide-1-phosphate (Cer1P) (108-111). As
expected, phosphorylation of ceramide in Cer1P allows a switch of ceramide
properties: comprehensive studies indicate that Cer1P inhibits apoptosis
and can induce cell survival (112-114). 
Ceramide kinase (CERK) was first observed in brain synaptic vesicles (109)
and found to be highly expressed in brain, heart, skeletal muscles and liver
(108). It appears that at least two different CERK isoforms exist in neural
tissue, a calcium dependent enzyme at the plasma membrane level and a
second cytosolic enzyme (115, 116). The former enzyme localizes at
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synaptic-vesicles suggesting a possible role for CERK in neurotransmitter
release (108, 109, 117).
CERK specifically utilizes ceramide transported to the Golgi apparatus by
CERT (118). Stable downregulation of CERT by RNA interference results in
strong decrease in Cer1P levels, suggesting that Cer1P formation mostly
relies on ceramide de novo synthesis (118). Together with CERK and Cer1P
phosphatases, CERT could modulate an appropriate balance between the
intracellular levels of ceramide and Cer1P. However it is important to
mention that short-term pharmacological inhibition of CERT appears to slow
down SM synthesis without decreasing Cer1P synthesis (119), suggesting
either an alternative route for delivery of ceramide to CERK at the Golgi
complex or a process which is dependent on long term responses. 
Maintenance of equilibrium between ceramide and Cer1P seems to be
crucial for cell and tissue homeostasis and accumulation of one or the other
results in metabolic dysfunction and disease.
Recently, S1P was reported to function not only as an intracellular but also
as an extracellular mediator of cell growth through endothelial-
differentiation gene family receptors (120). Cer1P could exert similar
functions at the plasma membrane level. Further research is necessary to
study if ceramide could reach the plasma membrane transported by CERTL
allowing plasmatic membrane CERK to form Cer1P.
Plasma Membrane, not just a lipid bilayer
Structural organization of the membrane
The plasma membrane is the densest structure of eukaryotic cells and it
defines the outer limit of the cell with its environment. Far from being a
passive skin around a cell, plasma membranes are highly dynamic structures
with a central role in a vast array of cellular processes (121, 122).
Plasma membrane of eukaryotic cells comprises three major classes of
lipids: glycerophospholipids, sphingolipids and sterols, principally
cholesterol (123). Glycerophospholipids are the main building blocks of
eukaryotic membranes and differ from sphingolipids (ceramide based lipids)
in that they are built on a glycerol backbone. (124). Sphingolipid acyl chains
are characteristically highly saturated, this allows them to pack tightly in the
lipid bilayer and results in a liquid ordered phase with little opportunity for
lateral movement or diffusion. This characteristic makes  sphingolipids
suitable to contribute heavily to the structure of the outer leaflet (30).
Conversely, glycerophospholipids are rich in unsaturated acyl chains that are
typically kinked, this means they pack loosely thus increasing the fluidity of
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the lipid bilayer. The inner leaflet has a higher content of unsaturated
phospholipids. This lipid asymmetry in membranes accounts for the greater
fluidity of the inner layer relative to the outer layer (Figure 3).
Figure 3 Schematic representation of lipid raft structures in a plasma membrane. 
The phospholipid bilayer of cellular plasma membranes contains many different lipid components
such as glycerophospholipids, sphingolipids and cholesterol.  The compositions of the inner and outer
membrane leaflets are different. The cytoplasmic monolayer is largely composed of
aminophospholipids as phosphatidylserine (4) and phosphatidylethanolamine (3). By contrast, the
choline-containing lipids SM (6) and phosphatidylcholine (5) and a variety of glycolipids (7, 8) are
significant components of the exofacial leaflet of plasma membranes [45]. Sphingomyelin (6) together
with cholesterol and different glycosphingolipids (7, 8), form highly organized microdomains called
lipid rafts on the plasma membrane. Since these microstructures are formed by lipid species with long
saturated acyl chains, rafts are rigid platforms which float in the more fluid surrounding membrane
that consists of phospholipids with saturated (1) and unsaturated (2) fatty acyl chains and less
cholesterol. Lipids rafts are enriched in glycosylphosphatidylinositol (GPI)-anchored proteins (8) at
their external surface and studded with transmembrane integral proteins.
Sphingolipids molar ratio relative to glycerophospholipids and cholesterol
varies within cell types. For instance, glycosphingolipids are a very minor
component in certain cell types such as erythrocytes but they have been
shown to be particularly abundant in neurons and oligodendrocytes where
they make up 30% of total lipids in myelin sheets (125, 126). Cholesterol
affects the consistency of the plasma membrane making the outer surface
firm and decreasing its permeability (127). With its rigid ring structure,
cholesterol fills interstitial spaces between fatty acid chains of the nearest
phospholipids, restricting their movement. At the same time cholesterol
helps plasma membrane to maintain its fluidity, separating the long
saturated fatty acid tails of phospholipids, avoiding their condensation.
Despite the significance of ceramide metabolism in the synthesis and
degradation of sphingolipids, ceramide content is normally very low in cell
membrane and increases in ceramide concentration are highly localized and
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temporally regulated. The occurrence of ceramide in the lipid bilayer directly
affects both the structural organization and the dynamic properties of the
cell membrane (10, 128).
Lipid rafts
Many cellular processes such as endocytosis, exocytosis and membrane
budding involve changes in membrane topology.  While biological
membranes are typically in a fluid or liquid-disordered state at physiological
temperatures, combinatorial interactions between specific lipids drives the
formation of dense, liquid-ordered domains, or 'lipid rafts' within
membranes (13, 122, 133, 134) (Figure 3). The characteristics of these
microdomains differ from those of the whole membrane. They are generally
enriched in lipids with saturated acyl chains, especially SM and cholesterol
which pack tightly within the lipid bilayer (131, 132). These separated
regions seem to exist as preformed entities in the membrane of resting cells
(129) and are present in different parts of the lipid bilayer (130). 
The straight saturated acyl chains of sphingolipids in rafts are more
extended than unsaturated chains of surrounding phospholipids and as a
result lipid rafts extend 1 nm beyond the phospholipids background (135).
The isolation of biologically relevant lipid rafts is problematic. In the past,
highly saturated lipid rafts have been isolated based on their detergent
resistance (136). More recently, it has been shown that these detergent
resistant membranes (DRMs) are in fact a product of the extraction method
and do not reflect any specific membrane structure. Therefore it is
important to recognize that rafts are not equivalent to DRMs (137). The
majority of studies have investigated lipid rafts mainly at the plasma
membrane, due to their accessibility from the outside of the cell (138-140).
However many intracellular organelles contain raft-like domains (136, 141-
144). Membranes of the Golgi are rich in cholesterol/SM (145-147) and it
has been suggested that rafts function in sorting of lipids and proteins in the
secretory and endocytic pathways. In particular, raft like domains are
thought to be abundant in the trans-Golgi (144, 148) and in late endosomes
(143).
Lipid rafts are dynamic structures without any characteristic morphology
(149): during the steady state, rafts may be very small, nanometers in
diameter (131, 150, 151) but upon proper stimuli they can coalesce into
large domains making even micrometer-size rafts (151). The fundamental
principle by which lipid rafts exert their functions is a segregation or
concentration of specific membrane proteins and lipids to form distinct
microdomains (139) that represent specialized signaling organelles within
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the plasma membrane (152). These dynamic membrane sites have been
implicated in mechanisms of cell polarity (153), membrane trafficking
including endocytosis (141, 154) and exocytosis (155-157) and in
intracellular signaling (152, 158-160). 
Proteins which localize into lipid rafts often show post-translational
modifications with lipids such as glycosylphosphatidylinositol (GPI)-anchors,
palmitoylation, prenylation, myristoylation, (161) or directly bind
cholesterol or phospholipids as caveolins (134, 162) and annexins (163),
respectively.
Figure 4 Scheme of lipid raft reorganization upon ceramide formation by SMase activity.
Hydrolysis of sphingomyelin through the enzyme Smase generates ceramide in the outer leaflet of the
cell membrane. For its biochemical features, ceramide mixes poorly with the other rafts components
and shows self-assembling capability in the membranous environment forming large distinct
ceramide-enriched membrane platforms which serve to reorganize the cell membrane, resulting in
clustering of activated receptor molecules.
Ceramide enriched platforms 
As a highly hydrophobic second messenger, ceramide presumably acts at the
level of lipid rafts in transducing external signal. Rafts are the primary site of
action of the enzyme SMase that releases ceramide from SM (164) (Figure
4). The tight interaction between SM and cholesterol serves as the basis for
raft formation. Ceramides, on the other hand, mix poorly with cholesterol
and have a tendency to self associate and segregate into highly ordered
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microdomains (13, 165). The nature of ceramide has a strong impact on
membrane structure. In fact, long chain saturated ceramide molecules are
intermolecularly stabilized by hydrogen bonding and van der Waal forces
(25, 166) and form gel or liquid ordered domains that induce lateral phase
separation of ?uid phospholipid bilayers into regions of gel and liquid-
crystalline (?uid) phases. Moreover, the small size of ceramide polar
headgroup results in a low hydration and allows ceramide molecules to pack
tightly avoiding any interference with surrounding lipids (167). In fact it has
been shown that as little as 5 mol% ceramide is sufficient to induce
ceramide partitioning in the lipid bilayer and to drive the fusion of small
inactive rafts into one or more large active ceramide-enriched membrane
platforms (166). 
Among lipids, diacylglycerol structurally seems to resemble ceramide. Both
are very minor components of membrane being formed and removed
rapidly at specific locations in response to signalling. As well as ceramides,
diacylglycerols also give rise to phenomena of lateral phase separation in
small domains within phospholipid bilayers. Both ceramide (10) and
diacylglyercol (11) are non-lamellar forming lipids, which are important for
cellular processes such as pore formation, vesicle fusion and budding, as
well as membrane protein function. Both ceramide and diacylglycerol are
lipid second messengers that play important roles in many signaling
pathways. The amount of DAG formed can reach 2 mol% in some
physiological situations (Preiss 1986). DAG is known   to induce structural
changes in membrane at as little as 2 mol% and appears to be generally
more efficient than ceramide in the promotion of non lamellar lipidic
phases. The fact that ceramide and DAG membrane effects differ from each
other quantitatively rather than qualitatively suggests that the physical
rather than the chemical properties of these compounds are responsible for
the observed differences. If it is assumed that ceramides and diacylglycerols
have a physiological role in the (transient) destabilization of the lamellar
structures, the different potencies of the various lipid groups adds a new
possibility in the modulation of membrane structure and dynamics. 
The ceramide-enriched membrane platforms serve as clustering
components to achieve a critical density of receptors involved in signaling.
In fact, rafts are too small to engage in membrane processes (152, 168). This
high density of receptors seems to be required for effective transmission of
the signal into cells. For example, CD95 signaling is amplified a hundred-fold
by the formation of ceramide-enriched membrane platforms (169). 
The neuronal plasma membrane is particularly enriched in lipid rafts (170).
More than 1% of total brain protein is recovered in a lipid raft fraction,
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whereas less than 0.1% of total protein is associated with lipid raft isolated
from non neuronal tissues (171). In cultured neurons, lipid rafts are
distributed throughout the cell surface including the soma and dendrites. As
well as across cell types, lipid and protein raft composition differs according
to neuronal developmental stage. Mature neuron lipid raft content is higher
than that of immature neurons and astrocytes. (172). Synaptic proteins such
as synaptophysin or synaptotagmin localize in lipid rafts (173, 174) and lipid
rafts are critical for maintaining the stability of synapses and dendritic spines
(175). Neurotransmitter signaling seems to occur through a clustering of
receptors and receptor-activated signaling molecules within lipid rafts.
Several lipid raft associated neurotransmitter receptors have been isolated
from brain tissues, examples include: nicotinic acetylcholine receptors (176),
gamma aminobutyric acid type B receptors (177), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor and N-methyl-D-aspartate
receptors (175, 178, 179). Aberrant organization of SM and cholesterol in
rafts has been linked to loss of synapses and changes in nerve conduction
(175). Depletion of sphingolipids or cholesterol leads to gradual loss of
inhibitory and excitatory synapses and dendritic spines (175). Rafts also play
an important role in neuronal cell adhesion (180), localization of neuronal
ion channels (181, 182) and axon guidance (183). In oligodendrocytes, rafts
mediate the interaction between myelin associated glycoprotein on myelin
and its receptor on neurons (184). 
Ceramide signaling in apoptosis
Apoptosis is an essential process for normal embryonic development and to
maintain cellular homeostasis within mature tissues. A proper balance
between regulation of normal cell growth and cell death is the basis of life.
Deregulated apoptosis is a feature of most pathological conditions such as
neurodegeneration, auto immune disorders and cancers. In
neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's
and Prion's diseases aggregated misfolded proteins contribute to the
neuronal pathogenesis; in multiple sclerosis, autoimmune mechanisms
accompany the demyelination; in HIV-associated dementia, viral products
are crucial for neuronal demise. Factors affecting neurodegeneration can
differ, but these devastating disorders are all characterized by a massive loss
of specific populations of neurons or damage to neuronal transmission. 
Premature death of terminally differentiated cells such as neurons and
oligodendrocytes results in progressive and irreversible functional deficits
since these post mitotic cells cannot be easily replaced (185). The role of
ceramide in apoptosis is extensive and complex and despite intense
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investigations remains controversial (186). Increase of ceramide levels lead
to cell death (187, 188); in contrast, depletion of ceramide can reduce the
progression of apoptosis (189-191). However, ceramide is indispensable for
proper function of the central nervous system (CNS) (192-194). Very likely its
levels inside the cell determine its dual role: protection and cell sustenance
at low concentrations but death and threat when over produced. This
outlines the importance for cells to maintain a strict ceramide balance by a
tight regulation of sphingolipid based signaling networks. 
Ceramide can induce apoptosis via different routes and different
intracellular organelles are the target of its action. SM hydrolysis by neutral
and/or acid SMases is known to be a very important pathway for production
of pro-apoptotic ceramides (195). However, the de novo synthesis pathway
has also been reported to be relevant in the generation of a signaling pool
of ceramide leading to cellular apoptosis (196-198). These two pathways can
induce apoptosis independently or jointly (Figure 5).
Figure5 Ceramide production occurs in response to diverse apoptotic stimuli and with different
mechanisms.
Many inducers of cell death activate one or more ceramide generation pathways. For example both
SM hydrolysis (by either a nSMase or an aSMase) and the de novo pathway have been implicated in
the actions of TNFα, radiation, doxorubicin and UV. Ultimately,ceramide production results in cell
death regardless of the pathway.
The sequential events involved in apoptosis signaling in ceramide catabolic
pathway are: first the activation of SMases which generates a rapid and
transient increase of ceramide and second, the generation of ceramide-
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enriched membrane platforms. In contrast, the ceramide de novo pathway
requires multiple enzymatic steps and it is responsible for a slow but robust
accumulation of ceramide over a period of several hours.
SMase activation occurs in response to stimulation of cell surface receptors
of the tumor necrosis factor (TNF) receptor superfamily. These receptors
transmit apoptotic signals initiated by specific ligands such as TNF alpha,
TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligands. TNF induced
cellular responses are mediated by either one of the two TNF receptors,
TNFR1 (p55) or TNFR2 (p75) which elicit different intracellular signals (199).
SM hydrolysis in response to apoptotic signals involves both nSMase and
aSMase but their activation occurs through different mechanisms (200,
201). The cytoplasmic tail of the TNFR1 contains two distinct portions that
differently associate with nSMase or aSMase (202, 203). Activation of
aSMase requires the C-terminal of the TNFR1 identified as death domain
(DD) (204). DD associates with the adaptor protein TRADD (TNF receptor 1-
associated death domain) that together with another cytoplasmic protein,
termed FADD/MORT-1 (205) induces activation of aSmase (206). ASMase is
normally present in the endosomal/lysosomal compartment. However,
upon phosphorylation by protein kinase C, aSMase translocates from its
intracellular locations to the plasma membrane where it reaches SM (207).
ASMase is reported to be functional at physiological pH after translocation
to the plasma membrane (208). The ceramide produced by aSmase activates
the aspartyl protease cathepsin D (209) that can subsequently cleave the
pro-apoptotic Bcl-2 family member Bid. Activation of Bid induces
cytochrome c release from mitochondria (210) and activation of caspase-9
and-3, leading to apoptotic cell death by the intrinsic pathway (211).
Conversely, activation of nSMase requires a short motif adjacent to the DD
of TNFR1, called neutral sphingomyelinase domain (NSD). The NSD binds an
adaptor protein, FAN (factor associated with nSMAse) which couples
nSMase to TNFR1 (212). The ceramide generated by nSMase leads to the
activation of ceramide-activated protein kinase (CAPK) (14) and ceramide-
activated protein phosphatases (CAPPs) (213), direct downstream targets of
ceramide. CAPK, Ser/Thr protein kinase, is involved in the mitogen-activated
protein kinase (MAPK) cascades that induce the extracellular-signal
regulated kinases (ERK) activation. ERK cascade leads to cell cycle arrest and
cell death.
CAPPs, which comprise the serine threonin protein phosphatases PP1 and
PP2A (214), mediate the effect of ceramide on several substrate.
Dephosphorylation and inactivation of retinoblastoma gene product (RB)
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(215) and antiapoptotic proteins such as Bcl-2 and Akt (216) and
downregulation of the transcription factors c-Myc (217) and c-Jun (218) lead
to apoptosis. 
Although aSMase and nSMase seem to induce death receptor dependent
and independent mediated apoptosis through apparently separate
mechanisms, both enzymes are activated by the same stimuli, i.e. UV light
(219), hypoxia (220, 221), radiation (191, 222), TNF-related apoptosis-
inducing ligands (223) and the DNA-damaging drug doxorubicine (224).
Disruption of rafts or prevention of ceramide generation by inactivation of
aSMase, renders cells resistant to receptor clustering and apoptosis
indicating that aSMase plays an important role in death receptor-mediated
apoptosis (228, 2, 225). Accordingly, aSMase-deficient mice are resistant to
the induction of apoptosis by CD95 (226) and TNF alpha signaling (227).
However, selective activation of nSmase has been reported to occur for
some apoptotic stimuli as CD40 (229), ethanol (230), free oxygen radicals
(231) and chemotherapy drugs (232). In contrast, specific activation of
aSMase with subsequent formation of ceramide-enriched membrane
domains occurs after infection with Pseudomonas aeruginosa (233),
Staphylococcus aureus (234) or rhinovirus (235). 
Instead, exposition to the chemotherapeutic agent etoposide (198) and
cannabinoids (236), retinoic acid (237) and B cell receptor (BcR)-induced
apoptosis (238) all involve a large increase in ceramide levels formed
specifically through the de novo pathway (Figure 5). However, the
downstream targets of the de novo ceramide dependent cell death are
largely unknown.
In conclusion, evidence suggests that ceramide acts either by changing the
physical state and organization of cellular membranes or by direct binding
and activation of target proteins. The spatial reorganization of plasma
membrane driven by generation of ceramide may serve to cluster signaling
molecules and to amplify death signaling. However, rather than a specific
mechanism for apoptosis induction, this process appears to represent a
generic mechanism for transmembrane signaling. In fact, receptors that are
not involved in apoptosis (IL5, LFA 1, CD28, CD20) (239) can activate the
SMase signaling pathway with subsequent raft clustering into
microdomains. Beside its effect at the level of cellular membranes, ceramide
is capable of direct binding with components that lead to death as CAPP,
CAPK, Protein Kinase C-ξ, cathepsin D (240) and mediate induction of
signaling cascades that lead to apoptosis, growth arrest and inflammation. 
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Aging
Sphingolipids hold a major role in regulating development and lifespan (241)
and deregulation in sphingolipid metabolism increase the risk and
progression of age-related neurodegenerative disease (242,243). Since
ceramide is the core of sphingolipids, its contribution to cellular
pathophysiology is object of intense study. A close connection between
ceramide levels and aging comes from studies carried on Saccharomyces
cerevisiae where a gene involved in ceramide synthesis has been identified
as a regulator of yeast longevity. This gene called longevity assurance
homolog 1 (LAG1), together with LAC1, functions as a key components of
CerS in vivo and in vitro (244) and its lost correlates with a marked increase
in yeast lifespan (245). The human homolog LAG1Hs (CerS1) is highly
expressed in the brain, testis and skeletal muscles and specifically generates
C18-ceramide (43). This conclusion seems to be supported by cell culture
studies where overexpression of CerS1 with increased C18-ceramide
generation resulted in apoptosis (246). Interestingly, C18-ceramide
generated by CerS1 was found to downregulate the expression of the
enzyme telomerase (247). Telomerase functions by elongating the end of
existing chromosomes and thus preventing cellular senescence. Since
cellular aging is dependent on cell division, these enzymes play a critical role
in long term viability of highly proliferative organ systems (248). Specifically
C18-ceramide is able to mediate a negative regulation of the human
Telomerase Reverse Transcriptase (hTERT) promoter, whereas different
ceramides generated by other ceramide synthases do not have such a
function. Telomerase is expressed in neurons in the brains of rodents during
embryonic and early postnatal development and is subsequently
downregulated (249). Terminally differentiated neurons are postmitotic,
therefore there is not need to maintain the telomere length (250).  However,
telomerase is constitutively expressed in restricted regions of the
hippocampus and the olfactory bulbs which are continuously supplied with
neural stem and progenitor cells (251). These cells are required for adult
neurogenesis throughout life because they produce new neurons and
support brain cells. Therefore, besides the telomeric roles, telomerase was
found to protect the post-mitotic neuronal cells from stress-induced
apoptosis and may serve a neuron survival-promoting function in the
developing brain and be important for regulating normal brain functions.
Thus, the regulation that C18-ceramide seems to exert on telomerase
expression may contribute to increase neuronal vulnerability of the adult
brain in various age-related neurodegenerative disorders.
Several studies support the role of ceramide in inducing senescence and in
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activating genetic/biochemical pathways involved with aging. Accumulation
of ceramide occurs normally during development and aging in single cells
(252) and young cells treated with exogenous ceramide exhibit a senescent-
like phenotype (253).
In addition, a significant change in ceramide metabolic enzyme activities
seems to occur in specific organs or even in specific cell types with aging
(252, 254). The activities of the sphingolipid catabolic enzymes (SMase and
CDase) seem to change more robustly than that of the anabolic enzymes
(SMS and CerS). 
ASMase and nSMase activity significantly increase in rat brain during aging
(255) demonstrating that aging is accompanied by an increase in SM
turnover. NSMase was also reported to be dramatically activated in
senescent fibroblasts (252). ACDase, nCDase and alCDase activities are
increased specifically in brain tissue from aging rats and among the isoforms
of CDases, alCDase shows the highest activity (255). Increase in the CDase
activity in kidney and brain indicates an increase in the production of
sphingosine and its contribution toward aging in these tissues. In contrast,
CerS shows a lower activity, suggesting a minor contribution of ceramide de
novo synthesis to ceramide accumulation (255).
Ceramide and neurodegeneration
Lipid storage disorders
Ceramide is defined as a central element in the metabolic pathways of
sphingolipids. All sphingolipids are synthesized from ceramides and are
hydrolyzed to ceramides. In addition to CDase and SMase, there are other
hydrolytic enzymes which hydrolyze complex sphingolipids producing
ceramides as product. More than ten specific acid exohydrolases are
responsible for intracellular glycosphingolipids digestion in a stepwise action
that takes place within the lysosome. Deficiency or malfunctioning of one of
these enzymes results in accumulation of the corresponding lipid substrate
in the lysosomal compartment leading to cellular enlargement, dysfunction
and death. Due to its high synthesis of lipids, the brain is the organ mainly
affected by accumulation of lipid products. Their abnormal storage and slow
turnover results in severe dementia and mental retardation. Inherited
metabolic disorders which have been linked to lysosomal dysfunction
belong to a family of diseases identified as lysosomal storage disorders
(LSDs). LSDs include Farber's disease, caused by the dysfunction of aCDase;
Krabbe's disease (Globoid leukodystrophy), caused by the absence of
GalCer/3-galactosidase; Gaucher's disease due to the absence of GlcCer/3-
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glucosidase and Niemann-Pick disease characterized by the absence of
aSMase. 
Farber's disease
Farber's disease is an inherited disorder characterized by high levels of
ceramides due to deficient activity of lysosomal aCDase (256). The rate of
ceramide synthesis is normal but ceramide resulting from degradation of
complex sphingolipids cannot be hydrolyzed and it is confined into the
lysosomal compartment (257). There is  a significant correlation between
the ceramide accumulated in situ and the severity of Farber disease (258).
The abnormal ceramide storage in the brain results in neuronal dysfunction,
leading to progressive neurologic deterioration. The inflammatory
component of this disease consists in chronic granulomatous formations
(259). Granuloma are small areas characterized by the presence of
lymphocytes, monocites and plasma cells (260) and appear to result from a
dysregulation of leukocyte functions. However, the sequence of molecular
mechanisms leading from defect in ceramide metabolism to leukocyte
dysregulation is still unknown.
Krabbe's disease and Gaucher's disease
Krabbe's disease is a disorder involving the white matter of the central and
peripheral nervous systems. It is characterized by a deficiency in the
lysosomal enzyme galactocerebrosidase (galactocerebroside beta-
galactosidase) which is necessary to digest galactocerebroside in myelin
forming oligodendrocytes and Schwann cells (261). Abnormal storage of
galactosylceramide due to the lack of this enzyme leads to myelinating-cell
death. Since galactosylceramides are almost exclusively found in the myelin
sheaths of nerve, apoptosis of myelin forming cells leads to a complete
arrest of the myelin formation with consequent axonal degeneration. This
accounts for the severe degeneration of motor skills observed in the
disease.
Another glycosphingolipid called psychosine is normally broken down by
galactoceramidase. 
Psychosine is present in the normal brain tissues at very low concentrations,
owing to its rapid breakdown to sphingosine and galactose by
galactosylceramidase. In its absence, psychosine accumulates in the brain
acting as cytotoxic metabolite (262) and therefore contributing to
oligodendroglial cell death. Psychosine was also found to cause axonal
degeneration in both the CNS and peripheral nervous system by disrupting
lipid rafts (263). Myelin and/or oligodendrocyte debris produced by
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oligodendrocyte death in Krabbe's disease activates microglial cells, resident
macrophages in the brain, which are the primary mediators of
neuroinflammation (264).
Because a pathological hallmark of this rapidly progressive demyelinating
disease is the presence of multinucleated macrophages (globoid cells) in the
nervous system (265) the disease is also known as globoid cell
leukodystrophy. However, the function of these cells is unclear.
Gaucher's disease is characterized by the lysosomal accumulation of
glucosylceramide (glucocerebroside) due to defects in the gene encoding
the lysosomal hydrolase glucosylceramidase, also called glucocerebrosidase
(266). In the brain, glucocerebroside accumulates due to the turnover of
complex lipids during brain development and the formation of the myelin
sheath of nerves (267). The cells most severely affected are neurons because
they process large amounts of gangliosides which are components of their
membranes and synapses. Enzymes involved in ganglioside degradation are
highly expressed in brain tissue and are of particular importance in the first
few years of life when axons elongate, dendrites branch and synapses
develop (267). Deficiency of these enzymes causes neuronal storage of
gangliosides leading to loss of neurons and their axons, resulting in cortical
atrophy and white matter degeneration. Cells and organs that do not
process large amounts of gangliosides are either normal or show mild
storage without cell damage. 
Although glucocerebrosidase is present in lysosomes of all cell types,
Gaucher's disease patients solely develop storage of glucocerebroside in
cells of the mononuclear phagocyte system. Macrophages participate in the
degradation of invading microbes, the natural turnover of blood cells and in
tissue modeling. Because of this, it is not surprising that in many of the
lysosomal storage disorders accumulation of storage material also takes a
prominent place in tissue macrophages. 
Niemann pick's disease
Defects in SM degradation results in a neurodegenerative condition known
as Niemann-Pick disease (NP). This kind of disorder exists in three major
forms. Both NP type A and type B are caused by defects in lysosomal aSMase
activity. Affected individuals cannot convert SM to ceramide with
consequent accumulation of SM (268). NP type C diseases are caused by
defects in a protein that is located in membranes inside the cell and is
involved in the movement of cholesterol and lipids within cells (269). A
deficiency of this protein leads to the abnormal accumulation of cholesterol
and glycolipids in lysosomes.
76
Chapter 2
Although the clinical presentation of NP type C disease is heterogeneous,
most patients exhibit cerebellar atrophy, elevated liver and brain levels of
cholesterol and SM as well as marked paucity of Purkinje cells and
progressive degeneration of the CNS. Neuronal storage is accompanied with
a variety of cellular inclusions as well as occasional presence of
neurofibrillary tangles, meganeurites or axonal spheroids.
Neurodegenerative dementia: Alzheimer', Parkinson' and Prion' s diseases
Neural cells are very complex morphologically. The large plasma membrane
surfaces of neurons are important for neuronal trafficking, neuron-neuron
communication and signalling transduction. During aging and
neurodegeneration membrane dysregulation and dysfunction are often
found.  These alterations in membrane microenvironment occur very early
in the CNS (270) (271). Heightened oxidative stress has a profound impact
upon membrane lipid-protein organization and signal transduction (272).
These changes might be at the basis of diseases such as Alzheimer's disease,
Parkinson's disease (PD), synucleopathies, prion diseases, and other
dementias.
Lipid rafts have been shown to be involved in the regulation of APP
processing and in Aβ peptide formation (273), and represent the principal
sites within the membrane where β-secretase and γ-secretase generate the
pathological amyloid β peptide (274-278).
Other lipid raft components, such as the gangliosides GM1 and GM2, have
been associated with induction of Aβ transition from a α-helix-rich structure
to a β-sheet-rich conformation (279, 280). Ganglioside binding with Aβ
accelerates Aβ fibril formation (281) which gradually causes membrane raft
disruptions and thereby has profound consequences on signal transduction
and neurotransmission.
Prion protein (PrPc) is a GPI-anchored protein (282) and together with its
pathological variant associates with lipid rafts (283). Moreover, the
conversion of PrPc into PrPSc has been shown to occur in these membrane
domains (284). Alpha-synuclein associates specifically with lipid rafts (285)
and abnormalities of lipid rafts in the frontal cortex occur during the
development of PD pathology (286). Massive modification of fatty acid
content gives rise to more viscous and liquid ordered rafts in PD brains than
in the age-matched control group (286). Also, lipid rafts from AD brains
exhibit aberrant lipid profiles compared to healthy brains (287).
Similar lipid changes are also observed in epilepsy and ischemia/stroke (288,
289). Elevations of intracellular ceramide levels, which may in turn be
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associated with induction of apoptotic cell death, have been reported in
brain tissues and CSF of AD brain (290) together with reduced SM (291) and
altered ganglioside levels (292). In line with this, increase of aCDase (293)
and sSMase activity (294) has been detected in the brain of AD patients. 
The key enzyme in ceramide de novo synthesis, SPT, is regulated by APP
processing (295) suggesting that this could be one of probably many
mechanisms responsible for the alterations in lipid metabolism at the
plasma membrane.
Conclusion
Ceramide is an important signaling molecule involved in the regulation of
the development and death of neurons. The level of ceramide generated can
dictate whether development is stimulated or whether apoptosis is induced.
Ceramide is beneficial for early growth and development of neuronal cells
(297, 298) and at low levels it has trophic effects promoting cell survival and
division. Ceramide is a vital component in cellular signaling and regulates
intra- and intercellular functioning. At higher concentrations however it is
often toxic and supports pro-apoptotic actions in many cell types (299).
Moreover the initial abnormal formation of ceramide can potently induce
more ceramide accumulation in a self-sustaining way (187, 300). This
induces drastic consequences leading to tissue damage and organ failure
(301) The mechanisms by which ceramide induces these disparate effects is
not known, but might involve activation of different downstream signaling
pathways or its effects in membrane structure.
These apparently contradictory roles can be understood only when we
consider ceramide formation as a balanced and vulnerable system.
Ceramide is critical for normal cellular function but must be at proper levels.
In healthy cells appropriate ceramide levels are maintained by a finely tuned
and precisely coordinated ceramide metabolism. This is, however, a fine line
to tread and deviation in either direction can have drastic consequences.
Where ceramide is concerned, growth arrest or apoptosis are only a slight
tilt away.
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Abstract
The Goodpasture antigen-binding protein (GPBP) plays a critical role in brain
development. Knockdown of GPBP leads to loss of myelinated tracts in the
central nervous system and to extensive apoptosis in the brain during early
embryogenesis. GPBP was initially identified as a protein associated with the
autoantigen in Goodpasture autoimmune syndrome, where it was shown to
be a kinase that regulates type IV collagen organization. GPBP isoforms bind
and transport ceramide from the endoplasmic reticulum to the Golgi
apparatus and are therefore also known as ceramide transporters (CERT).
Ceramide dysregulation is involved in autoimmunity and neurodegenerative
disorders.
In order to analyze the possible role of GPBP in neuroinflammation and
neurodegeneration we studied the basal GPBP expression in normal rat
brain. High levels of immunoreactivity were detected in neurons of the
cerebral cortex, hippocampal formation, the basal ganglia, the olfactory
bulb and nuclei of the thalamus, the hypothalamus and the septal area.
Lower expression levels of GPBP were observed widely throughout the
brain, suggesting that GPBP plays an important role in central nervous
system neuron function.
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Introduction
The Goodpasture antigen-binding protein (GPBP) has attracted attention
over the last few years because of the crucial role that it seem to play in a
variety of cellular functions in both physiological and pathological conditions
(Hanada et al., 2003; Revert et al., 2007; Granero-Molto et al., 2008). Several
investigations have revealed a complex story of isoforms and multiple
cellular localizations. Raya et al. (1999) characterized a 624 amino acid
isoform as a serine/threonine kinase that binds and phosphorylates the
noncollagenous NC1 domain of the α3-chain of type IV collagen, the
Goodpasture antigen. Therefore, the protein was called Goodpasture
antigen-binding protein, GPBP. It was thought that the kinase activity of
GPBP might play a role in the etiology of Goodpasture's syndrome, an
antibody-mediated autoimmune disorder characterized by rapidly
progressive glomerulonephrititis and pulmonary hemorrhage (Stanton and
Tange, 1958; Raya et al., 1999). In line with this, altered phosphorylation of
specific serines has been shown to change intracellular proteolysis, affecting
antigen-processing and presentation (Krebs, 1994).
Subsequently, in 2003, Hanada and colleagues (Hanada et al., 2003)
discovered that a shorter variant of GPBP that lacks a serine rich domain of
26 amino acid residues due to an alternative spicing event has a function in
the trafficking of the lipid ceramide from the endoplasmic reticulum (ER),
where it is produced, to the Golgi apparatus, where it is converted to
sphingomyelin. Hence they named this protein, already known as GPBPΔ26
(Raya et al., 2000), CERT. Hanada et al. (2003) also showed that the longer
isoform had ceramide transport properties in vitro and therefore, GPBP was
renamed as CERTL.with the consequence that two different names have
been used to identify the two variants. Therefore, in order to avoid
confusion; we will refer to all isoforms as GPBPs. Thus the longer splice
variant is named GPBP/CERTL and the shorter splice variant is named
GPBPΔ26/CERT, in reference to previous papers, while relating the specific
isoform to their functions. In keeping with their structural homologies, both
proteins function as ceramide transporters. However, the presence of the
26-residue serine-rich motif confers unique properties to the longer isoform
GPBP/CERTL. This motif allows GPBP/CERTL to be secreted extracellularly
and likely is also responsible for its more prominent kinase activity
compared to GPBPΔ26/CERT (Revert et al., 2008). GPBP/CERTL is also able to
bind type IV collagen with high affinity, in contrast to GPBPΔ26/CERT which
has low-affinity binding to type IV collagen (Raya et al., 2000).
In addition, it has been recently shown that GPBP/CERTL exists, in turn, as
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multiple isoforms due to an alternative translation initiation (Revert et al.,
2008). In fact, its mRNA, in addition to the traditional initiation codon,
presents a non canonical translation ACG initiation site located upstream of
the known AUG. These conventional and alternative start sites result,
respectively, in the synthesis of two polypeptides of 77 and 91 kDa,
harboring different amino terminal domains that confer distinct functions to
the isoforms and control their cellular localizations. The 91 kDa product
partly enters the secretory pathway where it undergoes covalent
modifications to yield a 120 kDa polypeptide (Revert et al., 2008). Similarly,
GPBPΔ26/CERT exists as different isoforms resulting from canonical
(approximately 77 kDa) and noncanonical (91 kDa and 120 kDa) mRNA
translation initiation.
In a zebrafish model, GPBP/CERTL has been shown to be an important factor
for normal brain ontogenesis and it is mostly expressed at early stages of
embryogenesis. In contrast, the levels of its spliced shorter variant
GPBPΔ26/CERT are initially very low and gradually increase at later
developmental stages. Specific knockdown of the GPBP/CERTL isoform
induces extensive apoptosis and tissue loss in brain and muscle (Granero-
Molto et al., 2008). The relative expression of these two isoforms varies
between tissues, i.e., GPBPΔ26/CERT is widely expressed in normal adult
human tissues, while GPBP/CERTL accumulates in several autoimmune
conditions such as lupus erythematosus, lichen planus, pemphigus and
Goodpasture's syndrome (Raya et al., 2000). Transgenic overexpression of
human GPBP in mice leads to abnormal organization of the type IV collagen
network in the kidney glomerular basement membrane. These disturbances
lead to production and deposition of IgA at the glomerular basement
membrane (Revert et al., 2007). Moreover, it has been shown that the pro-
inflammatory cytokine TNFα induces transcription of GPBP/CERTL by
increasing nuclear levels of NFκB (Granero et al., 2005). These data further
confirm the link between GPBP/CERTL and the immune system.
Ceramide is a sphingolipid that, in addition to its functional role in the
structure of the membranes, acts as a lipid second messenger in various
signaling systems that determine cellular fate (Mathias et al., 1998; Hannun
and Obeid, 2002). Studies on the role of ceramide signaling in the central
and peripheral nervous system have revealed that it is involved in the overall
regulation of terminal differentiation of neurons (Bieberich et al., 2001),
growth of neurons (Schwarz and Futerman, 1997), cellular senescence and
neuronal death (Haimovitz-Friedman et al., 1997). Impaired regulation of
the amount of ceramide in the cell was shown to have effects consistent
with neuronal death in Parkinson's disease (France-Lanord et al., 1997) and
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Alzheimer's disease (France-Lanord et al., 1997; Cutler et al., 2004).
Whether such impaired regulation is due to abnormal expression of GPBPs
has yet to be clarified.
Since many aspects of the in vivo physiological function of GPBPs remain
unknown, the immunohistochemical study of the localization and
abundance of GPBPs in specific tissues is important. The localization of these
proteins has already been described for kidney, lung and skin. In this study,
we investigate the localization of GPBPs in adult rat brain under basal
conditions. We demonstrate that these proteins are present in neuronal
cells and are widely distributed throughout the whole brain with particularly
high expression in certain regions of the cerebral cortex, forebrain,
hippocampus and diencephalon.
Materials and methods
Animals
Five-month old male Wistar rats weighing around 600 g were obtained from
the Department of Experimental Animal Services, Maastricht University, The
Netherlands, for a research protocol approved by the Committee on Animal
Welfare in accordance with Dutch governmental rules.
Tissue preparation
One group of rats (n=10) was anesthetized (100 mg/kg ketamine and 15
mg/kg xylazine) and subsequently perfused transcardially with Tyrode
solution (0.1 M) and fixative containing 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.6). The solutions were either kept at 4°C or at room
temperature during perfusion. Brains were removed and post-fixed for 2 h
followed by overnight immersion in increasing sucrose gradient (10% to
30%) at 4°C. Brain tissue was then quickly frozen with CO2 and stored at 
-80°C.
Another group of ten animals was killed by an overdose of pentobarbital
(Nembutal, 150 mg/kg) and brains were removed and fixed by immersion in
4% paraformaldehyde, 15% picric acid and 0.05% glutaraldehyde in
phosphate buffer (pH 7.6) for four days. The fixative was either kept at 4°C
or at room temperature during fixation. The brains were then quickly frozen
and stored at -80°C until further processing. For the immunohistochemical
analysis, the brains were cut into series of 30 or 50 μm coronal cryostat
sections which were stored at -80°C.
To study the distribution of staining of GPBPs in the brain by
immunohistochemistry, we first optimized the fixation method. The brains
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of the perfused animals showed a more intense staining compared to the
postfixed brains (data not shown). Additionally, the brains that were fixed in
ice-cold buffers showed more intense staining compared to brains fixed with
buffers at room temperature (data not shown). All photomicrographs
showing immunohistochemical staining are from brain tissue from rats
perfused with cold (4°C) fixative.
Western Blot
Rat cortex and hippocampus were isolated as described before (Van den
Hove et al., 2006) and placed in ice cold lysis buffer containing PBS, 0.1%
SDS, 0.1% Triton X-100, 1% glycerol, 1 mM EDTA, 1 mM EGTA, 30 mM NaF,
and 16.7 mM Na3VO4 and a Complete Protease Inhibitor Cocktail tablet per
50 mL of buffer, following manufacturers recommendations (Roche
Diagnostics, Almere, The Netherlands). Glass beads and a bead beater
(Biospec products, Bartlesville, OK, USA) were used for the homogenization
of the tissue.
Figure 1. Western blot of GPBPs in rat brain. The proteins were transferred and blotted with polyclonal
anti-CERT antibody epitope 300-350 and polyclonal anti-GPBP antibody (Raya et al., 1999) (C =
cerebral cortex and H = hippocampal formation).
(Biospec products, Bartlesville, OK, USA) were used for the homogenization
of the tissue. The homogenization consisted of 3 cycles of 30 s in 350 μl (for
hippocampus) or 1.0 ml (for frontal cortex) lysis buffer. 10% SDS-PAGE gels
were loaded with 40 μg of total protein and transferred to a 0.45 μm
nitrocellulose membrane (Millipore, Amsterdam, The Netherlands). The
membrane was blocked for 1 h with Odyssey blocking buffer (Westburg,
Leusden, The Netherlands) diluted in PBS (1:1) and incubated with rabbit
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anti-CERT (diluted 1:2500; epitope 300-350 of human GPBP from Bethyl
Laboratories, Montgomery, TX, USA) or rabbit anti-GPBP (1/300; as
described in Raya et al., 1999) in the aforementioned blocking buffer
overnight at 4°C. After PBS washes, the membrane was incubated with goat
anti-rabbit-Alexa 680 (diluted 1:10,000 in blocking buffer; Rockland, USA) for
1 h at room temperature. Finally, the membrane was washed with PBS, dried
and scanned using the Odyssey infrared imaging system (Westburg,
Leusden, The Netherlands). 
Immunohistochemistry
Four antibodies were used. These were a rabbit polyclonal anti-CERT
antibody (diluted 1:500; epitope 300-350 of human GPBP, Bethyl
Laboratories, USA), a rabbit polyclonal anti-CERT antibody (diluted 1:500;
epitope 1-50 of human GPBP, Bethyl Laboratories), a rabbit polyclonal anti-
human GPBPs antibody (1:500; as described in Raya et al., 1999) and a
monoclonal mouse anti-GPBPs mAb-14 (1:1000; as described in Raya et al.,
1999 and characterized by Revert et al. 2008). This latter polyclonal anti-
human GPBP was produced by immunizing rabbits with GST-FLAG-GPBP
following standard procedures. Briefly, specific antibodies against GPBP
were purified sequentially from rabbit serum by immunoadsorption on a
GST-FLAG-GPBP-sepharose column and further removal of GST-specific
antibodies by immunoadsorption on a GST-sepharose column.
The polyclonal anti-CERT antibody binds to the 300-350 amino acid
sequence while the polyclonal anti-GPBP antibody binds to the N-terminal
region. Consequently, both antibodies recognize both isoforms. The
monoclonal antibody 14 raised against the FFAT epitope, binds to the
approximately 77 kDa isoforms of both the GPBP/CERTL and the
GPBPΔ26/CERT. Due to post translational modifications that occur in the
secretory pathway, it reacts very weakly with the 91 and 120 kDa products
(Revert et al., 2008).
Immunohistochemistry was carried out using 30 μm or 50 μm thick free-
floating sections which were incubated overnight at room temperature with
the primary antibody. After rinsing with Tris-buffered saline (TBS) with 50
mM Triton (TBS-T), sections were incubated with the corresponding
secondary antibody: biotinylated donkey anti-mouse IgG (diluted 1:400;
Jackson ImmunoResearch Laboratories Europe Ltd., Newmarket, Suffolk,
UK) or biotinylated donkey anti-rabbit IgG (diluted 1:800; Jackson
ImmunoResearch Laboratories Europe Ltd). Subsequently, sections were
incubated with the ABC-kit (Vector Laboratories, Burlingame, CA, USA) for
10
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1.5 h. To visualize the horseradish peroxide (HRP) reaction product, the
sections were incubated with 3,3’-diaminobenzidine tetrahydrochloride
(DAB). No labeling was evident in control experiments in which the primary
antibodies were replaced with the pre-immune serum in the
immunostaining protocol using tissue from cortex and from hippocampal
regions. A control antibody anti-ErbB2 (rabbit IgG anti-human Erb2, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) in place of primary polyclonal
antibodies resulted in a different patterns of immunoreactivity in the
cerebral cortex and hippocampal formation (Supplementary Fig. 2). A mouse
IgG1 anti-human rapsyn (Sigma Aldrich, St Louis, MO, USA) isotype control,
incubated with the same secondary, did not stain brain tissue
(Supplementary Fig. 2). Sections were photographed with an Olympus AX70
microscope (Olympus, Hamburg, Germany). Pictures were taken with Cell P
software (Olympus). Brain regions were identified according to the atlas of
Paxinos and Watson (1982).
NeuN, GFAP, Ox-42 fluorescent double-labeling immunohistochemistry
Free floating sections from brain tissue of rats perfused with cold fixative
were co-incubated with a rabbit polyclonal anti-CERT antibody (diluted 1:50;
epitope 300-350 of human GPBP, Bethyl Laboratories) and a mouse
monoclonal antibody raised against NeuN (diluted 1:50; Chemicon
International Inc, Temecula, CA, USA), OX-42 (diluted 1:100; BD Biosciences,
Breda, The Netherlands) or GFAP (diluted 1:50; Sigma, St. Louis, MO, USA)
overnight at room temperature.
After washes, sections were incubated with the corresponding secondary
antibodies: Alexa -488-conjugated donkey anti rabbit IgG antibody (diluted
1:100; Jackson ImmunoResearch Laboratories Europe Ltd.), streptavidin
Alexa-594 (diluted 1:50; Invitrogen, Breda, The Netherlands) and Alexa-594-
conjugated donkey anti mouse IgG antibody (diluted 1:100; Invitrogen).
For the GPBP colocalization with NeuN, primary and secondary antibodies
for each target were incubated separately in subsequent steps to reduce
crossreactivity in antibody-antigen interactions. Negative controls were
performed using the secondary antibodies with only one of the primary
antibodies. Sections were mounted on coated glasses with 80% glycerol in
TBS. Images were captured using an Olympus AX70 microscope using Cell P
software and processed with Adobe Photoshop.
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Figure 2. Distribution of GPBPs-positive cells in the cerebral cortex of adult rat brain. (A) Overview of
the motor and sensory cortex. (B) Higher magnification of layers IV, V and VI of the sensory cortex. (C)
Higher magnification of layer V of the sensory cortex. (D) Magnification of layers I, II and III of the
sensory cortex. Scale bars: A = 1 mm; B = 500 μm; C, D = 200 μm.
Results
Characterization of anti-GPBPs antibodies
To study the specificity of the antibodies, we performed Western blot
analyses using cerebral cortex and hippocampal brain tissue. Both the anti-
CERT (epitope 300-350) and anti-GPBP polyclonal antibodies detected a
band of 77 kDa in the cortex and in the hippocampus (Fig. 1). Additionally,
both antibodies recognized a band around 50 kDa which has been previously
described (Revert et al., 2008). The anti-CERT antibody showed also 
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Figure 4. Distribution of GPBPs-positive cells in the basal ganglia of adult rat brain. (A) Caudate
putamen. 
(B) Globus pallidus. 
(C) Overview of substantia nigra. 
(D) Substantia nigra. 
Scale bars: A, B, D = 200 μm; C = 500 μm.
reactivity for a polypeptide band around 30 kDa, which has been proposed
to correspond to GPBP/CERTL. These molecular weights are comparable to
polypeptides described in earlier studies which reported a molecular weight
for GPBPs ranging from 30 to 120 kDa (Revert et al., 2008). The specificity of
the mouse anti-GPBPs mAb-14 has been previously demonstrated (Raya et
al., 1999). A Western blot of cerebral cortex and hippocampal brain tissue
that was incubated with the secondary antibodies only (thus omitting the
primary antibodies) showed no signal (not shown).
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Figure 5. Distribution of GPBPs-positive cells in
the septal area, amygdala and hypothalamus of
adult rat brain. (A) Septal area. (B) Amygdala. (C)
Paraventricular hypothalamic nucleus.
Abbreviations: CA, central amygdaloid nucleus;
EP, endopiriform nucleus; LA, lateral amygdaloid
nucleus; LS, lateral septal nucleus; MC,
magnocellular division; MS, medial septal
nucleus; PD, parvicellular division; PC, piriform
cortex; III, third ventricle; IV, fourth ventricle.
Scale bars: A, B = 500 μm; C = 200 μm
Figure 6. Distribution of GPBPs-positive cells in
the anterior thalamus. Abbreviations: SM, stria
medullaris of thalamus; AD, anterodorsal
thalamic nucleus; AV anteroventral thalamic
nucleus; PV, paraventricular thalamic nucleus; III,
third ventricle. Scale bar = 500 μm.
Figure 7. Distribution of GPBPs-positive cells in
the olfactory bulb. Scale bar = 200 μm.
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Immunoreactivity of GPBPs in rat brain
To demonstrate the specific recognition of GPBPs by the antibodies, we
tested four different antibodies: three polyclonal and one monoclonal
directed against different epitopes shared by the isoforms, GPBP/CERTL and
GPBPΔ26/CERT. Immunohistochemical staining for each antibody showed a
very similar distribution pattern throughout the brain. In supplementary Fig.
1 we show the staining of cortex and hippocampus from three of the
antibodies. Together with the Western blot data, these results demonstrate
the specific binding of the antibodies to GPBPs.
Staining of GPBPs was observed throughout the rat brain (Figs. 2-7).
Representative photomicrographs of the cerebral cortex (Fig. 2),
hippocampal formation (Fig. 3), basal ganglia (Fig. 4), septal area, amygdala
and hypothalamus (Fig. 5), thalamus (Fig. 6) and olfactory bulb (Fig. 7)
illustrate the remarkable abundance of this protein in different brain
regions. As can be seen in the photomicrographs, virtually all neurons were
positively stained for GPBPs.
In the cerebral cortex positive staining was present in all areas and layers,
although the staining intensity varied with respect to the different lamina
(Fig. 2). There was a clear difference between the intensely stained layers II
and V compared to less intense staining of cells in layers III, IV and VI
although neurons in the deepest stratum of layer VI, just above the fibers of
the corpus callosum (Fig 2A), showed also a strong positive labeling. In the
cell sparse layer I the few neurons present were also positive for GPBPs (Fig
2D). In the cerebral cortex, bundles of apical dendrites were intensely
stained (Fig. 2B, C).
Intense staining was observed in the hippocampal formation, in the CA1-
CA3 fields and the dentate gyrus (Fig. 3). Here, cells gave an impression of
very dark staining because their somata were so compactly packed. In fact,
strong staining of their cytoplasm was evident and staining extended into
their apical dendrites many of which could be followed for a significant part
of their entire length (Fig. 3D, E). Comparable intense staining was observed
in the indusium griseum and in the dorsal tenia tecta, the dorsal and
anterior extensions of the hippocampus, respectively. In the hypothalamus,
staining was also widespred with some nuclei, e.g. the paraventricular nuclei
(Fig. 5C) and the mammillary nuclei, containing strongly stained neurons. All
the nuclei in the thalamus were well stained with the staining mainly
restricted to cell bodies (Fig. 6), although some staining of proximal
dendrites was evident. Strong staining was observed throughout the
olfactory bulb (Fig. 7). No immunoreactivity was seen in the white matter.
Thus, axons were not apparently stained but in certain areas there appeared
to be staining of neuropil above background.
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Expression of GPBPs in neurons
The wide distribution and morphology of GPBPs-positive cells in the brain
suggested that the GPBPs antibodies stained neurons exclusively. To
investigate this possibility, double staining using different cell markers in
combination with GPBPs antibodies was carried out.
Double fluorescent labelling of GPBPs together with the neuronal marker
NeuN (Fig. 8), the astrocyte marker GFAP (Fig. 9), or the microglial marker
OX-42 (Fig. 10) demonstrated that GPBP is expressed in neurons and not
astrocytes or microglia.
Colocalization of GPBP with NeuN showed that GPBPs staining was most
intense in the cytoplasm of neuronal cell bodies (Fig. 8). Robust staining was
also present in many proximal dendrites. Strong staining was observed in the
cytoplasm with lighter staining in the nuclei and absence of staining in
nucleoli. However some neurons of the hypothalamus did not present a
clear nuclear but rather a mainly perinuclear staining.
No positive immunofluorescent staining for GPBPs was found in astrocytes
(stained with GFAP, Fig. 9) and in resting microglia (stained with OX-42, Fig.
10).
Figure 8. Fluorescent photomicrographs of GPBPs and NeuN staining showing cortical neurons in rat
brain. The left column shows fluorescent staining with polyclonal anti-CERT antibody (epitope 300-
350), the middle column shows staining with the monoclonal antibody NeuN and the right column is
the merge of the left and the middle column. Note the proximal dendrites in the pyramidal neurons in
the lower row. Scale bars: A = 100 μm and B = 20 μm.
10
8
Chapter 3
Figure 9. Fluorescent labelling of GPBPs (epitope 300-350) and GFAP in rat brain (A) hippocampus.
(B) thalamus. The left column shows fluorescent staining with polyclonal anti-CERT antibody (epitope
300-350) the middle column shows staining with the antibody GFAP; merge on the right. 
Scale bars = 200 μm.
Figure 10. Fluorescent labelling of GPBPs (epitope 300-350) and OX-42 in rat brain (A) hippocampus.
(B) thalamus. The left column shows fluorescent staining with polyclonal anti-CERT antibody (epitope
300-350) the middle column shows staining with the antibody OX-42; merge on the right. 
A = 50 μm and B = 200 μm.
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Discussion
This study presents a comprehensive analysis of the distribution of GPBPs in
neurons in rat brain in basal conditions.
A recent study in zebrafish (Granero-Molto et al., 2008) has shown that
GPBPs play a role in development. Both isoforms showed a changing
expression during early embryogenesis. Selective GPBP/CERTL knockdown
(leaving the GPBPΔ26/CERT isoform intact) induced apoptosis and tissue loss
with a clear reduction of the myelinated tracts, thin axons and edema during
brain development.
The GPBPs' kinase activity and ceramide transport function, along with the
presence of several isoforms with distinct localizations inside and outside
the cell, reveal a pleiotropic protein that likely exerts numerous important
functions, which mostly remain to be investigated. We studied their
expression in rat brain tissues where GPBPs immunolabeling was detected in
neurons, mainly concentrated in the soma and proximal dendrites. Due to
their ceramide trafficking function, the cytoplasmatic signal for GPBPs could
be related to their presence in ER and Golgi organelles. However, given the
array of isoforms that these proteins display, other subcellular localizations
could be present. Moreover, since the nucleus also appears to be lightly
stained, additional investigations are needed to further elucidate the GPBPs
role in this compartment.
In our study, four different antibodies detected very similar patterns of
neuronal expression of GPBPs. However, in glial cells expression of GPBPs
was not detected by immunohistochemistry even though these proteins
likely are present at a basal level because the ceramide transport function of
GPBPs is essential for membrane biogenesis (Hanada et al., 2003). In any
case, under normal conditions, neurons are the cell population that shows a
stronger expression of GPBPs. 
In the present study we demonstrated a widespread distribution of GPBPs
throughout the whole brain, although in certain areas the intensity of
staining varied among neurons, some of which showed distinct morphology.
Such differences may relate to specific functional requirements of these
cells. Since we expected GPBPs genes to be ubiquitously expressed in the
brain due to their essential role in the transport of ceramide, evidence of
different intensities of expression among neuronal populations is of great
interest. Ceramide seems to be the key compound at critical points in
numerous signaling pathways such that this differential expression pattern
among neurons could be related to the activation of specific functional
processes. For example staining of the apical dendrites of pyramidal neurons
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in the cerebral cortex and the hippocampus versus minimal or absent
dendritic staining in other regions emphasizes the possibility of a distinct
regulation among diverse neuronal cell types.
To relate protein levels as revealed in the present immunohistochemical
study to gene expression in different brain regions, we compared our
findings with the gene expression levels of GPBPs as represented in the Allen
Brain Atlas (Lein et al., 2007). Although this atlas is designed for detailed
analysis of gene expression profiles in the mouse brain and we used rat
brains in our study, very similar patterns for gene and protein expression
were apparent and were consitent with our immunohistochemical findings.
Thus, high levels of GPBPs gene expression are present in cerebral cortex, in
the septal complex, thalamus, hypothalamus, olfactory bulb, the amygdala
and in some hippocampal regions.
Some differences were noted between the gene and the protein expression:
GPBPs were detected at higher levels than the corresponding mRNAs in
some specific regions in the hypothalamus, the hippocampal formation and
the olfactory bulb. This could either reflect differences of gene expression
between mouse and rat, or alternatively be explained by translational
regulation processes.
Ceramide is the fundamental molecule and key intermediate of all
sphingolipids that are indispensable constituents of myelin and other
membranes of the nervous system (van Echten-Deckert and Herget, 2006).
However, they not only contribute to structural function by serving as
building constituents, but also appear to be involved in the overall
regulation of several other functions such as terminal differentiation of
neurons, cellular senescence, proliferation, and cell death (Cutler et al.,
2002). GPBPs also act as ceramide transfer proteins and could contribute
actively to mechanisms by which ceramide could induce profound changes
inside the cell. Moreover, proteins that are involved in complex regulation at
the transcriptional and translational level such as GPBPs might act as
putative modulators of ceramide metabolism (Revert et al., 2008). In line
with this, their activity has been shown to be essential to prevent severe
damage related to oxidative stress (Rao et al., 2007; Granero-Molto et al.,
2008). In mice the lack of both isoforms affects organogenesis, leading to
early embryo death (Wang et al., 2009) in which the major subcellular
defect manifests with a ceramide accumulation and consequent
degeneration in ER and mitochondria (Wang et al., 2009).
Recent reports of abnormal ceramide metabolism in aging, Alzheimer's
disease, Parkinson's disease and stroke (Cutler et al., 2004; Haughey et al.,
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2004; Sawai et al., 2005) further suggest that disturbances in ceramide
regulation are correlated with neuronal damage and cellular death leading
to cognitive impairment or motor dysfunctions, suggesting the strong
involvement of ceramide metabolism in neurological diseases (Cutler et al.,
2002; Takahashi et al., 2004; Bras et al., 2008). Interestingly, during
pathological processes seen in neurodegeneration, GPBPs' isoforms may be
differentially expressed (Mencarelli et al. unpublished results). The strong
presence of GPBPs that we detected in the brain in the present study
together with their intriguing properties such as the presence of different
isoforms, the extracellular localization, kinase activity and ceramide
transport function suggest involvement for GPBPs in many neuronal
functions and possible implication in neurodegenerative processes.
Finally, further analysis with specific antibodies to each of the different
splicing variants are needed to elucidate the precise subcellular localizations
and expression levels of GPBPs and to facilitate our understanding of their
functional role in the central nervous system.
Acknowledgements
We are very grateful to Marianne Markerink and Santiago Sampedro
Millares for their excellent technical assistance. Juan Saus and Francisco
Revert were supported by a SAF2006-12520-C02-01 grant from the Plan
Nacional I+D+I from the Ministerio de Ciencia e Innovación.
11
2
Chapter 3
Supplementary Figure 1. Immunohistochemical labelling of GPBPs in rat brain using different
antibodies. The upper panel shows an overview of the cortex at bregma 0.2 mm. Scale bar is 500 μm.
The middle panel shows a higher magnification of the cortex sections shown in the upper panel. The
lower panel shows pictures of the hippocampus at bregma -2.12. Scale bar is 200 μm. The left column
shows immunostaining with polyclonal anti-CERT antibody (epitope 300-350) the middle column
shows staining with mAb 14 (described in Raya et al., 1999) and the right column shows the
immunostaining polyclonal anti-GPBP antibody, described in Raya et al., 1999. The corresponding
preimmune serum did not show any immunoreactivity on rat brain tissue (not shown).
Scale bar = 100 μm
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Supplementary Figure 2. Immunohistochemical staining of cerebral cortex and hippocampus with
anti-CERT and with isotype control antibodies. A, C, E, G, I show the cortex. B, D, F, H, J show the
hippocampus. A, B: staining with polyclonal anti CERT antibody epitope 300-350. C, D: staining with
polyclonal anti CERT antibody epitope 1-50. E, F: staining with the mouse monoclonal antibody anti-
GPBPs mAb-14. G, H: Negative control staining with a polyclonal control antibody (rabbit anti-human
ErbB) that, incubated with the same secondary, resulted in a very faint signal, revealing a complete
different pattern. I, J Negative control staining with a monoclonal control antibody (mouse IgG1 anti-
human rapsyn) that did not reveal any positive signal when incubated with the same secondary as
used in E, F. The scale bar in the two panels A and B is 100 μm.
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Abstract
Ceramides are lipids that are abundant in brain tissue where they have an
important structural role in cellular membranes. Ceramides are also
powerful intracellular signaling molecules controlling cell death, growth and
differentiation. So far, the ceramide transfer protein (CERT), a shorter splice
variant of the Goodpasture antigen-binding protein (GPBP), is the only
known protein with the ability to shuttle ceramide from the endoplasmic
reticulum to the Golgi apparatus. GPBP/CERT are widely distributed in the
central nervous system where they act as key factors for normal brain
development and homeostasis. Ceramide accumulates in neurons during
acute neurodegeneration. The objective of this study was to define whether
levels of the ceramide transfer protein GPBP/CERT are altered in the acute
neurodegenerative process. We used design-based stereology to quantify
the number of GPBP/CERT immunoreactive cells in the striatum of 
6-hydroxydopamine (6-OHDA) lesioned rats as an animal model of
Parkinson's disease (PD). In addition, gray value measurement was
performed to quantify GPBP/CERT immunoreactivity-levels within individual
cells. No difference in the striatal expression levels of GPBP/CERT proteins
was found between diseased and control animals, suggesting that the
expression pattern of GPBP/CERT in the striatum is not affected in the 
6-OHDA rat model of PD.
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Introduction
Ceramides are lipids abundant in brain tissue where they were first
discovered by Johann LW Thudichum in 1884 (for a review[38]). They have
an important structural role in cellular membranes and also act as signalling
molecules inside the cell [1]. The balance of ceramide levels extensively
regulates cell functions [14].
Due to their hydrophobic nature, ceramides were thought to function
exclusively at the site of their synthesis. The existence in the cell of a protein
capable of transfering ceramide between two different locations in the
cytoplasm was demonstrated in 2003 by Hanada and colleagues [17]. The
ceramide transfer protein (CERT), the shorter splice variant of the
Goodpasture antigen-binding protein (GPBP) [28] shuttles ceramide
between the endoplasmic reticulum (ER) and the Golgi in a non-vesicular
manner. The ceramide transporter GPBP/CERT is widely distributed in the
brain with higher expression levels in neurons compared to other cell types
[25]. Knock-down of the longer isoform GPBP in zebrafish results in
extensive loss of myelinated tracts and cell death in the brain during
embryogenesis [16]. Knock-out mice for both isoforms CERT and GPBP, die
early as a consequence of heart defects due to ER and mitochondrial
degeneration.
Ceramide levels are increased in neurodegenerative diseases such as
Alzheimer's disease [10], Parkinson's disease (PD) [9], dementia with Lewy
bodies and amyotrophic lateral sclerosis [11]. Ceramides were augmented in
the cerebrospinal fluid of Alzheimer's disease patients and serum ceramides
are early predictors of cognitive impairment in Alzheimer's disease [30].
We hypothesised that the protein levels of the ceramide transporter also
change during acute neurodegeneration.
To study GPBP/CERT levels in a neurodegenerative condition, we used an
experimental model to mimic the dopamine depletion. Rats were
chronically dopamine (DA) depleted by bilateral striatal injections of 
6-hydroxydopamine (6-OHDA). 6-OHDA, being similar to DA, shows high
affinity for the dopamine transporter, which carries this neurotoxin inside
the dopaminergic neurons. 6-OHDA accumulates in the cytosol and
undergoes prompt auto-oxidation, promoting a high rate of free radical
formation [12]. As a consequence intra-striatal 6-OHDA injection
permanently damages the dopaminergic nigrostriatal pathway. The loss of
dopaminergic input to the striatum disrupts the basal ganglia circuit and is
responsible for the most prominent symptoms of PD in the extent that the
degree of neurological deficit is related to the loss of striatal DA [18]. 
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Nigral dopaminergic neurons are naturally exposed to oxidative stress
because in the presence of molecular oxygen DA undergoes spontaneous
oxidation, leading to the formation of reactive oxygen species (ROS) [15, 23].
In turn, conditions known to promote elevated cellular levels of ROS can
lead to ceramide accumulation ([19]) which is associated with the induction
of apoptotic cell death [6, 13, 38].
Here, we have conducted a design-based stereology investigation to
quantify GPBP/CERT immunoreactive cells in the striatum of rats treated
with bilateral injections of 6-OHDA.
Methods
All experimental procedures were approved by the Animal Experiments and
Ethics Committee of Maastricht University. Animal and surgical procedures
used have been described in detail before [36]. Fourteen male Lewis rats at
the age of 12 weeks received stereotactic bilateral injections at two sites per
hemisphere with either 2 μl of 6-OHDA (5 μg/μl dissolved in 0.9% saline and
0.2% ascorbic acid; Sigma, Zwijndrecht, the Netherlands) or saline (0.9%
saline and 0.2% ascorbic acid) in the striatum. To protect noradrenergic
neurons from 6-OHDA, the rats received 20 mg/kg desipramine one hour
before surgery.
After 2 weeks post injection, rats were perfused transcardially with Tyrode's
medium (0.1 M) and fixative containing 4% paraformaldehyde, 15% picric
acid and 0.05% glutaraldehyde in 0.1 M phosphate buffer (pH 7.6). Brains
were removed and postfixed for 2 h in the same medium followed by
overnight immersion in 15% sucrose in 0.1 M phosphate buffer at 4°C. Then
brain tissue was quickly frozen with solid CO2 and stored at -80°C. The brains
were cut serially in 30-μm thick coronal sections on a cryostate and were
collected free-floating in series. Of every rat, one series was selected for
immunohistochemical stainings. 
Immunohistochemistry for GPBP/CERT was carried out using free-floating
coronal sections which were incubated for 72 hours at 4°C with the primary
antibody, a rabbit polyclonal anti-GPBP/CERT antibody (diluted 1:500;
epitope 1-50 of human GPBP, Bethyl laboratories, USA). After rinsing with
Tris-buffered saline including 50 mM Triton, sections were incubated with
the secondary antibody, donkey anti-rabbit biotinylated IgG (diluted 1:800;
Jackson ImmunoResearch Laboratories Europe Ltd, Suffolk, United Kingdom)
at RT. Subsequently, sections were incubated with the ABC-kit (diluted
1:800, Vector laboratories, Peterborough, United Kingdom) for 1.5 h. To
visualize the horseradish peroxide reaction product, the sections were
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incubated with 3,3’-diaminobenzidine tetrahydrochloride (DAB). To stop the
reaction, the sections were rinsed in TBS. No labeling was evident in control
experiments in which the primary antibody was omitted from the
immunostaining protocol (not shown). Tyrosine hydroxylase (TH)
immunohistochemistry was carried out as previously described [36] using
mouse anti-TH (diluted 1:2000, kindly supplied by Dr. C. Cuello, Canada) as
primary antibody [37]. After rinsing steps with TBS, and incubation with the
secondary antibody (diluted 1:400 donkey anti-mouse biotin; Jackson
Immunoresearch Laboratories, West Grove, USA), the labeling was
visualized with ABC/DAB procedure as mentioned above.
For the stereologic procedures, a stereology workstation consisting of an
Olympus BX51 microscope (Olympus, Tokyo, Japan), motorized specimen
stage, color video camera and a PC with StereoInvestigator stereology
software (MBF Bioscience, Vermont, USA) was used. The number of cells
expressing GPBP/CERT and labelled with the abovementioned polyclonal
antibody were quantified in a part of the striatum, with a rostral boundary
at Bregma 1.60 mm where the corpus callosum crosses the midline and a
caudal boundary at Bregma -0.90 mm where the fornix enters the
diencephalon. The dorsal and lateral boundaries of this region consisted of
the corpus callosum and the medial boundary was defined by the lateral
ventricle. A ventral boundary was set by drawing a line from the tip of the
lateral ventricle to the rhinal fissure [20] . The region of interest was
delineated using a 4x objective. The optical fractionator technique [32] was
used to determine the total numbers of cells positive for GPBP/CERT.
Positive cells were counted using a 100x objective in unbiased virtual
counting spaces distributed in a systematic random fashion throughout the
delineated region of interest. The total number of positive cells in the region
of interest was estimated as a function of the number of cells counted and
the sampling probability [32]. For, quantifying the number of TH
immunoreactive (THir) neurons, a similar stereological approach was used.
After exactly tracing the boundaries of the substantia nigra pars compacta
(SNc) on microscopic video images displayed on a monitor, numbers of
neurons were evaluated with the Optical Fractionator [31]. All neurons
whose nucleus top came into focus within unbiased virtual counting spaces
distributed in a systematic-random fashion throughout the delineated
regions were counted. The total numbers of neurons were estimated as a
function of the numbers of counted neurons and the corresponding
sampling probability. For more details see [36].
GPBP/CERT immunostained neurons were evaluated also by gray value.
Mean gray values for regions of interest (bregma 0.7 and - 0.4) were
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calculated using ImageJ software, with images photographed at a
magnification of x 40. The mean gray value of cells in the selected regions
was used as a measurement for the expression levels of GPBP/CERT in the
striatum. The statistical analysis of the data was done with GraphPad Prism
(Version 5.01 for Windows, GraphPad Software, San Diego CA). The mean
and the standard error of the mean (SEM) were determined for the numbers
of cells expressing GPBP/CERT and the striatal volume in both 6-OHDA and
control rats. 
An unpaired two-tailed t-test was performed to compare the means of the
6-OHDA group and the control group, the result was considered statistically
significant if its p-value was smaller than 0.05. Three unilateral 6-OHDA
lesioned rats were used (disease induction and handling similar to animals
describes above). Brains were removed, striatal samples were dissected in
two hemispheres the 6-OHDA-injected and from the control hemisphere.
The samples were quickly frozen with solid CO2 and stored at -80°C striatal
brain homogenization is performed as described previously [25]. Proteins
were separated by SDS-PAGE using precast Criterion Tris-HCl Glycine 4-20%
gradient gels (Bio-Rad, CA, USA) followed by electroblotting to nitrocellulose
membrane (Millipore, Amsterdam Zuid-Oost The Netherlands). The
membranes were incubated with the following primary antibodies: rabbit
polyclonal anti-GPBP/CERT antibody (epitope 1-50 of human GPBP, Bethyl
laboratories, USA) and mouse monoclonal anti-GAPDH antibody (Ab9484,
Abcam, Cambrdige, UK), used as a protein loading control. After PBS washes,
the membrane was incubated with goat anti-rabbit-Alexa 800 and donkey
anti-mouse-Alexa 680 (Rockland, USA). The membrane was washed with
PBS, dried and scanned using the Odyssey infrared imaging system
(Westburg, The Netherlands). The mean intensity of the GPBP/CERT band
was measured in ImageJ and corrected for protein loading with the mean
intensity of the GAPDH band.
Results
Injections of 6-OHDA into the striatum resulted in a substantial loss of THir
cells in the SNc as compared to the sham group. High-precision design-based
stereological analysis revealed a significant 6-OHDA-induced reduction in
the total number of THir cells in the SNc of about 65% bilaterally (P<0.01)
Figure 1. 
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Figure 1: Mean total numbers of THir- neurons 
of sham-operated rats and rats subjected to 
dopamine depletion. Data represent means and 
SEM per group. Since the left and right SNc 
showed a similar cell count, the data were 
pooled. The P values from the corresponding 
post hoc LSD tests are provided as 
*P < 0.05
6-OHDA starts its toxic effects in the striatum with dopamine nerve terminal
disruptions and consequent progressive retrograde degeneration of nigro-
striatal dopamine neurons in the SNc. Therefore in this study we selected
the striatum as area of investigation (Figure 2 C), instead of the SNc where
the massive death of dopaminergic neurons (Figure 2 A and B) would have
masked the quantification of GPBP/CERT levels. For the quantification of
GPBP/CERT positive cells in diseased and control animals, the striatum was
delineated as depicted in Figure 2C. Figure 2D shows a high-power
photomicrograph of the striatum with the 100x objective used during the
counting procedure. GPBP/CERT positive cells were neurons as described
previously [26]. Intensely stained neurons were present in the striatum,
although there was considerable regional variation in the intensity of the
stained cells. The stereological analysis revealed no differences in the
volume of the striatum in 6-OHDA treated rats compared to the group of rats
that received a sham treatment (p= 0.61; Figure 2E). Additionally the
quantification of the total numbers of GPBP/CERT positive cells in the
striatum using the fractionator technique showed no significant difference
between the saline treated group and the 6-OHDA injected group (p=0.48;
Figure 2F). 
To further confirm these results, a quantitative Western blotting analysis of
the striatum of 6-OHDA-treated and -untreated hemispheres was performed
with the same antibody anti-GPBP/CERT used in the immunohistochemical
study. The result is consistent with the previous analysis since no difference 
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Figure 2: Tyrosine hydroxylase immunohistochemistry of the substantia nigra pars compacta (SNc) of
sham treated rats (A) and 6-OHDA treated rats (B). The delineation of the striatum used in the
stereological procedure (C) and a representative high-power photomicrograph of the striatum stained
for GPBP/CERT (D). The volume of the striatum (E) and the estimated total number of cells positive for
GPBP/CERT in the striatum (F) are not different between sham treated and 6-OHDA treated rats.
Means were compared with an unpaired two-tailed t-test, data are shown as values of individual
animals and the mean of the group.
in GPBP/CERT protein levels were detected in the 72 kDA protein band of
untreated and 6-OHDA treated samples (Figure 3A and B).
No significant difference was found in the level of GPBP/CERT expression
level within individual cells in the striatum of diseased and control animals
(p=0.07; Figure 3). 
Table 1: Details of the stereologic analysis
Region Obj B (μm2) H (μm) D (μm) t (μm) ∑OD ∑Q- CEpred[n]
Striatum 100x 900 6 400 7.57 331 655 0.039
Obj., objective used; B and H, base and height of the unbiased virtual counting spaces; D, distance
between the unbiased virtual counting spaces in mutually orthogonal directions x and y; t, measured
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Figure 3: (A) Western blot of striatal 
brain homogenates detected with anti-
GPBP/CERT and anti-GAPDH 
antibodies shows comparable protein 
amounts between the 6-OHDA-
injected (L) and the control (R) 
hemisphere in three animals (1-2-3). 
(B) Quantification of the 72 kDa 
GPBP/CERT band in the Western blot 
of brain homogenate shown in (A). The 
mean intensity of the bands was 
measured and corrected for GAPDH 
intensity, no significant difference in 
GPBP/CERT expression was found. (C) 
Gray value quantification of 
GPBP/CERT expression in individual 
cells of the striatum at Bregma -0.4 
and 0.7. A minimum of 30 cells per 
animal were quantified and no 
statistically significant difference in 
mean gray value was found between 
the SHAM and 6-OHDA rats (P=0.07).
actual average section thickness after histological processing; ∑OD, average sum of unbiased virtual
counting spaces used; ∑QD, average number of counted neurons; CEpred[n], average predicted
coefficient of error of the estimated total neuron numbers using the prediction method described in
[31] and [32].
Discussion
Protein levels of the ceramide transfer protein GPBP/CERT were not altered
in the striatum in the acute neurodegenerative process of the 6-OHDA
model. This lack of difference might be explained by several reasons. First,
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the mode of action of 6-OHDA: injection of 6-OHDA selectively kills
dopaminergic neurons after entering the cells via the dopamine transporter,
inducing acute effects which differ significantly from the chronic progressive
course of PD [4]. Dopaminergic neurotoxicity of 6-OHDA is associated with
membrane lipid alteration, cellular loss of phospholipid asymmetry and
membrane blebbing [5, 40]. This membrane-associated oxidative stress
occurs together with accumulation of ceramide species [27, 33].
Additionally, it has been described that 6-OHDA promotes a high rate of free
radical formation in the cytosol of neurons and ROS production also leads to
ceramide accumulation [2, 19]. In our experiments the analysis of the
striatum takes place days after the cellular induced toxicity by 6-OHDA.
Conversion of palmitate to ceramide in the de novo pathway requires
multiple enzymatic steps and it is responsible for a slow but robust
accumulation of ceramide over a period of several hours [22]. We studied
levels of GPBP/CERT days after the induction of apoptosis by 6-OHDA to
assure the production of ceramide by the de novo pathway.
Second, a defining pathological hallmark of PD is the presence of neuronal
Lewy body formed by protein aggregates. After 6-OHDA lesioning,
cytoplasmatic inclusions of aggregate proteins do not occur [35]. The role of
protein aggregations in the pathogenesis of PD has not been fully
determined, but altered protein processing in the cell could have a negative
impact on normal cellular function. Some of the genes involved in Lewy
body disease have also an effect on ceramide metabolism (for review, see
[8]). In this regard, knock down of LASS2, an aging-associated gene that
encodes a ceramide synthase, results in a premature increase in the number
of inclusions in Caenorhabditis elegans [39]. Therefore, ceramide and its
transporters could play a role in protein self aggregation processes. 
Moreover, mutations that occur in glucosylcerebrosidase gene have been
found to predispose to PD [7] and Lewy body disorders [24].
Glucocerebrosidase is an enzyme that catalyzes the breakdown of the lipid
glucosylcerebroside to ceramide and glucose. This enzyme is highly enriched
in the brain. Loss of glucocerebrosidase activity and a toxic gain-of-function
can cause Parkinson disease-like α-synuclein pathology [29].
It is important to bear in mind that post translational refolding of normal
protein, including the normal prion protein and the amyloidogenic
processing of amyloid precursor protein, is affected by the content of
sphingomyelin and cholesterol in lipid rafts at the level of the plasma
membrane [3, 21, 34, 36]. Consequently, dysregulation of sphingolipid
metabolism, that seems to be strongly involved in protein aggregation in
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many neurodegenerative disorders, is a condition that is missing in a 6-
OHDA model.
Third, the antibody used in this study recognizes both isoforms, GPBP and
CERT. Therefore we cannot rule out the possibility that significant changes
in GPBP expression are masked by CERT expression which is higher at basal
levels compared to GPBP [28]. These two variants may differ in various
properties such as stability, clearance rate, tissue and cellular localization,
temporal pattern of expression, up or down regulation mechanisms and
responses to agonists or antagonists. Moreover, the presence or level of
specific splice variants may vary depending on the pathophysiologic state of
a particular condition. Specific antibodies for each isoform were unavailable
at the time of this study; the development of these antibodies should help
to resolve this issue.
All the data generated using the 6-OHDA model may help to determine if
GPBP/CERT could be critical in the molecular pathways leading to
degeneration of nigral cells induced by accumulation of toxins. However, our
results are only indicative and need post-mortem confirmation to estimate
the real occurrence of such processes. Thus to confirm our findings future
investigation of intra- and extracellular ceramide abundance and localization
in PD brain and thus its possibility to bind to CERT/GPBP are desirable.
Conclusions
We tested the hypothesis that GPBP/CERT expression levels were affected in
the acute brain injury process of a 6-OHDA PD rat model. Using quantitative
stereology we did not observe differences in the number of striatal cells
expressing GPBP/CERT. Correlating with this result, also gray value
quantification did not detect differences in GPBP/CERT expression levels
within individual cells in the acute brain injury process of a 6-OHDA PD rat
model. Whereas ceramide levels are known to increase in
neurodegenerative diseases, this is the first study to report on the
expression levels of the ceramide transporter GPBP/CERT, which were found
to remain stable in the PD model used. 
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SUMMARY
Serum amyloid P component (SAP) is a non fibrillar glycoprotein belonging
to the pentraxin family of the innate immune system. SAP is present in
plasma, basement membranes and amyloid deposits. This study
demonstrates, for the first time, that the Goodpasture antigen binding
protein (GPBP) binds to human SAP. GPBP is a nonconventional Ser/Thr
kinase for basement membrane type IV collagen. Also GPBP is found in
plasma and in the extracellular matrix. In the present study we demonstrate
that GPBP specifically binds SAP in its physiological conformations,
pentamers and decamers. The START domain in GPBP is important for this
interaction. SAP and GPBP form complexes in blood and partly colocalize in
amyloid plaques from Alzheimer's disease patients. These data suggest the
existence of complexes of SAP and GPBP under physiological and
pathological conditions. These complexes are important for understanding
basement membrane, blood physiology and plaque formation in
Alzheimer's disease.
Serum amyloid P component (SAP) is present in the blood as single
uncomplexed pentamers and decamers (1). SAP has been found to decorate
amyloid deposits in different amyloid diseases where it was first identified
(2). In Alzheimer's disease (AD), SAP colocalizes with amyloid-ß deposits (Aß)
(3,4) in the brain and is thought to protect the amyloid from proteolysis (5).
Below we will first introduce known properties of SAP and subsequently of
the Goodpasture-antigen binding protein (GPBP), which we identify and
characterize as a new SAP binding protein in this paper.
SAP is a 23 kDa glycoprotein (6) of the pentraxin family which is
characterized by Ca2+-dependent ligand binding (7-10). SAP self-association
and aggregation is also influenced by Ca2+ (11). 
SAP binds to proteins involved in immunological responses (12-15) and can
activate the classical complement pathway through interaction with C1q
(16). In addition, SAP interacts with extracellular matrix (ECM) components
such as proteoglycans (8,17), fibronectin (18), laminin (10) and collagen IV
(9). Collagen molecules are heterotrimers composed of three alpha chains.
In collagen IV, each of these α-chains consists of an amino-terminal 7S
domain, a central helical structure and a carboxyl-terminal globular non-
collagenous (NC1) domain. The distribution of SAP in basal membranes
(BMs) coincides with the restricted localization of the α3-α4-α5
heterotrimer of collagen IV (17). 
The NC1 domain of the collagen IV α3 subunit (α3(IV)NC1) is the
autoantigen in Goodpasture (GP) syndrome, an autoimmune disease in
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which autoantibodies are observed along glomerular and alveolar BMs,
causing glomerulonephritis and lung hemorrhage (19). 
The Goodpasture antigen binding protein (GPBP) binds to the α3(IV)NC1 in
the glomerular basal membrane (GBM) of GP patients (20). GPBP exist in
different isoforms which are found in the extracellular compartment; either
soluble or associated with the surface of the plasma membrane (21,22) and
in blood (23). A shorter splicing isoform, CERT, is located inside the cell and
functions as carrier for ceramide from the ER to the Golgi apparatus (24).
GPBP and CERT (also known as CERTL and GPBPΔ26, respectively) are
identical in sequence with the exception of an additional 26 amino acid
domain present only in GPBP (25).
Because both SAP and GPBP have been reported to self aggregate (11,25)
and have similar properties the question arose as to whether SAP and GPBP
could bind to each other. Thus, the aim of the present study was to
characterize in detail the direct interaction between these proteins using
surface plasmon resonance (SPR), far Western blotting and microscale
thermophoresis technology (MST). We report, for the first time, that SAP
binds to GPBP and moreover, that SAP and GPBP are co-localized in amyloid
plaques from AD patients. Our data suggest the existence of complexes of
SAP and GPBP under normal and pathological conditions.
EXPERIMENTAL PROCEDURES
Purification of SAP protein from human serum
SAP was purified from human plasma through an immuno-affinity procedure
applying Ca2+-ion dependent interactions of SAP with complement factor
C4b-binding protein (C4BP). A monoclonal antibody against C4BP (CLB-
C4BP), which is directed against the alpha chains of human C4BP [a kind gift
from Dr Jan van Mourik, Sanquin Research, Central Laboratory of the Blood
Transfusion Service (CLB), Amsterdam, the Netherlands] was coupled to
CNBr-activated Sepharose 4B (GE healthcare, Hoevelaken, the Netherlands)
according to manufacturers instructions. Human plasma was fractionated by
barium citrate precipitation and eluted with 30% ammonium sulfate. After
precipitation with 70% ammonium sulfate the protein fraction was dialyzed
against Tris buffered saline (TBS: 50 mM Tris-HCl pH 7.4, 150 mM NaCl)
supplemented with 3 mM CaCl2 and applied to the anti-C4BP column. After
binding of the C4BP-SAP complex, the column was washed with TBS
containing 3 mM CaCl2 until OD280nm < 0.05. Subsequently, SAP was
specifically eluted with TBS containing 2 mM EDTA. Purified human SAP
appeared as a single band (>95% purity) on a Coomassie Blue-stained 4-15%
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SDS gel and fractions were pooled and frozen at -80°C until use. The identity
of SAP was confirmed by peptide mass fingerprinting using a tandem
MALDI-TOF protein analyzer (Applied Biosystems 4800)
Production of recombinant GPBP and CERT proteins
For recombinant expression of GPBP and CERT we used the vector pHILD2
(Invitrogen, Breda, the Netherlands). The expression cassettes were
synthesized (GeneArt, Regensburg, Germany) using the cDNA sequences
that encode the human GPBP protein (NP_005704.1) and the human CERT
protein (NP_112729.1) preceded by a cassette including an EcoRI restriction
site, a standard Kozak consensus for translation initiation, followed by a
sequence encoding for MAPLA and a FLAG tag peptide (DYKDDDDK). An
EcoRI site was introduced after the stop codon. The plasmids were
transfected and expressed in Pichia pastoris (Invitrogen). FLAG-tagged
recombinant proteins were purified from the cell lysate with an anti-FLAG
M2 affinity agarose gel column (Sigma, A2220, Zwijndrecht, the
Netherlands) according to the manufacturer's instructions. The unbound
material was washed off the column with TBS and FLAG-tagged proteins
were eluted using 100 μg/mL FLAG peptide (Sigma, F3290).
CERT and CERT mutants constructs were synthesized by LifeTechnologies,
GeneArt (Regensburg, Germany) in pET28b (Novagen) expression vectors
through a PCR-based method. Flag-tagged proteins were produced by
overexpression in E. coli BL21(DE3) pLYSs (Promega, UK), induced with 1 mM
IPTG for 4 hours at 37°C. Recombinant protein was isolated using the FLAG-
tag as described above.
Sample preparation and SPR analysis
SAP self-aggregation was controlled by optimization of the buffers. To this
end, native SAP was diluted at final concentrations of 25, 50 and 100 nM in:
1) sodium acetate buffer pH 4.5; 2) sodium acetate buffer pH 4.5 with 5 mM
Ca2+; 3) 25 mM HEPES buffer pH 7.4; 4) 25 mM HEPES buffer pH 7.4 and
sonicated; 5) 25 mM HEPES buffer with 0.01% Tween 20 at pH 7.4 and
sonicated. Sonication was performed before SPR experiments using a probe
(Beun-De Ronde B.V., Abcoude, the Netherlands) for 3 pulses of 30 s each
with a 30 s rest on ice between pulses. Each sample was centrifuged at
20,000 g for 5 min to remove protein aggregates immediately before SPR
analysis.
SPR experiments were performed on a Biacore T100 apparatus (GE
healthcare) (26). The guidelines from the manufacturer were followed for
the preparation of the sensor surfaces and interpretation of the
13
8
Chapter 5
sensorgrams. Purified human SAP, GPBP and CERT (50 μg/mL in 10 mM
sodium acetate buffer pH 4.5) were covalently coupled via amine groups
onto the carboxymethylated dextran surface of CM5 sensor chips (GE
healthcare) resulting in a signal of up to 15000 resonance units (RU).
Injection of specific antibodies recognizing both GPBP and CERT
demonstrated the presence of the proteins immobilized in each flow cell
[rabbit polyclonal anti-GPBP/CERT, epitope 1-50 of human GPBP/CERT,
Bethyl Laboratories, Montgomery, TX; rabbit polyclonal anti SAP (P-16),
Santa Cruz Biotechnology, CA]. Analytes for binding studies were prepared in
25 mM HEPES buffer pH 7.4, 150 mM NaCl with 0.01% Tween 20. To
perform binding experiments, protein samples (purified SAP, human
collagen IV (Sigma), human laminin (Sigma), bovine serum albumin (BSA,
Sigma), were injected onto the chip over a concentration range of 100 nM -
1 μM at a flow rate of 10 μL/min for 5 min at 25°C. To test the effect of Ca2+
on protein-protein interaction, the same buffer with addition of 5 mM Ca2+
was used for some of the experiments. 
Wild type and five mutant CERT proteins were serially diluted in 25 mM
HEPES, 150 mM NaCl, 0.01% Tween 20, pH 7.4, over a wide concentration
range (up to 500 nM) by using 2-fold dilution steps. Samples were injected
over a SAP-coated surface of CM5 sensor chip (density, 5000 RU), for 3 min
at a flow rate of 30 μL/min, at 25°C. At the end of each run, the sensor
surface was regenerated (removal of bound complex) by using 25 mM NaOH
before additional samples were injected. As an internal reference, a control
channel was routinely activated and blocked in absence of protein. The
signals from the control channel were subtracted from the signals generated
by the flow cells containing immobilized protein. Analysis was performed on
the data using BIAevaluation 3.0 software. Sensorgrams were recorded and
normalized to a base line of 0 RU.
Microscale Thermophoresis binding analyses
Microscale thermophoresis (MST) is a new immobilization-free technique
for the analysis of biomolecules interaction (27-29). The term Microscale
Thermophoresis refers to the directed movement of molecules in optically
generated microscopic temperature gradients. This thermophoretic
movement is determined by the entropy of the hydration shell around
molecules. The microscopic temperature gradient is generated by an IR-
Laser. The readout method of the interaction analysis is based on
fluorescence. In a typical MST-experiment the concentration of the labeled
molecule is kept constant, while the concentration of the unlabeled
interaction partner is varied. The MST signal will detect the binding by a
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quantification of the change in the normalized fluorescence (27).
MST analysis was performed on the Monolith NT.115 instrument
(NanoTemper, München, Germany). In brief, a constant concentration of 1-
50 nM of NT647-labeled GPBP was incubated for 20 min at room
temperature in the dark with different concentrations of SAP (up to 5000
nM) in PBS/0.01% Tween 20. Afterwards, 3-5 μL of the samples were loaded
into glass capillaries (Monolith NT Capillaries, Cat # K002) and the
thermophoresis analysis was performed (LED 40-51%, IR laser 80%).
Statistical analysis was performed with Origin8.5 software.
Gel filtration chromatography
A Superose 6 column with a bed volume of 24 mL (Perkin-Elmer Series 4
FPLC system) connected to a FPLC system (GE healthcare) was washed with
ethanol (20% v/v) and 0.5 M NaOH, and pre-equilibrated with 3 column
volumes of 25 mM HEPES buffer (pH 7.4) with 150 mM NaCl. Samples of
purified SAP were run on this column with a buffer flow rate of 0.4 mL/min.
The approximate molecular mass of the fractionated proteins was calculated
from peak elution volumes by comparison with molecular weight
standards(thyroglobulin, 669 kDa; ferritin, 440 kDa; fibrinogen, 340 kDa;
IgG, 160 kDa; BSA, 67 kDa; ribonuclease A, 13.7 kDa; GE healthcare).
Immunoprecipitation and Western blot
Immunoprecipitation and co- immunoprecipitation of SAP and GPBP from
human serum were performed after depletion of albumin (ProteoExtract
Albumin Removal Kit; Calbiochem, La Jolla, CA) to increase the resolution of
the lower-abundance proteins of interest. Albumin depleted serum was
centrifuged at 20,000 g for 30 min. Pull down of endogenous SAP and
endogenous GPBP was performed with mAb 4E8 (Sigma) and mAb 3A1-C1,
respectively. Rabbit polyclonal anti Dok-7 antibody (H-77, Santa Cruz
Biotechnology, Heidelberg, Germany) and a mouse monoclonal anti syntaxin
6 (clone 3D10, Abcam, Cambridge, UK) were used as isotype controls. After
incubation (1 μg antibody per 15 μL serum; at room temperature for 1 h),
samples were centrifuged at 20000 g for 30 min at 4°C. Pellets were washed
three times in 50 μL PBS and boiled in reducing sample buffer containing
mercaptoethanol to dissolve immunocomplexes.
Brain tissue from 8 months old control and Alzheimer's transgenic mice
(APPswe PS1ΔE9 C57BL/6) were thawed and homogenized as described (30).
In brief rat cortex was placed in ice cold lysis buffer containing PBS, 0.1%
SDS, 0.1% Triton X-100, 1% glycerol, 1 mM EDTA, 1 mM EGTA, 30 mM NaF,
and 16.7 mM sodium orthovanadate and a Complete Protease Inhibitor
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Cocktail tablet (Roche Diagnostics, Almere, the Netherlands) per 50 ml of
buffer, following the manufacturers recommendations. Glass beads and a
bead beater (Biospec products, Bartlesville, OK) were used for the
homogenization of the tissue. The homogenization consisted of 3 cycles of
30 s in 1.0 ml lysis buffer.
Total protein concentration was determined by a conventional method (BCA
protein assay Kit, Pierce). For immunoprecipitation, 2 mg brain
homogenates were incubated for 1 h at room temperature with 3 μg of one
of the following mAbs: anti-SAP (4E8), anti-GPBP (3A1-C1) or anti-A? (human
recombinant antibodies bapineuzumab, solanezumab and 20C2, produced
recombinantly in house, based on published sequences). Negative controls
consisted of IgG mAb anti syntaxin 6 (clone 3D10) or anti-rapsyn (clone
1234, Sigma). Next we added goat anti-mouse (Euroegentec, Maastricht, the
Netherlands) during 30 min at room temperature (1 μg per sample).
Samples were centrifuged at 20000 g for 30 min at 4°C and
immunocomplexes were processed as described above.
Proteins were separated by SDS and native-PAGE using precast Criterion
Tris-HCl glycine 4-20% gradient gels (Bio-Rad, Veenendaal, the Netherlands)
followed by electroblotting to nitrocellulose membrane (Millipore,
Amsterdam Zuid-Oost, the Netherlands). The membranes were incubated
with primary antibodies specific for SAP (4E8), or GPBP using either mAb
3A1-C1, or polyclonal rabbit anti-GPBP epitope 1-50 (Bethyl laboratories). or
specific for Aβ using anti-Aβ (6E10). After PBS washes, the membrane was
incubated with goat anti-rabbit-IRdye 800 and donkey anti-mouse-IRdye 680
(Rockland Immunochemicals, Gilbertsville, PA). Finally, the membrane was
washed with PBS, dried and scanned using the Odyssey infrared imaging
system (Westburg, Leusden, the Netherlands).
Far Western
For far-Western experiments SAP (80 ng) and BSA (2 μg) (Sigma) were
separated by SDS-PAGE under reducing conditions and transferred to
Immobilon P membranes (Millipore). For renaturation of SAP, the
membranes were incubated in TBS with Tween 20 (0.05%) over night.
Renatured proteins were probed for 1 h at 37°C with either GPBP, CERT or
CERT mutants (30 μg/mL) in the same buffer (20). Next, membranes were
blocked with 5% BSA. Bound material was detected using anti-GPBP (3A1-
C1), anti-SAP (4E8) and donkey anti-mouse-Alexa 680 followed by detection
as described above. BSA was detected by standard Coomassie staining.
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Immunohistochemistry in kidney
Sections of monkey control kidney tissue (macaques) (Probetex, San
Antonio, TX) were incubated over night at room temperature with primary
antibodies [mouse monoclonal anti-GPBP antibody (3A1-C1) and anti-SAP
(4E8)], followed by the corresponding secondary antibody [donkey anti-
mouse biotinylated IgG (Jackson ImmunoResearch Laboratories Europe Ltd.,
Newmarket, Suffolk, UK)]. Subsequently, sections were incubated with the
ABC-kit (Vector Laboratories, Burlingame, CA) followed by 3,3-
diaminobenzidine tetrahydrochloride (DAB).
Slides were mounted with 80% glycerol in TBS. Images were acquired using
an Olympus AX70 microscope (Olympus, Zoeterwoude, the Netherlands)
and recorded using Cell P software (Olympus).
Immunohistochemistry in human brain
In order to investigate the presence and localization of GPBP in human brain,
post mortem specimens from 3 male and 3 female donors were studied by
immunohistochemistry. This material was obtained from the Netherlands
Brain Bank (Amsterdam, the Netherlands). Staging of AD was
neuropathologically evaluated according to the Braak and Braak criteria (see
Table 1) (31). For immunohistochemical staining, 5 μm cryosections were
mounted on coated glass slides (Menzel Gläser super frost PLUS,
Braunschweig, Germany), and fixed in acetone for 10 min. Next, sections
were incubated overnight with primary antibodies, including rabbit anti-SAP
(Dako), mouse monoclonal anti-Aβ (clone 6F/3D; Dako), affinity purified
rabbit antibody specific for the residue 300-350 of human GPBP/CERT
(Bethyl laboratories) or polyclonal rabbit anti-GPBP/CERT epitope 1-50.
Subsequently, sections were incubated with EnVision goat-anti-mouse
horseradish peroxidise (HRP) or EnVision goat-anti-rabbit HRP (Dako).
Peroxidase labeling was visualized by EnVision DAB (EV-DAB; Dako). Sections
were counterstained with hematoxylin. For co-localization studies,
cryosections were incubated in thioflavin S solution to stain Aβ fibrils and
washed subsequently three times in ethanol 70%. Sections were incubated
with a mix of primary antibodies: anti-SAP (mAb-14) (32) in combination
with anti-GPBP/CERT 1-50 or 300-350 diluted in PBS containing 1% BSA.
After washing in PBS, sections were incubated with a mix of secondary
antibodies: biotin conjugated goat-anti-rabbit (Dako) and EnVision goat-
anti-mouse HRP (Dako). Upon washing with PBS, sections were incubated
with streptavidin Alexa-633; HRP signal was developed with rhodamin
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tyramide (in presence of 0.01% H2O2). Slides were covered with Aqua-
Poly/Mount (Polysciences Inc, Warrington, PA).
RESULTS
Binding of SAP and GPBP to type IV collagen
Previously it has been reported that both SAP and GPBP specifically bind to
α3(IV)NC1 monomer (20,33). In order to analyze if this binding occurs in
vivo, we studied whether SAP and GPBP colocalize in glomerular basal
membrane (GBM), which expresses collagen IV. To this end, frozen monkey
kidney sections were stained by immunohistochemistry. SAP showed a
linear staining pattern along the GBM as described (34) (Figure 1A upper
panel). A monoclonal antibody that recognizes GPBP specifically (mAb3A1-
C1) also resulted in a strong staining of the GBM (Figure 1A middle panel).
Thus, the reported immunoreactivity of polyclonal antibodies against both
GPBP and CERT to tubules and glomerulus in human kidney (20) can be at
least partially attributed to the expression of the longer isoform GPBP.
We further examined the binding of SAP and GPBP to collagen IV by SPR
technology. Collagen IV bound to immobilized human GPBP and human SAP
(Figure 1B and C).
Binding of SAP to several ligands is dependent on the presence of Ca2+
(7,8,35). Binding of collagen IV to SAP was enhanced by 3-4 fold by the
addition of 5 mM Ca2+ (Figure 1C). In contrast, binding of collagen IV to GPBP
was independent of the presence of Ca2+ (Figure 1B). Binding of BSA to
immobilized SAP or GPBP was minimal (data not shown). Kinetic analysis of
the binding of soluble collagen IV to immobilized SAP and to GPBP was
performed by SPR. Collagen IV (concentrations ranging between 10 to 250
nM) bound to GPBP strongly; increasing the concentration of collagen IV up
to 250 nM did not saturate this binding (Figure 2A). As expected, collagen IV
also bound to immobilized SAP (Figure 2B) and in this case binding was
already almost saturated at 10 nM collagen IV. These data suggest that once
collagen IV has bound to immobilized GPBP, additional collagen IV can bind
by forming GPBP-collagen-collagen complexes. In contrast, SAP binding to
collagen IV does not induce formation of larger collagen aggregates Binding
of collagen IV to CERT was also studied and compared with GPBP (Figure 2C).
Collagen IV rapidly associated with both immobilized proteins. However,
collagen IV dissociated faster from CERT than from full-length GPBP.
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Figure 1. Collagen IV binds to SAP and to GPBP
(A) Representative monkey kidney sections with glomeruli stained for GPBP and SAP; SAP with mAb;
GPBP with mAb 3A1-C1. No staining was observed when the primary antibodies were omitted. Scale
bars represent 100 μm. (B-C) The detection of the protein-protein interaction was performed with
specific antibodies against SAP and GPBP using SPR technology. (B) Collagen IV was filtered (0.45-μm
Millipore filter), and then injected (100 nM) over immobilized GPBP (101 RU; flow rate, 15 μL/min;
injected volume, 60 μL) in 25 mM HEPES buffer pH 7.4, 150 mM NaCl (either without Ca2+ or with
5 mM Ca2+). In panel (C) collagen IV was injected at 100 nM over immobilized SAP (101 RU; flow rate,
15 μL/min; injected volume, 60 μL) in 25 mM HEPES buffer pH 7.4, 150 mM NaCl (either without Ca2+
or with 5 mM Ca2+).
Binding of laminin to immobilized GPBP
SAP has been shown to bind laminin, another important component of
basement membranes (10). However, the binding of GPBP to laminin has yet
to be reported. By SPR binding experiments we found that laminin binds to
immobilized GPBP (Figure3). Binding of laminin to GPBP was enhanced by
approximately 25% with the addition of 5 mM Ca2+ (Figure 3).
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Figure 2. Collagen IV binds to
SAP, GPBP and CERT Overlay of
sensograms resulting from the
injection of different
concentrations (10-250 nM) of
collagen IV over immobilized
GPBP (96 RU, flow rate, 15
μL/min; injected volume, 60 μL)
(A) and over immobilized SAP (96
RU, flow rate, 15 μL/min; injected
volume, 60 μL) (B). Binding of
collagen IV (100 nM) to
immobilized GPBP and CERT (50
μg/mL in 10 mM sodium acetate
buffer pH 4.5) (C). The
sensograms were corrected for
the signal in the empty cell (i.e.
calculated as the difference
between the signal in Fc2 (flow
channel 2) that contained the
immobilized ligand and the signal
in Fc1 (empty channel), which
includes injection noise,
instrument drift, and nonspecific
binding).
GPBP binds SAP and is present in amyloid brain plaques
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Figure 3. Laminin binds to GPBP
(A) Binding of laminin (100 nM) to
immobilized GPBP (215 RU; flow
rate, 15 μL/min; injected volume, 60
μL) in buffer containing 5 mM Ca2+ or
buffer without Ca2+. The binding was
first recorded in the absence of
added Ca2+. The experiments were
performed by SPR technology.
Binding of SAP to immobilized GPBP
Since SAP and GPBP bind to collagen IV, and colocalize at GBM, we asked the
question whether they could interact with each other. We measured the
binding of GPBP to immobilized SAP by far-Western (Figure 4A) (36,37). For
this purpose, membranes containing SAP (80 ng) and BSA (2,000 ng) as
negative control were incubated in renaturation buffer over night and
subsequently probed with GPBP. Our experiment showed that GPBP strongly
bound to SAP but not to BSA, suggesting that SAP and GPBP interact. This
interaction is dependent on renaturation of SAP on the membrane since
Western blot separation of SAP followed by immediate membrane
incubation with GPBP without renaturation did not lead to significant
binding of GPBP to SAP (Figure 4A).
We further investigated the molecular characteristics and the kinetics of this
binding by SPR. SAP is a highly interactive protein prone to extensive self-
aggregation (38). We found that by careful selection of buffer conditions as
pH, presence/absence of Ca2+ and of detergent, it was possible to control the
process of self association (Figure 4B). Human SAP was found to be highly
aggregated (>250 kDa) at pH 7.4 (with or without Ca2+) and did not migrate
into a 4% polyacrylamide gel under native and non-reducing conditions.
However, it was found that sonication of SAP in HEPES buffer pH 7.4 with
0.01% Tween 20 to a large extent prevented this protein aggregation and
precipitation; sonication disrupted aggregates and the presence of the
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detergent stabilized SAP in physiological pentameric and decameric species.
High temperature treatment, high salt and organic solvent were also tested
but resulted in irreversible denaturation (data not shown). We studied the
binding of fluid phase SAP to immobilized GPBP and CERT by SPR (Figure 4C
and D). Interestingly, we found that SAP (stabilized as pentamers and
decamers, as described above) binds both GPBP and CERT in the absence of
Ca2+. Conversely, in the presence of 5 mM Ca2+ this binding was reduced 5-7-
fold.
SAP interaction with both GPBP and CERT was characterized by a rapid
association rate; however, SAP binding to GPBP was stronger than to CERT.
To explore in more detail the different affinity of SAP for the two protein
isoforms, we immobilized SAP on the sensor chip and applied as analyte a
peptide containing 14 (385-398) of the 26 amino acids encoded by exon 11
of GPBP. Exon 11 encodes a short domain that is absent in CERT. This peptide
was shown to bind immobilized SAP (Figure 4E) which supports the notion
that this region of GPBP participates in the interaction with SAP. Kinetic
analysis of SAP binding to immobilized GPBP was performed by varying the
concentrations of SAP added (ranging from 25 nM to 100 nM) (Figure 5). We
found that the binding of SAP to GPBP does not saturate, suggesting that
GPBP-SAP-SAP complexes can be formed, in analogy to what is described for
type IV collagen binding above (Figure 2A and B). Therefore, these data
indicate that SAP binding to GPBP in solid phase is non saturable, making it
difficult to reliably estimate the binding constant. In this respect, the SPR
data should be regarded as qualitative evidence, demonstrating the direct
binding of proteins involved.
Binding of SAP to GPBP in solution
Microscale thermophoresis (MST) was performed in order to determine the
dissociation constant of SAP to fluorescently labeled GPBP in fluid phase. 10
nM of NT-647 labeled GPBP was mixed with increasing SAP concentrations.
After a short incubation time the samples were loaded into glass capillaries
and a thermophoretic analysis was performed on the Monolith.NT115 using
51% LED-Power and 80% IR-Laser power. The normalized fluorescence
Fnorm is plotted for different concentrations of SAP. An apparent KD of 5.7
nM +/- 2.66 nM was determined for this interaction (Figure 6).
Binding of different molecular weight species of SAP to immobilized GPBP
To further study the capacity of the different SAP species to interact with
GPBP, we isolated fractions of SAP by size exclusion chromatography for
immediate SPR analysis. Three peaks were separated by gel filtration FIGURE
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Figure 4. Solid phase interaction of SAP with GPBP
(A) Far-Western blot experiments. Human SAP and BSA were separated by SDS-PAGE, transferred to a
nitrocellulose membrane and renatured. As a negative control for the renaturation, SAP was kept in
6M urea ('SAP without renaturation'). After blocking, membranes were incubated with either GPBP or
with CERT as a probe using immobilized SAP as bait. Bound proteins were detected with mAb anti-
SAP, anti GPBP (3A1-C1) or a polyclonal antibody against GPBP/CERT. The presence of BSA was
confirmed by Coomassie. Both GPBP and CERT bound specifically to renatured SAP, but not to BSA or
denatured SAP.
(B) SAP aggregation is influenced by pH, the composition of the buffer and the presence or absence
of Ca2+. The treatment of SAP before the Western blot was performed as follows: SAP was diluted at
10 ng/μL: (lane 1) in 10 mM sodium acetate buffer pH 4.5; (lane 2) in sodium acetate buffer pH 4.5 in
the presence of 5 mM calcium; (lane 3) in 25 mM HEPES buffer pH 7.4; (lane 4) in HEPES buffer pH 7.4
in the presence of 5 mM calcium; (lane 5) in HEPES buffer pH 7.4 followed by sonication with a probe
sonicator for 3 pulses of 30 s each with a 30 s rest on ice between each pulse; (lane 6) in 25 mM HEPES
buffer pH 7.4 followed by sonication as aforementioned in the presence of 0.01% Tween 20. Different
percentages of Tween 20 (1%, 0.1% and 0.001%) were tested before choosing the optimal at 0.01%.
SAP was separated using native-PAGE and SDS-PAGE 4-20% gradient gels. The proteins were
transferred to nitrocellulose membranes and incubated with anti-SAP antibody. 10 ng/μL SAP diluted
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in sodium 10 mM acetate buffer pH 4.5 and run in native conditions separated unique SAP species of
25 kDa (monomers). 10 ng/μL SAP diluted in HEPES buffer pH 7.4 , sonicated in the presence of 0.01%
Tween and run in native PAGE separated SAP species corresponding to: high molecular aggregates >
250 kDa, 250 kDa (decamers) and 100 kDa (pentamers). As expected, independently of the buffer in
which SAP has been diluted, in SDS-PAGE, SAP separated as a band of 25 kDa (monomers).
(C) Binding of SAP to immobilized GPBP (215 RU; flow rate, 15 μL/min; injected volume, 60 μL). The
binding was recorded in 25 mM HEPES buffer pH 7.4, 150 mM NaCl. The presence of 5 mM Ca2+
decreased the binding of SAP to immobilized GPBP. 
(D) Binding of SAP to immobilized CERT (215 RU; flow rate, 15 μL/min; injected volume, 60 μL). The
binding was first recorded in the absence of added Ca2+ in 25 mM HEPES buffer pH 7.4, 150 mM NaCl.
The presence of 5 mM Ca2+ decreased the binding of SAP to immobilized CERT. The general shape of
the curves revealed that SAP had very fast association rates with both proteins, although SAP
remained bound to GPBP for a longer period at the end of the injection. 
(E) Binding of a peptide containing amino acids 385-398 from GPBP exon 11 to immobilized SAP (215
RU; flow rate, 15 μL/min; injected volume, 60 μL) in 25 mM HEPES buffer pH 7.4, 150 mM NaCl.
chromatography from SAP (sonicated in HEPES buffer pH 7.4 with 0.01%
Tween 20) (Figure 7A). SAP peaks I to III corresponded to high molecular
aggregates (> 250 kDa), decamers (250 kDa) and pentamers (125 kDa) as
judged from native-PAGE gels (Figure 7B, native). SAP peaks separated by
SDS-PAGE under reducing conditions corresponded to 25 kDa (monomers)
(Figure 7B, denatured). SAP decamers and pentamers (peaks II and III,
respectively) bound immobilized GPBP, whereas SAP aggregates (peak I) did
not (Figure 7C-E). Likewise, peak IV which consists of benzamidine was
found not to bind to GPBP (Figure 7F). In summary, these data indicate that
SAP pentamers and decamers, the physiologically active species, bind to
GPBP and that the binding observed (in the previous experiments, Figures
4C and D and 6) was not a result of non-specific binding of SAP aggregates.
Figure 5. Overlay of sensograms
resulting from the injection of
different concentrations (25-100
nM) of SAP over immobilized GPBP
(96 RU, flow rate, 15 μL/min;
injected volume, 60 μL). The
sensograms were corrected for the
signal in the empty cell (i.e.
calculated as the difference between
the signal in Fc2 and the signal in
Fc1, which includes injection noise,
instrument drift, and nonspecific
binding).
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Figure 6. SAP binds to GPBP 
in solution Microscale 
thermophoresis (MST) was 
performed in order to 
determine the dissociation 
constant of SAP to 
fluorescently labeled GPBP. 
10 nM of NT-647 labeled 
GPBP was mixed with 
increasing SAP concentrations. 
The normalized fluorescence 
Fnorm is plotted for different 
concentration of SAP. A Kd of 
5.7 nM +/- 2.66 nM was 
determined for this interaction.
SAP and GPBP form complexes in blood under physiological conditions
SAP is present in human serum at a concentration between 30 and 50 mg/L
(37,38). Recently, the presence of GPBP in human serum has been described
(23). To study whether SAP associates with GPBP in serum, co-
immunoprecipitation experiments were performed. After precipitation with
anti-SAP antibodies, both SAP and GPBP were detected by Western blot.
Antibodies against GPBP epitopes 1-50 (Figure 8) and 300-350 (data not
shown) detected a GPBP fragment of approximately 35-37 kDa which has
been previously described (22). This fragment was not present in a pull-
down performed with an isotype control antibody, when detected with the
same GPBP-specific antibodies. Based on the antibody specificities, these
results suggest that SAP associates in the blood with a ~37 kDa GPBP
fragment containing the N-terminal region and the middle domain.
GPBP is present in brain amyloid plaques
Since SAP is a universal component of all types of amyloid deposits, possible
associations of GPBP with amyloid deposits in human brain were studied by
immunohistochemistry. Stainings were performed on cryostat sections of
post mortem temporal cortex specimens from aged donors, including: non-
demented controls, control cases with amyloid deposits and with cortical
changes (though not sufficient to be classified as AD), and AD patients (Table
1).
Considerable SAP immunoreactivity was found to be associated with Aß
plaques in the AD and demented cases (81, 135 and 294, Figure 9A middle
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Figure 7. SAP decameric and pentameric species bind to GPBP
Purification of different SAP species was performed by Superose 6 column size exclusion
chromatography. Samples diluted in 25 mM HEPES buffer (pH 7.4), 150 mM NaCl were then injected
at a concentration of 0.5 mg/mL and were chromatographed at a flow rate of 0.4 mL/min. Four peaks
were observed. (B) Fractions from peaks I to IV from the Superose 6 gel filtration column were
separated using native-PAGE and SDS-PAGE 4-20% gradient gels. The proteins were transferred to
nitrocellulose membranes and incubated with anti-SAP antibody. Upper panel, native electrophoresis.
Lower panel, denatured electrophoresis. The anti-SAP antibody detected bands of molecular weights:
> 250 kDa in peak I, 250 kDa (decamers) in peak II and 100 kDa (pentamers) in peak III in native
conditions, and 25 kDa (monomers) in denatured conditions in fractions from peaks I to III. (C to F)
Sensograms resulting from the injection of peaks I to IV over immobilized GPBP (96 RU, flow rate,
15 μL/min; injected volume, 60 μL). (C) No binding was observed with SAP peak I which corresponds
to high molecular weight SAP aggregates. (D and E) 50-150 RU were observed in SAP peak fractions II
and III, which correspond to decamers and pentamers respectively (F) Peak IV corresponds to
benzamidine and did not bind to immobilized GPBP.
Figure 8. SAP-GPBPs complexes in plasma
SAP was immunoprecipitated with mouse mAb anti SAP, (clone
4E8, Sigma) followed by immunoblotting with the same antibody
to detect immunoprecipitated SAP (first lane) and a polyclonal
antibody against GPBP/CERT1-50 detect GPBPs (second lane).
The control using an isotype control mAb (mouse monoclonal
anti-syntaxin 6, clone 3D10) for immunoprecipitation was
negative when detected with the same polyclonal antibody
against GPBP (third lane).
GPBP is efficiently co-precipitated with SAP in a band of ~37 kDa,
suggesting that a part of GPBP molecule corresponding to the
amino terminal domains of the protein interacts with SAP.
Results shown are representative of 5 experiments.
right panel). SAP was less abundant but also associated with Aß plaques in
the non demented control cases (not shown). Polyclonal antibodies reacting
with GPBP/CERT stained vague, globular plaque-like structures (e.g. case 47,
Figure 9A upper right panel and case 294, Figure 9A middle left panel).
Occasional dense deposits, possibly representing plaque cores were
observed (case 115, not shown). Plaque-associated microglia were
immunoreactive in the AD cases (e.g. case 264, Figure 9B). Additionally,
microglia in the white matter were strongly immunopositive for GPBP/CERT,
in all cases (e.g. case 47; Figure 9A, upper left panel); In the demented
control case 294, plaques and associated microglia in the grey matter were
strongly immunoreactive (Figure 9A, lower panel), as were white matter
microglia.
In order to determine possible colocalization of GPBP/CERT with SAP in
tissue specimens, double immunofluorescent stainings were performed. To
visualize fibrillar Aß deposits, sections were also stained with Thioflavin S. In
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a Upon immunostaining for Aß, the two AD cases (Braak 5C) were found to have many Aß plaques,
however no classical or neuritic plaques. The AD / Lewy body variant case (case 135) did show all
types of Aß plaques, ranging from diffuse to neuritic, as did the demented case that did not fulfill the
neuropathological criteria of AD (case 294). The non-demented controls (cases 47 and 115) were
selected to have many cerebral Aß deposits, and had many Aß plaques ranging from diffuse to
classical type.
b Clinical diagnosis with neuropathological confirmation (CTL: control; AD: Alzheimer's disease)
c Neuropathological staging of cases based on occurrence and distribution of neurofibrillary changes
according to the criteria of Braak & Braak (1991) 
d Neuropathological staging of cases based on occurrence and distribution of amyloid deposits
according to the criteria of Braak & Braak (1991) 
e M: male, F: female
f Post mortem delay time (hours : minutes)
reference: 
Braak,H., and Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol.
82 (1991) 239-259.
AD case 264, SAP was found to completely colocalize with fibrillar Aß in
plaques, whereas GPBP/CERT was associated with cellular structures in the
centre of the plaque, possibly representing recruited microglia partially
colocalizing with SAP (Figure 9B).
A number of GPBP immunopositive neuronal cells were observed, also in
plaques; occasionally the endothelial cell lining as well as the basement
membrane of a blood vessel were GPBP immunopositive (Figure 9B upper
panel).
Additionally we performed immunoprecipitation experiments using
homogenates from control and AD mouse brains to confirm the interaction
of SAP with GPBP and to distinguish between GPBP and CERT (Figure 9C).
Immunoprecipitation of either GPBP (mAb 3A1-C1) or SAP from brain lysates
from the AD mouse model co-isolated Aß (detected with 6E10) in a few
bands of ~100 kDa. The same bands were also found in a control experiment
following immunoprecipitation of Aß from AD mouse brain with a
Table 1. Overview of cases included for the immunohistochemical part of this studya
Case Diagnosisb Braakc Amyloidd
(0,A,B,C)
Age
(years)
Gendere PMDf
(h:min)
APOE
genotype
47 Non-demented CTL 1 B 98 M 8:40 3/3
115 Non-demented CTL 1 B 83 M 4:35 3/3
81 AD 5 C 78 M 7:45 4/4
264 AD 5 C 85 F 6:10 4/3
135 AD/Lewy body variant 4 B 95 F 5:15 3/3
294 Dementia with cortical changes 2 B 91 F 3:35 3/3
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Figure 9. GPBP is present in amyloid plaques
Immunohistochemical stainings of GPBP/CERT and SAP in midtemporal cortex of AD and demented
and non-demented control cases (cryostat sections). (A) Upper panel: Control case 47 (Braak 1B)
white matter (WM) immunostained with anti-GPBP/CERT300-350 shows many ramified microglia (see
insert) and to some extent endothelial lining of blood vessels, whereas in the grey matter (GM)
amyloid plaque staining and intense GPBP staining around the plaque core, reminiscent of clustered
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combination of recombinant human antibodies recognizing different
aggregation forms of Aß (bapineuzumab directed against plaques, 20C2
directed against fibrils, solanezumab directed against monomers). In wild
type littermates, these bands were not observed. The observed Aß bands
(~100 kDa) could correspond to Aß aggregates which are preserved using
the tissue disruption protocol and/or to amyloid precursor protein (APP).
The possible presence of APP would not be surprising since it is several
times upregulated in this animal model. Lower Aß molecular weight forms
were not detected using anti-Aβ (6E10) as reported previously (41). Western
blotting with a monoclonal anti-Aß revealed that immunoprecipitation of
either GPBP (mAb 3A1-C1) or SAP from brain lysates from an AD mouse
model, but not from wild type littermates, co-isolated Aß, which suggests
the presence of Aß-SAP and Aß-GPBP complexes in AD model mouse brain.
Immunoprecipitation with nonspecific immunoglobulins performed as a
control did not co-isolate Aß.
Functional implications of SAP to GPBP binding and protein-protein
interaction interface prediction
In order to identify the binding site of GPBP on SAP, we used two well-known
ligands of SAP [C1q and PE (16,32)] and analyzed by SPR if they could
compete with GPBP. To test this, either SAP alone, or SAP that had been
microglia, and in addition cytoplasmatic staining of neuronal cells is seen. Lower panel: Demented
control case (#294) with cortical changes but not sufficient to be classified as AD (Braak 2B).
GPBP/CERT1-50 immunostaining is seen in Aß plaques and microglia, especially microglia in the white
matter (upper right) and near the core of a classical plaque (see also higher magnification insert).
Similar as with anti-GPBP/CERT1-50, plaque and microglial staining was seen with anti-GPBP/CERT300-350,
but less pronounced. With anti SAP, in addition to plaques, also some cytoplasmatic neuronal staining
was observed (two central panels). (B) Immunofluorescence staining was performed to further
investigate co-localization of GPBP and SAP. Fibrillar Aß deposits in an AD case (case # 264) were
visualized with Thioflavin S, SAP with monoclonal SAP-14 followed by goat-anti-mouse HRP and
rhodamine-tyramide and GPBP with anti-GPBP/CERT1-50 and Cy5 labeled goat-anti-rabbit. Whereas
both SAP and GPBP immunoreactivity co-localize with thioflavin positivity, their exact distribution
differs (black and white Figures showing complete overlap in localization of thioflavin and SAP, but not
of GPBP). GPBP seems present in small cells resembling microglia clustered around Aß and SAP
deposits (arrow and lower panel (magnification)), as well as in many neuronal cells (arrowheads).
Partial overlap in localization of GPBP and SAP within Aß plaques was more clearly seen, when in the
separate channels the GPBP signal was visualized as red and thioflavin or SAP as green (inserts). Scale
bars represent 100 μm. (C) Western blotting with a mAb anti-Aß revealed that immunoprecipitation
of either GPBP or SAP from brain lysates from an AD mouse model (APPswe/PS1ΔE9), but not from
wild type littermates, co-isolated Aß, which suggests the presence of Aß-SAP and Aß-GPBP complexes
in AD model mouse brain. Aß, GPBP and SAP were immunoprecipitated from brain homogenates of
control and Alzheimer's transgenic mice using mouse mAb anti SAP, clone 4E8, Sigma; mAb GPBP
clone 3A1-C1; mAb ß Amyloid clone 6E10, Covance. immunoprecipitation with nonspecific
immunoglobulins was performed for control. Results shown are representative of 3 experiments.
GPBP binds SAP and is present in amyloid brain plaques
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Figure 10. Protein-protein
interaction interface prediction
of SAP with GPBP
(A) Human SAP pentameric
structure and predicted protein-
protein interaction hotspots as
obtained after structural analysis
using the ICM Pro package of the
published coordinates from
2a3y.pbd (46).
(B) Homology model for the
structure of GPBP including the
region important for the
interaction with SAP (shown in
red). The homology model was
built using the WhatIf-Yasara
Twinset and ICM Pro package,
while the coordinate file
2E3O.pdb (CERT START domain
structure) was used as a
template.
(C) GPBP structure and predicted
protein-protein interaction
hotspots based on the homology
model as shown in (B), a
structural bioinformatics analysis
was performed using ICM Pro to
predict potential protein-protein
interactions. Interaction scores
are color-coded with red having
high potential for interaction and
blue low potential. On the right,
exon 11 containing 26 aa is
indicated in red. The arrow
indicates a hypothetical protein-
protein interaction region
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preincubated with either PE or C1q were added as analytes and flown over
a surface onto which GPBP was immobilized. Using an equimolar ratio of
SAP and C1q, binding of SAP to GPBP was inhibited by 59%. In contrast SAP
preincubated with PE even at a 3-fold molar ratio of PE as compared to SAP
had no effect on the binding of SAP to GPBP.
Since the crystal structures of SAP and the GPBP START domain are
published (PDB IDs 2A3Y and 2E3O) we attempted to predict the possible
protein-protein interaction surfaces by structural bioinformatics analysis
using the ICM-pro package (Figure 10). For SAP, our in silico analysis
indicated the presence of two potential protein interaction hotspots with a
five-fold symmetry in the pentamer: one on the internal surface of the
pentameric ring (Figure 10A, red) around Glu86 and a second one more
dispersed on the outer side of the ring, around residues Gly122-Phe124
(light red). In the GPBP START domain an interactive region is located at the
protein surface near Ala501 (Figure 10B and C, arrow).
Binding of CERT mutants to SAP
In order to experimentally test the importance of the START domain for SAP
binding, we generated 5 CERT mutants containing 2 amino acid substitutions
each. We targeted the region near Ala501 and three additional regions with
hydrophobic amino acids near the protein surface. Protein surface
hydrophobicity is known to be a good determinant of protein-protein
recognition (42). For consistency with the numbering used above we will
refer to the GPBP amino acid numbering throughout (see Table 2).
Mutant 1: Ile439 (present in a short ?-strand that flanks the N-terminus of
Ala591-Ala618 helix) and Trp588 (located in a loop structure that precedes
Table 2. Mutagenesis of GPBPΔ26/CERT protein to identify amino acids relevant for SAP interaction
Mutanta mutation at GPBPb protein level Corresponding mutation at CERTc
protein level
1 I439A W588A I413A W562A
2 N460A Y461A N434A Y435A
3 Y461A F462A Y435A F436A
4 V498A W499A V472A W473A
5 P500G A501Q P474G A475Q
a Mutants listed according to the position of the mutation in the cDNA
b (NP_005704.1)
c (NP_112729.1)
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(A) Coomassie staining of immunopurified wild type and (1-5) mutant CERT proteins (2 μg of each
sample were loaded per lane). 
(B) Two-fold serial dilutions (3.9-500 nM) of wild type and mutant (1-5) CERT proteins in 25 mM
HEPES pH 7.4, 150 mM NaCl with 0.01% Tween 20 were tested for binding on immobilized SAP by SPR.
At each concentration, the highest binding signal was measured. 
(C) SAP was separated on a 12% SDS-PAGE gel, electroblotted to nitrocellulose and prepared for far-
Western analyses as described in Figure 4A. The membrane with renatured SAP was cut into strips and
probed with CERT mutants (1 to 5), WT (6) or mAb anti SAP (7). Membrane strips incubated with CERT
proteins were detected with anti-GPBP/CERT300-350.
Ala591-Ala618 helix) are predicted to be arranged closely in the 3D structure
of GPBP. This hydrophobic pair represents a potential protein contact site
which was effectively removed by substitution for two less hydrophobic Ala
residues. Mutant 2: Asn460 and the adjacent Tyr461 (present in a short
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alpha-helix that is located on the opposite side of the molecule as compared
to the other mutations) are substituted for two Ala residues; thereby
removing a potential protein interacting site. Mutant 3: Adjacent to the
changed amino acids of mutant 2, the hydrophobic Tyr461 and Phe462
residues were replaced with Ala residues. Phe462 faces the core of the
protein. Mutant 4: We substituted Val498 and Trp499 with two Ala residues.
These hydrophobic residues are located in an unstructured loop. Mutant 5:
The adjacent Pro500 and Ala501 were substituted with Gly and Gln,
respectively.
All mutants described above and the wild type protein were expressed in E.
coli and purified on a Flag column (Figure 11A). Using SAP as ligand, the
relative affinity of CERT and CERT mutant (1-5) proteins were tested by SPR
(Figure 11B). The binding of Mutants 2 and 4 to SAP was similar to the wild
type CERT, while mutants 1 and 3 showed reduced binding, and mutant 5
showed a greatly reduced binding for SAP. 
The relative affinity of CERT and CERT mutant (1-5) proteins were also tested
by far-Western blot with in blot-renaturation (Figure 11C). The results were
similar to those obtain by SPR, and showed reduced binding of mutants 1, 3
and 5 to SAP.
In conclusion, the START domain of GPBP and CERT significantly contributes,
or might even be essential for SAP binding.
DISCUSSION
Our results demonstrate, for the first time, that GPBP binds SAP. Both, GPBP
and SAP are present in amyloid plaques and co-precipitate with Aß.
Therefore, the interaction of GPBP with SAP might be involved in protein
aggregation in Alzheimer's disease and the resulting innate immune
response.
SAP is a very compact and highly structured molecule. Its incorporation
within specific types of BM may contribute to the structural conformation
and consequently the correct functionality of extracellular matrix proteins.
This is supported by its altered distribution in the GBM in glomerular
diseases (33,43).
Our SPR analysis has shown that GPBP binds type IV collagen, laminin and
SAP, while our immunohistochemical studies have shown the presence of
SAP and GPBP in GBMs. Intriguingly, this raises the possibility that SAP and
GPBP interact to support matrix extracellular proteins, helping to maintain
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their biologically active conformations in a particular group of tissues,
including kidney, lungs and choroid plexus; tissues that perform a filtering
function and are therefore more vulnerable.
We also found SAP and GPBP interaction in human blood. By
immunoprecipitation studies in human sera we were able to pull down
complexes of SAP and a N-terminal ~37 kDa fragment of GPBP which has
been previously described (22). However, it is worth noting that proteolysis
of GPBP remains a possibility as our in vitro mutagenesis show that the (C-
terminal) START domain of GPBP is important for interaction with SAP.
Moreover, full length GPBP is the only isoform which has been described so
far that is secreted and present in blood (23). Since this amino-terminal
domain is identical in the GPBP and CERT isoforms, our results demonstrate
that both GPBP and the shorter isoform CERT could form complexes with
SAP under physiological conditions. Several studies have investigated the 3D
structure of SAP in order to establish whether SAP stably associates with
another protein or exists free in solution (44-46). Despite these efforts, it
remains unclear how SAP can remain in physiological conformation (i.e.
avoid aggregation) in a high Ca2+ environment. One suggestion is that SAP
forms a complex with an as yet unidentified low molecular weight
component that prevents self-association (6). To date, no such factor or
protein has been reported. In our experiments, aggregation of SAP by Ca2+
might have reduced binding to GPBP, because GPBP specifically binds to
pentamers and decamers. 
Our molecular characterization of the SAP GPBP/CERT interaction suggests
that residues P500 and A501 (mutant 5) of the START domain of GPBP/CERT
are essential. Although, we cannot rule out the possibility that the loss of
SAP to CERT binding affinity seen with mutant 5 is due to drastic changes in
protein conformation, our results are in line with what is known about this
domain. The START domain of CERT binds one ceramide molecule in its
central amphiphilic cavity and mediates ceramide transfer from donor to
acceptor membranes (24). The Ω1 loop region of the CERT START domain
(496KRVWPAS502 in GPBP) is an important regulatory element for the
binding of ceramide (47,48). This Ω1 loop has been proposed to function as
a gate of the cavity. Specifically, the interaction between the W499 residue
of the Ω1 loop and the membrane results in a conformational change of the
protein which allows opening the cavity. We found that substitution of
either the V498 or W499 had no effect on the SAP to GPBP binding, whereas
mutation of the P500 and A501 abolishes SAP-GPBP interaction. This
suggests that GPBP binding to SAP is independent of the ceramide transfer
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function. This would be consistent with the notion that ceramide function is
important within the cell and that the SAP GPBP interaction described here
occurs primarily extracellularly.
SAP has been observed decorating the majority of Aß plaques in AD (49),
where it has been found to enhance Aß fibrilization. Also, SAP has been
shown to hamper the uptake of Aß by adult human microglia in vitro (50).
The binding of SAP and GPBP to plaques in AD raises the important question
of whether this interaction has a role in disease progression. It may be the
case that GPBP and SAP are found in the pathological plaques of AD because
these plaques, which consist of amyloid deposits, are 'sticky', and thus
incorporate GBPB and SAP from the extracellular matrix. On the other hand,
it has been reported that binding of SAP to amyloid fibrils slows proteolysis
of plaque material and contributes to the pathogenesis of amyloidosis (5).
Here we show that GPBPs are present in Aβ plaques, localized in the core
and partially colocalizing with SAP. In agreement with this, pull-downs of
extracts of AD mouse brain with antibodies against Aβ yield high molecular
weight aggregates containing GPBP, indicating that GPBP, similarly to SAP,
interacts with Aβ.
Additionally, we observed GPBP staining in the white matter corresponding
to round and ramified microglia. Interestingly, clustering of microglia was
only observed in SAP and C1q immunopositive Aß deposits, and has been
shown to precede neurodegenerative changes in AD brain (4).
SAP, when aggregated, can bind C1q and initiate the activation of the
complement system (16). Our finding that C1q and GPBP can compete for
their binding to SAP raises the question as to whether GPBP and C1q share
an identical SAP binding site. This implies that when SAP binds to GPBP, the
C1q binding site on the SAP molecule is blocked and this might help to
control the activation of the complement system.
These findings may then have important implications in several human
diseases where complement activation plays a role and SAP and GPBP are in
close proximity e.g. in AD. Our results further raise the question of whether
GPBP, similarly to SAP, could serve as an innate immune system regulator.
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Abstract
Alzheimer's disease (AD) is a complex multifactorial syndrome characterized
by intra- and extracellular deposits of amyloid beta (Aβ), neurofibrillary
tangles, dystrophic dendrites and increased levels of ceramide in the
cerebrospinal fluid. 
Goodpasture antigen-binding protein (GPBP) and its shorter variant, CERT,
are the only proteins known to carry the lipid ceramide. GPBP and CERT
localize in amyloid plaques from AD patients and are capable of binding
serum amyloid P component (SAP), a protein thought to stabilize aggregates
by preventing proteolytic cleavage. GPBP expression is regulated by tumor
necrosis factor (TNF-alpha) which has been shown to induce a cellular
response able to protect neurons against Aβ toxicity. We hypothesize that
GPBP plays a role in the pathogenesis of neurodegenerative diseases that
are characterized by the formation of protein aggregates. GPBP gene and
protein levels are increased in HEK cells over-expressing the amyloid
precursor protein (APP). Here GPBP is enriched at the plasma membrane
where it colocalizes with ceramide. GPBP is secreted and forms extracellular
complexes with Aβ. We showed that GPBP reduces Aβ aggregation and has
a protective effect against Aβ-induced toxicity in cultured neurons. Our
results indicate that GPBP takes part in the cellular response against Aβ-
induced toxicity and is involved in the pathophysiological mechanisms
associated with neurodegenerative processes. 
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Introduction
Protein aggregation is a complex process implicated in a variety of
neurodegenerative disorders such as Alzheimer's (AD) and Parkinson's
diseases, amyotrophic lateral sclerosis, motor neuron disorders, as well as
diseases of peripheral tissue like familial amyloid polyneuropathy (FAP).
Native normally functional proteins can spontaneously self-organize into
fibrous aggregates containing misfolded proteins in a β-sheet conformation,
termed amyloid. Sporadic neurodegenerative diseases are generally
associated with aging which is accompanied by oxidative modifications of
proteins.
GPBP is a non conventional Ser/Thr kinase that regulates protein folding and
secretion (2-4). More specifically, GPBP regulates molecular organization of
structural proteins at both extracellular and intracellular compartments. It
was shown that GPBP can bind and phosphorylate the non collagenous
domain of type IV collagen, seemingly inducing glomerular basement
membrane collagen network organization (2). In skeletal muscle
development, GPBP is critical for myogenesis, directing myofibrillar
organization through the targeting of GIP130 (GPBP-interacting protein of
130 kDa), a protein component of myofibrils (5).  Many proteins have been
shown to be multi-functional (6) and indeed, this seems to be the case for
GPBP. In fact, the human gene encoding GPBP, COL4A3BP, encodes for a
shorter protein isoform named CERT, generated by alternative splicing (7).
CERT is identical to GPBP but lacks a serine-rich domain of 26 amino acids.
The absence of this domain reduces kinase activity in this isoform (8). The
name CERT stands for ceramide transporter, a function attributed to this
protein shortly after discovery of GPBP. However, the GPBP isoform can also
bind the lipid ceramide in vitro (7). The supramolecular organization of
structural proteins seems to be more dependent on kinase rather than on
ceramide transfer activities of GPBP proteins. In fact, CERT cannot fully
rescue GPBP function in defective cell lineages (5). These two isoforms  are
highly conserved in evolution and have the distinct functions of protein
structural organization and ceramide traffic inside the cell [for a review (9)].
In basal condition, GPBP and CERT are widely distributed throughout the
brain and particularly abundant in neurons (10), indicating an important role
in the brain. Resting microglia show a very low expression of GPBP and CERT
but a positive signal for these proteins is detected in activated microglia of
AD human brain (11). 
Various animal models have clearly pointed the importance of these two
splicing variants in the CNS. In zebrafish GPBP is mostly expressed at early
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stages of embryogenesis relative to CERT and knockdown of GPBP leads to
the loss of myelinated tracts and extensive apoptosis during early
development (12). Loss of functional CERT in Drosophila causes increased
oxidative stress, accelerated aging and reduced life span (13).  GPBP and
CERT knockout mice are not viable due to defective development associated
with mitochondria degeneration, ER alterations and defective cell
proliferation (14). We have recently described the interaction that occurs
between GPBP and CERT with Serum Amyloid P component (SAP), a
universal component of amyloid deposits. Amyloid plaques are composed of
extracellular accumulations of amyloid-β peptide (Aβ) and other plaque-
associated proteins, surrounded by large, swollen axons and dendrites
(dystrophic neurites) and activated glia. We have detected a colocalization
of GPBP and CERT with SAP and Aβ fibrils in plaques of human AD brains
(11). Aβ-peptides are generated from a much larger precursor protein, the
amyloid precursor protein (APP), a ubiquitous type I cell surface protein of
as yet unknown physiological function. Proteolysis dictates both the level of
Aβ-peptides generated and the rate at which they are degraded (15). APP
can be processed via a non-amyloidogenic route involving α-secretase
cleavage within the Aβ domain. This latter cleavage precludes Aβ peptide
formation, generating instead a soluble APP ectodomain (sAPPα) along with
a C-terminal fragment (CTF) of 83 amino acids (C83) (16). Alternatively, APP
can be proteolytically processed via an amyloidogenic pathway which
involves initial cleavage by β-secretase (β-site APP-cleaving enzyme 1;
BACE1) to generate a soluble N-terminal fragment termed sAPPβ along with
a C terminal membrane associated fragment (CTF) of 99 amino acids (17,18).
The C99 fragment is then further processed by a γ-secretase complex
producing the Aβ-peptides and the APP intracellular domain (AICD) (19,20)
[for a review (21)].  AICD has been suggested to regulate gene transcription
of serine-palmitoyl transferase (SPT) (22), the enzyme that catalyzes the first
step of de novo biosynthesis of ceramide (23). CERT and GPBP are the only
proteins known to shuttle de novo synthesized ceramide. Considering that
GPBP associates with amyloid plaques and binds protein at the extracellular
level it seems likely that GPBP and CERT play important roles in the
molecular organization and self-association processes of amyloid fibrils.
Here we show that GPBP is upregulated by APP overexpression. Secreted
GPBP interacts directly with Aβ1-42 and is able to structure Aβ1-42 into
insoluble less toxic aggregates. This has a protective effect against Aβ-
induced toxicity in cultured neurons, suggesting a key role for this protein in
the pathogenesis of AD. 
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Material and methods
Human Embryonic Kidney (HEK) 293 cell culture 
Normal HEK293 and HEK-293 cells that stably express either wild type APP
(APPwt) or APP with the double mutation K651N/M652L, known as the
'Swedish' mutation (APPsw) (24), were cultured in Dulbecco's modified
Eagle's medium supplemented with 10% heat-inactivated fetal calf serum,
50 units/ml penicillin, 50 μg/ml streptomycin, 2 mmol/L glutamine at 37 °C
in a humidified incubator containing 5% CO2. Stable transfected cells
expressing the APP construct were maintained in G418 at a final
concentration of 200 μg/ml. The APP levels of APP-transfected HEK cells
were analyzed by Western blot to confirm that the over-expression of APP
protein level was the same in HEK APPwt and HEK APPsw cell lines. 
Preparation of cell lysates and Western blot 
HEK, HEK APP and HEK APPsw cells cultured in 25 cm2 tissue culture flasks
(80-90% confluency) were lysed via repeated passage through a 28 g needle
in 25 mM Tris, 25 mM NaCl, 0.1 mM EDTA, pH 7.4 containing PI cocktail. Lysis
efficiency was verified >99% by trypan blue staining. The resultant lysate
was centrifuged at 20,000× g for 30 min and the supernatant collected.
Protein content was determined by a conventional method (BCA protein
assay Kit). Before Western blot analysis, an aliquot of 10 μg of protein
extract from each individual sample was processed for Western blot analysis
and probed with anti GAPDH  antibody to ensure the same protein loading
[mouse monoclonal antibody (mAb) anti-GAPDH, Sigma] to (data not
shown). Based on the previous results, 40 μg of proteins were separated by
SDS-PAGE using precast Criterion Tris-HCl glycine 4-20% gradient gels (Bio-
Rad, Veenendaal, the Netherlands) followed by electroblotting to
nitrocellulose membrane (Millipore, Amsterdam Zuid-Oost, the
Netherlands). The membranes were incubated with primary polyclonal
antibody specific for APP [APP140, raised against the C-terminal 20 amino
acids of human APP (1)] and with specific mouse mAb clone 3A1-C1 against
GPBP [mAb GPBP 3A1-C1 have been described in (25)]. After PBS washes,
the membrane was incubated with goat anti-rabbit-IRdye 800 and donkey
anti-mouse-IRdye 680 (Rockland Immunochemicals, Gilbertsville, PA).
Finally, the membrane was washed with PBS, dried and scanned using the
Odyssey infrared imaging system (Westburg, Leusden, the Netherlands).
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Immunoprecipitation analysis
Protein extracts (100μg) were used for immunoprecipitation experiments
performed in a volume of 500 μL. Pull down of endogenous GPBP and stably
overexpressed APPsw was performed with 1 μg mAb 3A1-C1 and 6E10
respectively, added to the samples for 1 hour incubation, at room
temperature. Mouse mAb anti syntaxin 6335 (clone 3D10, Abcam,
Cambridge, MA) was used as isotype control (1 μg antibody per 15 μL).
Samples were thereafter centrifuged at 20,000× g for 30 min. Pellets were
washed three times in 50 μL PBS and boiled in reducing sample buffer
containing mercaptoethanol to dissolve immunocomplexes. Proteins were
separated by SDS-PAGE using precast Criterion Tris-HCl glycine 4-20%
gradient gels (Bio-Rad, Veenendaal, the Netherlands) followed by
electroblotting to nitrocellulose membrane (Millipore, Amsterdam Zuid-
Oost, the Netherlands). The membranes were incubated with primary
antibodies against APP (6E10) or GPBP using polyclonal rabbit anti-GPBP
epitope 1-50 (Bethyl laboratories). After phosphate buffered saline (0.1 M
PBS, pH 7.4) washes, membranes were incubated with donkey anti-mouse-
IRdye 680 and goat anti-rabbit IRdye 800 (Rockland Immunochemicals,
Gilbertsville, PA) followed by detection as described above.
Subcellular fractionation
Subcellular fractionation was performed as briefly described. 5 million HEK
APPsw  cells were harvested in 1 ml of homogenization buffer (0.25 M
sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1mM DTT and
20 mM HEPES pH 7.4) and lysed via repeated passage through a 28 g needle
containing a cocktail of protease inhibitors (PI) (Roche Diagnostics, Almere,
the Netherlands). After an incubation of 20 min in ice, homogenates were
centrifuged at 1,000 × g for 5 min to pellet nuclei and any cell debris.
Postnuclear supernatant was centrifuged at 200,000 × g at 4°C for 1 hour
using an SW41 ultracentrifuge rotor (Beckman, Mississauga, Ontario,
Canada) to obtain a membrane/organelle-enriched pellet and cytosol-
enriched supernatant. The membrane pellet was solubilized in 100 μl of
STEN-lysis buffer (50mM Tris pH 7.6, 150mM NaCl, 2 mM EDTA, 1% NP-40,
PI cocktail). After an incubation of 20 min on ice, resuspended pellet were
cleared by a spin at 16,000× g at 4°C for 15 min. Protein content was
measured by BCA assay and equal amounts of material (40 μg each) were
employed for immunoblotting analysis as described above.
Far Western
For far Western experiments, human recombinant GPBP (80ng) and Aβ
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peptide 1-42 (80ng) (Anaspec, San Jose, CA, USA) were analyzed by SDS-
PAGE under reducing conditions. A 17 kDa Lama antibody fragment (H6)
with myc and his6 tags, [a kind gift of Dr. A.J. Groot (26)], was used as a
negative control (80ng). Proteins were transferred to nitrocellulose
membranes (Bio-Rad Laboratories BV, Veenendaal, Netherlands), renatured
in Tris-buffered saline in the presence of Tween 20 (0.05%) and probed for
1 h at 37°C with 30 μg/mL of GPBP or Aβ peptide in the same buffer. Bound
material was detected using polyclonal rabbit anti-GPBP epitope 1-50
(Bethyl laboratories), mouse mAb anti-human Aβ (6E10, Covance,
Rotterdam, the Netherlands) and mouse mAb anti-human c-Myc (clone
9E10, Invitrogen, Breda, the Netherlands). Incubation with secondary goat
anti-rabbit-IRdye 800 and donkey anti-mouse-IRdye 680 (Rockland, USA)
was followed by detection as described above.
Cell surface biotinylation
HEK, HEK APPwt and HEK APPsw cells were grown to 90% confluency and
labeled with PBS containing sulfo-N-hydroxy- succinimidobiotin (sulfo-NHS-
SS-biotin) (0.5 mg/ml) for 30 min at 4°C. At the end of incubation, excess
free sulfo-NHS-SS-biotin was quenched with two times washings with 20
mM Glycine. The last washing was incubated for additional 15 min on ice.
Quenching solution was aspirated and cells washed three times with ice-cold
PBS.  Biotin-labeled cells were lysed and the lysate was clarified by
centrifugation at 14,000× g for 5 min at 4°C. The supernatant, containing
biotinylated and soluble cytoplasmic proteins, was collected. An aliquot of
supernatant was saved for examination of cytoplasmic protein actin (anti-
actin polyclonal rabbit antibody, Sigma) by Western blot analysis.
Biotinylated proteins were isolated by binding the streptavidin-agarose
beads for 2 hr at 4°C. Proteins labeled with the sulfo-NHS-SS-biotin were
eluted from the beads with Laemmli buffer containing 50 mM dithiothreitol
(DTT) (1:1) for 5 min at 95-100°C. The eluted proteins were separated from
the beads by centrifugation and analyzed by 4-15% gradient SDS-PAGE as
described above. 
Quantitative real time PCR Experiments
To investigate the expression of GPBP and CERT mRNA levels in HEK and HEK
APPsw cell lines, total RNA was extracted from confluent (70-80%) cells
using TRIzol reagent (Invitrogen, Breda, the Netherlands) according to
manufacturers' protocols. Quality and quantity of the RNA were determined
using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific,
Wilmington, MA). Total RNA (2 μgs) were reverse-transcribed using
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RevertAid First Strand cDNA synthesis kit (Fermentas, St. Leon Rot,
Germany), according to the manufacturer's protocol. Real-time
(RT) PCR primers were designed using Primer3plus
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi) for the
human GPBP, CERT, 18s rRNA, β-Actin, and ubiquinolcytochrome-c
reductase complex component (RIP).
All samples were analyzed using the LightCycler 480 SYBR Green I Master kit
(Roche, Almere, the Netherlands). Each RT-PCR analysis was performed
twice with independent cell cultures and the values are means ± SD from
triplicate samples. Human 18s rRNA, β-Actin and RIP were used as internal
controls. Samples without reverse transcriptase were used as negative
control to ensure non genomic contaminations. The RT-PCR was performed
on a LightCycler 480 system (Roche Applied Science, CA). The relative
amounts of GPBP and CERT expression levels compared with the 3
housekeeping genes were calculated using the ΔΔCt method. Statistical
analysis was performed using unpair t-test. The following primer sequences
were used:  human GPBP: 5’- GATTCAGCTCCCAGGTTGAA -3’ and 3’-
GGATCCAGAACAATCCCATTT -5’; human CERT:5’-ATAGAAGAACAGTCACA
GAGTG-3’ and 3’-CTGCACCATCTC TTCAACCTTTTG -5’; human β-Actin: 5’-
CTTCCTGGGCATGGAGTC-3’ and 5’-AGCACTGTGTTGGCGTACGTG-3’; human
RIP: 5’-TGTCACGGTTCCCATTAT GATATT-3’ and 3’-TGGAAT TTCCAAGTTC
AATGGA-5’ ; human 18s rRNA:
5’-GTAACCCGTTGAACCCCATT-3’ and 3’-CCATCCAATCGGTAGTAGCG-5’.
Immunofluorescence on HEK and HEK APPsw cells
HEK and HEK APPsw cells were seeded into 6-well plates containing sterile
glass coverslips for reattachment. Cells (80% confluent) were fixed with 3.7%
paraformaldehyde (PFA) at 37°C for 15 min, carefully washed three times
with PBS and incubated for 5 min in 500 μl of 0.5% bovine serum albumin
(BSA)-DMEM at room temperature. Without permeabilization, cells were
stained for GPBP (3A1-C1), for APP [pAb 5313 recognizing the N-terminal
domain of APP (27)], for ceramide (MID 15B4, Alexis, Grünberg, Germany)
and for alpha1 sodium/potassium ATPase plasma membrane marker
(α1Na+/K+ ATPase) (mAb7671, Abcam, Cambridge, MA) in 0.5% BSA-DMEM
for 60 min at 37°C. Cells were than washed three times with PBS and were
incubated with the corresponding secondary antibodies: Alexa-488-
conjugated donkey anti-rabbit IgG antibody (diluted 1:100; Jackson
ImmunoResearch Laboratories Europe Ltd. Newmarket, Suffolk, UK) and
Alexa-594-conjugated donkey anti-mouse IgG antibody (diluted 1:100;
Invitrogen, Breda, the Netherlands) for 30 min at room temperature in the
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dark. Coverslips were washed two times in PBS and one time in water to
remove all traces of PBS and mounted on slides using glycerol 10%. Negative
controls by omission of the primary antibody resulted in no signal (not
shown). Images were captured using an Olympus AX70 microscope.
Immunofluorescence signal was quantified using ImageJ software, the
average intensity of 50 individual cells is shown (bar graph). Datasets were
analyzed via analysis of variance with t-test. 
Immunohistochemistry in rat brain
Immunohistochemistry was carried out using 50 μm thick sections of rat
brains fixed by immersion in 4% PFA, 15% picric acid and 0.05%
glutaraldehyde in phosphate buffer (pH 7.6) for four days as described in
(10). Free-floating sections were incubated overnight at room temperature
with  mAb anti GPBP (3A1-C1). After rinsing with Tris-buffered saline (TBS,
50 mM Tris, 150 mM NaCl, pH 7.4) with 50 mM Triton (TBS-T), sections were
incubated with secondary antibody: donkey anti-mouse biotinylated IgG
(diluted 1:400; Jackson ImmunoResearch Laboratories Europe Ltd.,
Newmarket, Suffolk, UK). Subsequently, sections were incubated with the
ABC-kit (Vector Laboratories, Burlingame, CA) for 1.5 hours. To visualize the
horseradish peroxide (HRP) reaction product, the sections were incubated
with 3,3’-diaminobenzidine tetrahydrochloride (DAB). No labeling was
evident in control experiments in which primary antibodies were omitted
from the immunostaining protocol (data not shown). Sections were
photographed with an Olympus AX70 microscope (Olympus, Hamburg,
Germany). Pictures were taken with Cell P software (Olympus). 
Microscale Thermophoresis binding analyses
Microscale thermophoresis (MST) is a new immobilization-free technique
for the analysis of biomolecules interaction (27-29) as described in (11). MST
analysis was performed on the Monolith NT.115 instrument (NanoTemper,
München, Germany). In brief, 20 nM of NT647-labeled GPBP was incubated
for 20 min at room temperature in the dark with different concentrations of
either Aβ1-42 (3-100000 nM) or a control 17 kDa Lama antibody fragment
(H6) (1-35000 nM) in PBS/0.01% Tween 20. Afterwards, 3-5 μL of the
samples were loaded into glass capillaries (Monolith NT Capillaries, Cat #
K002) and the thermophoresis analysis was performed (LED 40-51%, IR laser
80%). Statistical analysis was performed with Origin8.5 software. 
Cell viability assay
To measure cell viability, SHSY-5Y cells were cultured in DMEM/F12
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(Invitrogen, Breda, the Netherlands) supplemented with 10% FBS,
glutamine, penicillin and streptomycin. The cells were plated on flat bottom
tissue culture treated 96-well plates (Sigma, Zwijndrecht, the Netherlands)
at a density of 1x10e5 cell per well and subsequently allowed to attach for
24 hours in a humidified 5% CO2 incubator at 37°C. After exchanging the
medium with serum-free DMEM/F12 and incubating the cells for another 24
hours, the medium was removed, replaced with 100 μL of serum-free
DMEM/F12 containing 0 (control) or 10 μM of Aβ1-42 and 0, 0.5 or 1 μM of
GPBP and cells were then incubated for another 24 hours. Cell viability was
assessed by quantifying methyl-thiazolyl-diphenyltetrazolium bromide
(MTT) reduction. 10 μL of a 5 mg/mL stock solution of sterile filtered MTT
(Sigma) dissolved in PBS was added to each well and incubated at 37°C for 3
hours. The resulting formazan crystals were dissolved in acidified
isopropanol with 10% Triton x-100 and the absorbance at 595 nm was
measured on a Victor X3 plate reader (Perkin-Elmer, Groningen, the
Netherlands).
Aggregation assay
Aβ1-42 was purchased from (Anaspec, San Jose, CA). The peptide was
solubilised in 0.22 μm filtered PBS, 0.1% trifluoroacetic acid (TFA) at the
concentration of 2 mM and frozen in stock aliquots. Stock aliquots were
diluted at the final concentration of 20 μM in a total volume of 400 μl
containing 0, 1 or 2.5 μM of affinity purified recombinant GPBP. The
solutions were prepared in 1.5 mL low-binding microcentrifuge tubes
(Eppendorf, Hamburg, Germany), which were contained in 50 mL falcon
tubes that were placed in a rotary shaking incubator (New Brunswick,
Nijmegen, the Netherlands) at 37°C. Samples were taken from the solution
immediately and at different time points after preparation (1, 2, 4, 8, 12 and
24 hours) for thioflavin T (ThT) fluorescence and Western blot analysis. ThT
fluorescence was analysed by adding 5 μL of the sample to 95 μL of 20 μM
ThT in a 96-well optiplate (Perkin-Elmer) and measuring fluorescence with
excitation at 450 nm and emission at 486 nm in a Victor X3 plate reader
(PERKIN-ELMER). Western blot analysis was performed by
electrophoretically separating 15 μl of sample under either native non-
reducing or denaturing and reducing conditions on 4-16% precast TGX
gradient gels (Bio-Rad). The samples were transferred to nitrocellulose
membrane, blocked with 5% BSA in PBS and probed with mouse mAb anti
GPBP antibody (3A1-C1) and human mAbs against Aβ (mAb 20C2, 3D6 and
m266) as described previously in (11). Bound antibodies were visualized by
scanning the membranes with an Odyssey imager (Li-Cor, Westburg,
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Leusden, the Netherlands) after incubating with IRdye800 conjugated goat
anti-human IgG and IRdye 680 conjugated donkey anti-mouse.
Results
Subcellular localization of GPBP 
In an effort to characterize the function of endogenous GPBP, we examined
its subcellular localization in normal rat brain by confocal microscopy.
A mAb directed against the 26 amino acid domain that characterises the
longer variant, GPBP, was used.  Survey of the coronal brain sections shows
a heterogeneous distribution of GPBP throughout the central nervous
system (CNS), all neuronal cells were found to be positive for GPBP without
enrichment in any specific neuronal population. Immunostaining shows that
endogenous GPBP associates with neuronal plasma membranes and
localises in the neuropil. This is in agreement with previous studies that
describe GPBP as a membrane-bound isoform that can be secreted (2).
A level of discrete staining could be observed in the processes of large
myelinated axons (≥1 μm) whereas the signal was only found extracellularly
in smaller unmyelinated axons (≤1 μm). This result suggests GPBP is found
associated with the myelin sheath, an   extended oligodendroglial plasma
membrane that wraps around axons. The neuronal cytoplasm remains
unstained. GPBP immunoreactivity is restricted to the grey matter, enriched
in neurons with no detectable signal in glial cells (astrocytes,
oligodendroglia, ependymal cells and microglia), consistent with our
previous study (10). 
The specificity of the antibody used was confirmed by blocking the binding
after pre-incubation with the antigenic peptide; under these conditions,
there was no detectable signal (data not shown). A previous study using an
antibody directed against both variants (GPBP and CERT) produced both
intracellular and extracellular staining (10). In the current study we
demonstrate that GPBP is responsible for the extracellular and membrane
associated signal but is not detected intracellularly. Overall, GPBP and CERT
have distinct complementary cellular expression patterns. 
HEK APPwt/sw cells are characterized by overexpression of GPBP 
We have recently shown that GPBP and CERT partially colocalize with Aβ
fibrils in plaques of human AD brains (11). To investigate the role of GPBP in
the processing of APP, we have used a cell model with elevated levels of
secreted Aβ peptide. Specifically, we use HEK APPwt and HEK APPsw, cell
lines which have been extensively used as a model system for the study of
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APP metabolism (28-31).
Cell lysates prepared from HEK and HEK cells overexpressing APPwt or
APPsw were blotted and probed with mAb anti-GPBP antibody (3A1-C1).
Actin was used as a loading control. A single band with a molecular mass of
120 kDa was detected in the HEK, APPwt and APPsw lines, however the
GPBP expression was higher in the APPwt and APPsw overexpressing -line.
The Swedish double mutation in the APP gene results in a markedly
increased Aβ secretion compared with HEK cells overexpressing APPwt.
However, no difference in the overexpression of GPBP was detected
between APPwt and APPsw HEK cells. Therefore, these results show that
GPBP expression is associated with APP protein increase at the plasma
membrane and not dependent on Aβ levels.
APP and GPBP cell surface distribution was further analyzed by
immunofluorescence staining on non-permeabilised HEK and HEK APPsw
cells. GPBP and APP levels were significantly increased in the HEK APPsw cell
surface relative to HEK cells (Figure 1, B). The plasma membrane marker,
α1 Na+/K+ ATPase, used as positive control was equally distributed in the two
cell lines (data not shown). Negative controls by omission of the primary
antibodies resulted in no signal.
RT-PCR was also used to verify the expression levels of GPBP and CERT in
HEK and APPsw cell lines (Figure 1 C). In line with the Western blot and
staining data, GPBP transcript levels are significantly up regulated in APPsw
relative to HEK (p<0.016). A less significant difference was observed in the
mRNA expression levels of the CERT isoform, again relative to HEK (p<0.2).
In summary, we have shown that stable overexpression of either APPwt or
APPsw in HEK293 cells results in increased levels of endogenous GPBP. 
GPBP is over-expressed at plasma membrane level
In order to further characterize the localization of GPBP overexpression,
equal amounts of protein from plasma membrane and cytoplasmic
subcellular fractions of HEK and HEK APPsw were blotted with mAb
detecting GPBP (3A1C1) and APP (6E10). GPBP and APP levels were
increased in the membrane fraction of HEK-APPsw relative to HEK 
(Figure 3 A). In the membrane fraction of APPsw cells a large band of ~100
kDa was detected for APP and high molecular weight bands above 250 and
~100 kDa were detected for GPBP. Very low levels of APP and GPBP were
detected in normal HEK cells. Neither GPBP nor APP was found in the
cytosolic fractions of HEK and APPsw cell lines. To test for cross
contamination, membrane and cytosolic fractions were probed with
markers for subcellular compartments: α1 Na+/K+ ATPase (plasma 
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Figure 1. Immunohistochemical localization of GPBP in hippocampal neurons in normal rat brain.
Light microscopy of neurons in the hippocampus (CA2) shows that GPBP staining is restricted to the
plasma membrane. GPBP immunostains diffusely in the neuropil. Bars in A represents 200 μm, in B 80
μm and in C 20 μm, in D 10 μm.
membrane) and GAPDH (cytosol) (Figure 3 A).
These results suggested that overexpression of GPBP in HEK APPsw occurs at
the plasma membrane level and does not accumulate inside the cell. An
effective way to study membrane proteins is via surface biotinylation.
Membrane proteins are labelled when a portion of the molecule that is
exposed to the extracellular space is linked to biotin that covalently attaches
to primary amines (e.g. lysine) present within the protein sequence;
Western blot analysis can then be used to characterize the biotinylated
protein. This approach was used to detect GPBP levels at the plasma
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membrane in HEK, APPwt and APPsw. Biotinylation of cell surface proteins
was consistent with immunostaining results and revealed an increase in
GPBP levels at the plasma membrane of both APPwt and APPsw cells (Figure
3 B). Detection of actin expression in the cell lysate was used as a loading
control for the three cell lines and indicates the same amount of loaded
protein.
The distribution of GPBP in plasma membrane was not always uniform
across the cell surface and we consistently observed distinct concentrated
patches and streaks of GPBP immunolabelling in HEK APPsw (Figure 2 B).
Since ceramide enriched platforms have been shown to be involved in the
regulation of APP processing and in Aβ peptide formation, we analyzed the
surface distribution of ceramide by immunofluorescence staining of HEK
and APPsw. Higher intensity ceramide staining was consistently observed in
APPsw cells relative to HEK cells (Figure 3 C). Furthermore, dual-label
immunostaining demonstrated virtually complete co-localization of
ceramide and GPBP on the cellular surface of the HEK APPsw plasma
membrane (Figure 3 D). In summary, the dramatic increase of GPBP
expression in APPsw occurs at the plasma membrane level and GPBP
colocalises with ceramide-rich platforms in these cell lines.
Figure 2 Stable overexpression of either APPwt or APPsw in HEK293 cells results in increased levels
of endogenous GPBP A) Whole cell extracts (40 μg protein) were analyzed by immunoblotting with
antibodies against GPBP (3A1C1), APP  (APP140) (1), Actin (Sigma). 
B-C) HEK and HEK APP cells were stained for GPBP (mAb 3A1C1) and APP (pAb 5313).
Immunofluorescence signal was quantified using ImageJ software, the average intensity of 50
individual cells is shown (bar graph). Datasets were analyzed via analysis of variance with t-test and
significant p-values are shown. 
D) To investigate the expression of GPBP and CERT mRNA levels in HEK and HEK APP cell lines, total
RNA was extracted and analyzed by RT-PCR. The relative amounts of GPBP and CERT expression
compared with the 3 housekeeping genes (human 18s rRNA, RIP, β-actin) were calculated using the
ΔΔCt method. Statistical analysis was performed using unpair t-test. Significant differences (p<0.05)
are shown above the panel.
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Figure 3 Protein levels of GPBP are increased at the plasma membrane in HEK APPsw compared to
HEK cells. A) HEK and HEK APPsw were fractionated into membrane and cytosol. Membrane and
cytosol extracts were separated by SDS-PAGE transferred to nitrocellulose and detected with mAb
anti-GPBP (3A1C1) and pAb anti-APP (140 Ab). In the membrane fraction of HEK-APP cells, a large
band of ~100 kDa is detected for APP and high molecular weight bands above 250 and 100 kDa are
detected for GPBP. Both proteins are hardly detected in normal HEK cells. To test for cross
contaminations, membrane and cytosolic fractions were probed with markers for subcellular
compartments: α1 Na+/K+ ATPase (plasma membrane), GAPDH (cytosol). B) Membrane surface
proteins of HEK (lane 1), HEK APPwt (lane 2) and HEK APPsw (lane 3) were selectively biotinylated.
Biotin-labeled cells were lysed and the biotinylated proteins were pulled down with streptavidin,
separated by 4-15% gradient SDS-PAGE, transferred to membrane and probed with mAb anti-GPBP.
Detection of actin expression in the cell lysate was used as a loading control used for the three
different samples. Two independent experiments were performed and a representative blot is shown.
C) Immunofluorescence signal for ceramide and α1 Na+/K+ ATPase was quantified using ImageJ
software, the average intensity of 50 individual cells is shown (bar graph). Datasets were analyzed via
analysis of variance with t-test and significant p values are shown. Ceramide levels are significantly
increased in the HEK APP cell surface compared to HEK cells. The plasma membrane marker is equally
distributed in the two cell lines. D) Immunofluorescence stainings for GPBP and ceramide were carried
out on both cell lines; here the HEK APP cells are shown, only. Colocalization (yellow) in the merged
images is particularly intense in the plasma membrane.
GPBP binds Aβ1-42
The results reported so far demonstrate that GPBP expression is upregulated
in response to constitutive overexpression of either APPwt or APPsw. Also a
colocalization between ceramide and GPBP at the level of the plasma
membrane is reported. In this context, we tested the hypothesis whether
GPBP might interact with APP.
As APPsw cells express endogenous GPBP, they are suitable for testing the
in vivo interaction of APP and GPBP. To explore the possibility that APP and
GPBP form a complex, we performed reciprocal immunoprecipitation (IP)
with monoclonal anti-Aβ (6E10) and anti-GPBP antibodies (3A1-C1) in
APPsw cellular lysates. Western blot analysis illustrated efficient IP of GPBP
and APP by their respective antibodies, APP was detected as a band ~100
kDa using mAb 6E10 and GPBP was detected as band of  approximately 200
kDa using polyclonal antibodies against GPBP epitopes 1-50 (Figure 4 A).
This high molecular weight GPBP band suggests that the protein is somehow
aggregated or that dimerization has occurred as already reported (8).
Western blots of APP IPs have shown that GPBP co-precipitated with APP.
The inverse IP strategy produced a similar result (Figure 4 A-B). IP using an
isotype control mAb (mAb antisyntaxin 6, Clone 3D10) was negative when
probed with the same GPBP and APP specific antibodies. The results are
representative of three independent experiments. However, the fact that
GPBP is secreted and that is found in amyloid plaques raises the question
whether GPBP is capable of amyloid β peptide binding. In order to further
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investigate whether Aβ1-42 associates with GPBP, we utilized a far Western
blotting technique in which membranes containing comparable amounts of
GPBP were probed with Aβ1-42 peptide and inversely, membranes containing
comparable amounts of Aβ1-42 peptide were probed with GPBP. By this
method we were able to demonstrate that GPBP can directly bind to the
Aβ1-42 peptide probe and viceversa (this has been already proved in the PhD
thesis of Dr Pilar Martínez-Martínez, La fosorilacion de serinas y el pigmento
de autoantigenos: Caracterizacion de GPBP, una nueva quinasa implicada en
autoinmunidad, Universidad de Valencia, July 2003) suggesting a direct
interaction between these two proteins (Figure 4 C-D). To exclude the
possibility that the binding event was an artifact of the covalent
immobilization of each protein, we investigated GPBP-Aβ1-42 interaction in
free solution by MST.  The GPBP/Aβ1-42 dissociation constant (KD) was found
to be 2.5 μM+/- 284 nM, indicating Aβ1-42 binding to fluorescently labeled
GBPB (Figure 4 E). No binding was observed when the experiment was
performed using a negative control peptide (not shown). 
GPBP reduces Aβ aggregation and has a protective effect against Aβ-
induced toxicity in cultured neurons 
Having shown that GPBP directly binds the Aβ1-42 peptide, we next tested
whether binding of GPBP to Aβ1-42 has a direct influence upon the in vitro
aggregation pattern of Aβ1-42. This was determined by allowing Aβ1-42
monomers to aggregate in the presence or absence of GPBP. The
aggregation of Aβ1-42 was followed by ThT fluorescence and Western
blotting. In the absence of GPBP the ThT fluorescence of Aβ1-42 peaked after
12 hours, with the addition of GPBP (2.5 μM) Aβ1-42 maximum ThT
fluorescence was halved. At a lower concentration of 1 μM, GPBP was less
effective at preventing Aβ1-42 fibrilization. This was consistent with Western
blot analysis where the amount of low molecular weight Aβ1-42 species
(below 20 kDa) was reduced by the addition of GPBP at both 1 μM  2.5 μM
concentrations, suggesting that GPBP is able to structure Aβ1-42 into
insoluble aggregates.
The toxicity effect of Aβ for neuronal cells, both in vitro and in vivo, is well
documented and this toxicity appears to play an important role in the
pathogenesis of AD (32). Using SHSY-5Y cells we were able to examine the
functional effects of GPBP on cell viability under stress from Aβ
accumulation. The addition of Aβ1-42 to the culture medium of SHSY-5Y cells
resulted in a 38% reduction in viability after 24 hours, as measured by MTT
reduction relative to control conditions. Interestingly, simultaneous addition
of GPBP ameliorated the toxic effect of Aβ1-42 in a concentration dependent
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Figure 4 GPBP binds Aβ1-42 A-B) Cellular lysates were immunoprecipitated (IP) with anti-Aß mAb
6E10, with mAb anti GPBP (3A1-C1) separated on a 4-15% gradient SDS-PAGE and probed  with 6E10
(A) and rabbit pAb anti-GPBP (epitope 1-50 of human GPBP, Bethyl Laboratories) antibodies (second
blot), respectively. APP was co-IP by anti-GPBP mAb and was detected with mAb anti-Aβ in a band
around 100 kDa (lane 2, A). GPBP was co-IP by anti-Aß mAb and detected with pAb anti-GPBP and
visible in a band of approx 250 kDa (lane 3, B). Control using an isotype control mAb (mAb anti-
syntaxin 6, Clone 3D10, Abcam) for IP was negative when detected with the same antibodies against
Aß and GPBP (lane 4, A-B). Molecular weight markers are indicated (kDa). The results are
representative of three independent experiments. C-D) For far Western Analysis of GPBP interaction
with Aβ1-42 peptide GPBP, Aβ1-42 peptide, IgG (negative control) and a 17 kDa Lama antibody
fragment (H6) (negative control) were loaded on SDS-PAGE and transferred into nitrocellulose
membrane. Membranes were incubated with Aβ1-42 peptide (C) and recombinant GPBP (D) followed
by detection with pAb anti-GPBP and 6E10 (C, D). The 17 kDa Lama antibody fragment (H6) was
detected with pAb anti Myc tag.  E) A dissociation constant of 2.5 μM+/- 284 nM for Aβ1-42 binding
to GPBP was determined by MST measurements.
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manner, with a 26% reduction in viability with 0.5 μM of GPBP and a 20%
reduction in viability with 1 μM of GPBP compared to 38% with Aβ1-42. 
The interaction of GPBP with Aβ1-42 seemed to change the aggregation
pattern of Aβ1-42 and the reduction of Aβ1-42 toxicity in SHSY-5Y cells by GPBP
suggest that this protein was able to organize Aβ1-42 into less toxic
structures.
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Figure 5 GPBP prevents the formation of thioflavin T positive Aβ aggregates A) 20 μM Aβ1-42 (Aβ)
was incubated with 1 μM or with 2.5 μM GPBP in 100 μl of 20 μM ThT in a 96-well plate at 25°C.
Fluorescence intensity was measured every 4 minutes with excitation at 450 nm and emission at 486
nm, each data point represents the mean fluorescent intensity of three wells. GPBP structures 
Aβ1-42 into insoluble aggregates B-C) Aβ1-42 (1), Aβ1-42 + 1 μM GPBP (2), Aβ1-42 + 2.5 μM GPBP (3)
and GPBP (4), were incubated at 37°C for 24 hours and 15 μl of each samples were taken at different
time points (0, 2, 4, 8, 12 hours are shown) and separated under either native non-reducing (B) or
denaturing and reducing (C) conditions on 4-16% precast gels for Western blot analysis. Samples with
GPBP (red signal) at both 1 μM and 2.5 μM concentrations show a reduction in the amount of low
molecular weight Aβ1-42 species (green signal) (C) suggesting that GPBP is able to structure Aβ1-42
into insoluble aggregates which fail to migrate into a 4% PAGE under native, nonreducing conditions
Recombinant GPBP reduces Aβ toxicity in a SHSY-5Y cell culture model D) SHSY-5Y cells were exposed
to 10 μM Aβ1-42 (Aβ) in the presence or in the absence of  1 μM GPBP for 24 hours. MTT reduction
was assessed by incubating the cells with 0.5 mg/ml MTT for 3 hours and measuring absorbance at
595 nm. The results were normalized to cells that were not exposed to Aβ1-42 or GPBP, each dot in
the graph represents a single well and data from two independent experiments were pooled. The
means of the Aβ1-42 and Aβ1-42 + GPBP groups were statistically significant (p<0.03) in an unpaired
t-test.
Discussion
Here we have shown that in the brain GPBP associates with neuronal plasma
membranes and is found in the neuropil, conversely the shorter splice
variant CERT stains neuronal cells intracellularly (10). We found that GPBP
accumulates at the plasma membrane level in response to APP over-
expression, suggesting a regulation that might occur upstream of 
Aβ production. Also, secreted GPBP interacts directly with Aβ1-42 and
promotes the formation of high-molecular weight Aβ aggregates while
simultaneously reducing the Aβ β-sheet aggregation pathway, interestingly
resulting in reduced Aβ1-42 peptide toxicity in cultured neurons. Positive
GPBP staining was found in activated microglia in AD human brains
indicating that GPBP may have a role in the immune and /or immunoeffector
function of these cells (11). Activated microglia classically cluster around
amyloid plaques and release pro-inflammatory cytokines into the milieu
(33,34). Consistent with a role in amyloid aggregate response, GPBP
expression is induced by the pro-inflammatory cytokine TNF (35).
Additionally, we found that C1q, the first component of the complement
cascade, and GPBP may share a common binding site on the SAP molecule.
C1q is present in fibrillar amyloid plaques and, through activation of
complement, has a role in the pathogenesis of AD. SAP bound to C1q can
activate the classical complement pathway and GPBP could be involved in
the regulation of complement activation by inhibition of C1q-SAP binding.   
Many proteins have alternative isoforms that possess distinct functions (6).
Since proteins are only present in their active form in the specific
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compartment where they are needed, subcellular localization of proteins
can be a useful indicator of protein function.  The distinct cellular
distribution of GPBP and CERT, together with the fact that these splice
variants have been widely conserved during evolution, suggest isoform-
specific functional roles for these proteins. If the function of CERT is to
transport the lipid ceramide from the ER to the Golgi (7), the longer isoform
GPBP has been reported to regulate  molecular/supramolecular
organization of structural proteins and to direct their assembly intra and
extracellularly (2,5). This may be of significance when we consider that GPBP
has been found associated with plaques from human AD patients and was
also found to interact with SAP, a universal component of amyloid deposits
(11). This suggests a possible role for GPBP in binding proteins prone to
misfolding and aggregation (3), such as Aβ.
APP is a ubiquitously expressed cell surface protein that, as well as
generating Aβ, has many reported functions (36). Several data support a role
for APP in mediating cell-cell or cell-matrix interactions, indeed APP has
been shown to directly bind type I collagen and other extracellular matrix
(ECM) molecules (37-40). Although most commonly linked to pathological
processes, several potential non-pathogenic functions have been attributed
to Aβ, including activation of kinase enzymes (41), protection against
oxidative stress (42,43), regulation of  cholesterol  transport (44,45) and
functioning as a  transcription factor (46,47). In healthy cells, it appears that
both amyloidogenic and non-amyloidogenic APP processing pathways
operate and that a precise balance between the two is maintained. Our
results indicate that GPBP is upregulated in response to APP over-
expression, and that this response appears to be independent of Aβ peptide
levels. However, we cannot exclude the possibility that very low levels of Aβ
peptide production may be responsible for the increase in GPBP expression.
The processing of APP has been shown to influence the expression levels of
many genes. For example, as well as Aβ peptides, amyloidogenic processing
of APP produces the APP intracellular domain (AICD), which has been
reported to affect expression levels of several genes by acting as a
transcription factor in the nucleus (48). Indeed, abnormal gene dosage of
APP can unbalance the amyloidogenic and non-amyloidogenic APP
processing pathways in neurons, resulting in abnormalities that can
contribute to neurodegeneration and consequent dementia in AD (49). We
were able to retrieve complexes of GPBP and APP in total cell lysate,
suggesting that this interaction occurs at the plasma membrane level and
prior to APP processing. Converging evidence from a number of studies
indicates that amyloidogenic processing occurs in ceramide-enriched
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membrane raft microdomains (50,51). This is consistent with our finding
that ceramide colocalises with APP/GPBP complexes at the plasma
membrane. It is possible that the role of GPBP at the plasma membrane is
dependent upon cell expression of ceramide, however, the precise
mechanism of APP-mediated up- regulation of GPBP remains to be
elucidated.
The toxicity of Aβ for neuronal cells is well established both in vitro and
in vivo, and this toxicity seems to play an important role in the pathogenesis
of AD (32). GPBP exists in several isoforms with molecular weight ranging
from 30 to 120 kDa (32, 50, 60, 77, 91, 120 kDa) (2,8) and it is possible that
each isoform has a distinct function. The GPBP 77 kDa polypeptide was
described as soluble extracellular isoform capable of interacting with type IV
collagen in the extracellular matrix. In this context, the finding that GPBP is
able to bind Aβ is not surprising. In vitro we demonstrate that GPBP strongly
promotes the formation of high-molecular weight Aβ aggregates while
simultaneously reducing the Aβ β-sheet aggregation pathway. β-sheet
oligomers and protofibrillar species, formed by Aβ1-42 or Aβ1-40, are
neurotoxic and powerful inducers of apoptosis. Our cell culture data show
that GPBP reduces the toxicity of Aβ1-42 peptide species, suggesting that
GPBP can organize Aβ into less toxic aggregates. Protein aggregation is a
complex process, involving several types of intermediate and resulting in
different forms of fibers or amorphous aggregates. However, it is not
established if and how these different aggregates are related to the
pathogenesis of AD. Although there is a large body of data on the
conformation and "cross-β" packing of Aβ in amyloid fibrils (52,53), which
are the end-products of aggregation, little is known about the basic building
blocks of the oligomers and protofibrils that precede them. 
What is known is that AD is linked to the formation of neurotoxic oligomeric
aggregates of the Aβ-peptide in the brain (54). In the present study, we have
presented data that supports a direct interaction between APP and GPBP
and have shown that GPBP binds Aβ and organizes Aβ aggregate structure.
Proteins in the plasma membrane typically help the cell interact with its
environment; GPBP may switch roles between; (i) stabilizing normal levels of
APP and (ii) reducing levels of cytotoxic Aβ by organizing these small
peptides into more structured non toxic species. Importantly, these
interactions are not limited to cell culture systems. We have previously
reported evidence for the molecular association of GPBP and APP in samples
prepared from AD mouse brains. We also found GPBP to localize in amyloid
plaques of post-mortem AD human brain (11), demonstrating that the 
in vitro results obtained in the present study are functionally significant and
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with in vivo relevance. More experimental evidence will be necessary to
demonstrate a critical function of GPBP in the pathology of AD, which could
lead us to a better understanding of the pathological process that take
places in neurodegenerative disorders.
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Precise regulation of protein function in the cell can occur by many
mechanisms, at any stage in the flow of information from gene to protein.
Protein function can be regulated by temporal and spatial control of the
gene product which can be targeted to specific cellular compartments as
required. Protein activity can also be regulated by the binding of effector
molecules, which often work by inducing conformational changes that
produce inactive or active forms of the protein. The various strategies of
functional control are not mutually exclusive and any one protein may be
subject to several modes of regulation. GPBP and its spliced variant CERT,
encoded by the collagen gene COL4A3BP, represent a good example of this
finely tuned cellular regulation. These two proteins differ solely by a 26
amino acid domain that appears to be sufficient to produce dramatically
different biological activities. In chapter 1 of this thesis we have summarized
the current available knowledge of these proteins, attempting to present an
integrated view of the background concerning their structure, properties
and functions. Throughout, we remain careful to consider each isoform
individually, as in much of the literature they can be mistakenly treated as
one and the same protein. On the contrary, the two isoforms have many
distinguishing properties. The shorter isoform CERT localizes inside the cell
and carries out the role of ceramide transporter, while GPBP associates with
membranes, can be secreted extracellularly and is likely to regulate
molecular organization of structural proteins. Moreover, the additional 26-
residue serine rich motif that distinguishes GPBP from CERT results in an
increased kinase activity. The role of CERT is intimately linked to ceramide
function, whereas a clear function for GPBP remains elusive. However, CERT
and GPBP share a common ceramide binding capability and are the only
proteins known to transport ceramide. Ceramide plays an important role in
a wide variety of physiological neuronal processes, ranging from lipid raft
formation in cell membranes to regulation of differentiation and apoptosis
(chapter 2). By implication, CERT and GPBP must underlie the regulation of
many physio-pathological processes. To investigate further, in chapter 3 we
first characterized the cellular localization and expression of these ceramide
transporters in normal rat brain. High levels of immunoreactivity were
observed throughout the brain, suggesting that GPBP and CERT play an
important role in central nervous system (CNS) neuron function. Strong
immunoreactivity was found in neurons of the cortex, hippocampus, the
basal ganglia, the olfactory bulb and some nuclei of the thalamus, the
hypothalamus and the septal area. Glial cells do not show immunoreactivity
for GPBP and CERT, suggesting that under basal conditions these proteins
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have very low levels of expression in non-neuronal cells. In chapter 4, in
order to further investigate the role of these proteins in the brain, we
examined the expression levels of GPBP and CERT in the acute
neurodegenerative process of the 6-OHDA rat model of Parkinson's disease
(PD). We found that GPBP and CERT expression levels were not altered in
diseased animals as compared to the control group. 6-OHDA induces a
vigorous inflammation and mimics the selective neuronal degeneration that
characterizes PD, however, this model does not produce all of the
pathological and clinical features of human parkinsonism. A defining
pathological hallmark of PD is the presence of neuronal Lewy body formed
by protein aggregates. After 6-OHDA lesioning, deposit of aggregate
proteins does not occur. The role of protein aggregation in the pathogenesis
of PD has not been fully determined, but altered protein processing in the
cell is known to have a negative impact on normal cellular function.
Moreover, dysregulation of sphingolipid metabolism, that seems to be
strongly involved in many neurodegenerative disorders, is a condition that is
missing in a 6-OHDA model. Therefore, in chapter 5 we have investigated
the expression levels of GPBP and CERT in human and transgenic mouse
Alzheimer's disease (AD) brain tissues characterized by aberrant protein
aggregation and progressive neuronal degeneration. We found GPBP and
CERT colocalised in amyloid plaques in post-mortem AD human brain. This
led us to study the relationship between these proteins and serum amyloid
P component (SAP), a ubiquitous amyloid deposit associated protein. We
found that GPBP interacts strongly with SAP, further supporting a role for
GPBP in amyloid disease. Notably, GPBP-SAP binding is reduced by C1q, a
well known ligand of SAP, raising the possibility that GPBP and C1q share a
common binding site on SAP molecule. SAP binds to proteins involved in
immunological responses and can activate the classical complement
pathway through interaction with C1q. This might indicate a role for GPBP in
the regulation of the complement system by inhibiting the C1q-SAP
interaction by steric hindrance. Moreover, we observed GPBP staining in
activated microglia of AD tissues, whereas in the non-disease state this
protein is found only in neuronal cells. Considering that GPBP associates
with amyloid plaques and has been shown to induce intra and extracellular
structural protein organization, it seems likely that GPBP has an important
role in the molecular organization and self-association processes of amyloid
fibrils. Also, GPBP could be involved in the removal of misfolded proteins by
activated microglia at the site of the AD plaques. Amyloid plaques are
extracellular structures composed of 38-43 amino acid peptides called
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amyloid beta (Aβ) peptides. Aβ-peptides are generated by aberrant
proteolysis of a much larger precursor protein, the amyloid precursor
protein (APP), a ubiquitous type I cell surface protein of as yet unknown
physiological function. In chapter 6, we have shown that in the brain GPBP
associates with neuronal plasma membranes and is found in the neuropil,
conversely the shorter splice variant CERT localizes in the cytoplasm of
neuronal cells. We next investigated whether GPBP has a role in the
processing of APP using a cell culture model overexpressing APP that results
in elevated levels of secreted Aβ peptide. We found that GPBP accumulates
at the plasma membrane level in response to APP over-expression,
suggesting a regulation that might occur upstream of Aβ production. This
suggests that perturbation at the plasma membrane level, due to
overexpression of APP and ceramide accumulation, may be sufficient for the
upregulation of GPBP levels. However, we cannot exclude the possibility that
very low levels of Aβ peptide production may be responsible for the increase
in GPBP expression. Secreted GPBP interacts directly with Aβ1-42 and
promotes the formation of high-molecular weight Aβ aggregates while
simultaneously reducing the Aβ β-sheet aggregation pathway, interestingly
resulting in reduced Aβ1-42 peptide toxicity in cultured neurons. Importantly,
the interaction between GPBP and Aβ1-42 is not limited to cell culture
systems. We have detected a molecular association of GPBP and Aβ
aggregates in samples prepared from AD mouse brains demonstrating that
the in vitro results have are functionally significant in vivo. Taken together
these findings suggest that GPBP has a role in the progression of brain
diseases that are characterized by protein misfolding/aggregation rather
than merely in response to neuron degeneration or damage. In line with this
role, high expression levels of GPBP are found in many autoimmune diseases
in which antigens may arise from abnormal protein domain organization.
GPBP was first identified as a collagen binding protein in Goodpasture
syndrome, an autoimmune disease in which autoantibodies are observed
along glomerular and alveolar basement membranes, causing
glomerulonephritis and lung hemorrhage. Recent evidence suggests that
the pathophysiology of neurodegenerative and inflammatory neurological
diseases has an immunological component involving complement, an innate
humoral immune defence system. Although historically viewed as an
immune-privileged organ, the CNS contains and synthesizes many
components of the immune system. Complement components play a central
role in the amplification of AD risk factors and neuronal death. C1q, the first
component of the complement cascade, is present in fibrillar amyloid
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plaques and, through activation of complement, has a role in the
pathogenesis of AD. Our finding that C1q reduces the binding of GPBP to
SAP, could suggest a cross talk between these three molecules at the plaque
deposition site. Additionally, in innate immune reactions of the brain,
microglial activation is the main cellular response to CNS dysfunction. We
found positive GPBP staining in activated microglia in AD human tissue
indicating that GPBP may have a role in the immune and/or immunoeffector
function of these cells. The rapid clearance of abnormally structured
proteins by microglia is important to inhibit inflammation as well as
autoimmune responses against neo-antigens.
Together, our findings provide new insight into the physiopathological roles
of GPBP protein. We suggest that GPBP may be involved in the innate
immune response in the specific context of protein misfolding/aggregation.
Through interaction with SAP, GPBP may inhibit SAP-mediated activation of
the complement cascade. This raises the possibility that GPBP is able to
modulate the innate immune response, placing this protein in a key position
in the regulation of autoimmunity, inflammation and neurodegeneration.
More research is required to fully characterize the mechanism of action of
GPBP; however, the data presented here provide further detail of the
increasingly apparent link between chronic inflammatory diseases such as
neurodegeneration and autoimmunity.
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